Animal Biotechnology: Opportunities & Challenges by unknown
NABC REPORT 4
Animal Biotechnology:
Opportunities & Challenges
*«K
«C
(y
NATIONAL AGRICULTURAL BIOTECHNOLOGY COUNCIL REPORTS
NABC Report 4 
Animal Biotechnology:
Opportunities & Challenges
The National Agricultural Biotechnology Council provides an open forum for the 
discussion of issues related to the impact of biotechnology on agriculture. The 
views presented and positions taken by individual participants in this report are 
their own and do not necessarily reflect the views or policies of the NABC.
NABC grants permission to copy the overview, workshop summaries, concluding 
remarks and workshop texts. Permission to copy individual presentations is 
retained by the authors.
Copying ofthis report or its parts for resale is expressly prohibited.
Photos on cover and pages 23, 73 & 175 courtesy of University Photography, Cornell.
Photo on page 1 courtesy of Agricultural Communications, Texas A&M University.
Additional copies are available for $5 
please make checks or purchase orders payable to: 
NABC / BTI
159 Biotechnology Building 
Cornell University 
Ithaca, NY 14853-2703
© 1992 NABC All rights reserved.
ISBN: 0-9630907-2-0
Library of Congress Catalog Card Number 92-062575
Printed by Braun & Brumfield, Ann Arbor, Michigan 
@ printed on recycled paper
NABC REPORT 4
Animal Biotechnology:
Opportunities & Challenges
Edited by June Fessenden MacDonald
ublished by
NATIONAL AGRICULTURAL BIOTECHNOLOGY COUNCIL 
ITHACA, NEW YORK 14853-2703
National Agricultural Biotechnology Council
Providing an open forum 
for exploring issues in 
agricultural biotechnology.
NABC is a consortium of not-for-profit agricultural research and educational 
institutions established in 1988.
Member Institutions
Boyce Thompson Institute
Cornell University
Iowa State University
Michigan State University
Ohio State University
Purdue University
Rutgers University
The Texas A&M University System
Tufts University
University of  California, Davis
University of Georgia
University of  Missouri, Columbia
University of  Nebraska,  Lincoln
Other Reports by NABC:
NABC REPORT 1, Biotechnology and Sustainable Agriculture: 
Policy Alterna-tives (1989)
 
NABC REPORT 2, Agricultural Biotechnology, Food Safety and Nutritional 
Quality for the Consumer (1990)
NABC REPORT 3, Agricultural Biotechnology at the Crossroads: Biological, Social 
and Institutional Concerns (1991)
ACKNOWLEDGMENTS
Many contributed to the success of the fourth annual NABC meeting and the production of this report. Special thanks goes to the Planning Com-
mittee at the host institution, Texas A&M University: co-chairs Paul Thompson 
and John Shadduck, with Gary Adams, Floyd Byers, Russell Cross, Nancy 
Turner, Robert Wells and James Womack, and to Gary Varner who organized 
the optional seminar on ethics and patenting. NABC gratefully acknowledges 
the help and support of Charles Arntzen, J. Charles Lee, and the Institute of Bio-
sciences and Technology. Also recognized is the important role of the workshop 
facilitators: Rick Bennett from the North Bay Public Policy and Education 
Team, Davis, California; Laura Meagher, Agricultural Biotechnology Center, 
Cook College, Rutgers University; Ellen Ritter, Agricultural Communications, 
Texas A&M University; and Barbara Gastel MD, Journalism, Texas A&M Uni-
versity, as well as the work of the several graduate and undergraduate students 
who assisted in the meetings success.
Special recognition goes to the efficient conference organizational service 
provided by Barbara Stow, with assistance from Kelly Hancock, of the Center 
for Biotechnology Policy and Ethics, Texas A&M University. Carolyn Grine of 
their College of Veterinary Medicine was also most helpful .
Very special thanks and recognition goes to Kate O'Hara, Design/Editorial 
Coordinator, NABC, who is responsible for the overall design and production of 
this report, not only for the additional work she had with the editor on sabbati-
cal leave, but also for her general oversight of meeting and report details.
Finally, the cooperation received during the production of this report from 
the meeting organizers, presenters, workshop chairs and participants was great 
and is sincerely appreciated.
June Fessenden MacDonald 
Deputy Director, NABC 
Editor
PREFACE
June Fessenden MacDonald
Deputy Director, NABC 
Biochemistry, Molecular and Cell Biology 
Cornell University
The National Agricultural Biotechnology Council (NABC), organized in 1988, added 5 new members in 1992, bringing the total membership to 13 
not-for-profit agricultural research and educational institutions. NABC’s prin-
cipal objectives are to:
—Provide an open forum for persons with different interests 
and concerns to come together to speak, to listen, to learn 
and to participate in meaningful dialogue and evaluation of 
the potential impacts of agricultural biotechnology 
—Define issues and public policy options related to biotechnol- 
ogy in the food, agricultural and environmental areas 
—Promote increased understanding of the scientific, economic, 
legislative and social issues associated with agricultural 
biotechnology by compiling and disseminating information 
to interested people
—Facilitate active communication among researchers, admin-
istrators, policymakers, practitioners and other concerned 
people to insure that all viewpoints contribute to the safe 
and efficacious development of biotechnology for the benefit 
of society
—Sponsor meetings and workshops and publish and distribute 
reports that provide a foundation for addressing issues
The Fourth Annual NABC Meeting (NABC 4), hosted by the Texas A&M Uni-
versity System, once again demonstrated the importance of an open forum 
where people with different values and strongly held viewpoints can come to-
gether as equal participants in a dialogue on agricultural biotechnology. For 
some participants it was the first time they had personally met someone with 
strongly held opposing views and truly listened to their arguments.
There was a more diverse group of participants, many attending their first 
NABC meeting, discussing issues of animal well-being, meat and animal prod-
uct safety and regulatory policy. The new topic addressed by NABC was the link-
ages between animal science, veterinary medicine and human medicine and how
they could be encouraged since these groups now have limited interaction. 
While discussions in this area were generally harmonious, the other areas elic-
ited more lively, even contentious, discussions. Still, participants in each work-
shop were able to reach some areas of consensus. This report, hopefully, com-
municates some of the flavor of the meeting.
The need for real communication and open procedures was never more evi-
dent than at NABC 4. Not only was the call for open dialogue sounded in every 
session, but also the need for improved communication, especially during 
policy development. Improved communication rivaled animal well-being as the 
prime topic during informal discussions. The highly publicized announcement 
of FDA policy one day before the meeting caused many participants, represent-
ing all sides of the animal biotechnology dialogue, to be concerned. Most par-
ticipants were not against the policy as announced, but rather they were con-
cerned that, regardless of the value of the policy, a process that leaves any stake-
holders feeling shut out of the process—and there were several at the meeting— 
does not enhance the government’s or biotechnology’s credibility in the eyes of 
the public.
NABC, in its 5 years of existence, provides opportunity for all stakeholders 
to come together in a consensus building setting on biotechnology and agricul-
ture. We believe that policies developed with an open forum with input from all 
interested stakeholders will benefit biotechnology through greater public accep-
tance of these policies. NABC has accepted the encouragement of communica-
tion and open dialogue among all stakeholders in agricultural biotechnology as 
a central mission.
NABC hopes this report will contribute to increased understanding of the 
range of viewpoints on animal biotechnology and stimulate improved dialogue, 
provide new information from different perspectives for all those interested in 
and affected by animal biotechnology and also provide a foundation for ad-
dressing some of the concerns facing society today in this burgeoning area of 
agricultural biotechnology.
In this single volume, NABC has tried to provide different readers with in-
sight into the opportunities and challenges in animal biotechnology. Part I of 
this report provides a synopsis of NABC 4, highlighting the issues raised by 
speakers and participants as well as statements and recommendations on which 
there was consensus by workshop participants. For those readers who desire 
more detail, the keynote addresses are found in Part II. Background papers and 
full workshop reports are combined topically in Part III.
Pleasant reading and productive dialogue.
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Overview
ABC 4, the fourth annual open forum on agricultural biotechnology,
was devoted to issues in animal biotechnology. The May 1992 meeting 
was held in College Station, Texas and hosted by Texas A&M University. 
Animal well-being, the safety of animal food products and regulatory issues 
were on the agenda along with the examination of links between animal bio-
technology and new opportunities in human and animal medicine. Previous 
NABC meetings had focused upon sustainability, food safety and quality, 
and the financial and regulatory prospects for agricultural biotechnology at a 
crossroads. Animal biotechnology, especially recombinant DNA research on 
agricultural animals, however, has opened doors to entirely new areas of hu-
man endeavor, many of which were not well understood in the past. The 
NABC 4 presentations and discussions on animal biotechnology revisited 
several themes that had been discussed at previous NABC meetings, but also 
broke ground in identifying several key topics that had not been examined 
at Ames, Iowa in 1989; at Ithaca, New York in 1990; and at Sacramento, Cali-
fornia in 1991.
As in previous meetings, the aim of the National Agricultural Biotech-
nology Council was first and foremost to establish an open setting in which 
all perspectives and interests can be represented with participants sharing 
ideas, asking questions and interacting with one another. Convening under 
the banner Animal Biotechnology: Opportunities and Challenges, more than 
150 representatives of industry, interest groups, government and universities 
opened the conversation on these topics with the goals of establishing a com-
mon base of knowledge among all participants, reaching consensus where 
possible, and specifying a limited number of recommendations to emerge 
as the product of the workshops. NABC 4 continued the trend of the three 
previous meetings by expanding the range of views and groups represented. 
Many of the participants, particularly those concerned with issues of animal 
well-being, were attending this open forum for the first time. Also, some par-
ticipants were presented for the first time with viewpoints in sharp contrast 
to their own. For this reason alone, NABC 4 clearly can be said to have served 
the NABC mission of promoting dialogue among those with different views.
NEW THEMES
The new topic to the NABC forum was the linkages between human medicine 
and animal agriculture. Although animal biotechnology was addressed at 
NABC 1 and at NABC 3, animal well-being as a special theme was a new fo-
cus for NABC.
Animal Well-Being
The dialogue on animal well-being had been conceptualized as an opportu-
nity to take up the question of whether developments in animal biotechnol-
ogy would produce any new or unanticipated issues for the well-being of ag-
ricultural animals. Although these topics were, indeed, discussed, presenta-
tions by keynoter Michael Fox, Vice President for Bioethics and Farm Ani-
mals, The Humane Society of the United States; David Meeker, Director of 
Research and Education, National Pork Producers Council; and Bernard 
Rollin, Professor of Philosophy at Colorado State University, moved the dis-
cussions into more philosophical and broad-ranging areas. This workshop 
became a forum in which those who saw themselves as representing animals 
and those who saw themselves as representing agriculture engaged in ener-
getic dialogue over the criteria and basis for extending concern to animals, 
without respect to whether biotechnology or, indeed, even agriculture was 
the topic of concern. As such, participants raised examples from human bio-
medical research and product testing, familiar forums for animal welfare de-
bates, as a means for sounding out each other’s basic views on animal issues.
The question of biomedical applications came up particularly with the 
“new creation” of: 1. precise animal models for human diseases; and 2. ani-
mals as “bioreactors” producing human pharmaceuticals. Rollin prompted a 
discussion of the dilemma of balancing the relief of great human pain and 
suffering from genetic diseases with the large numbers of animals that would 
experience great suffering. He suggested researchers could eliminate the pain 
centers of such animals, but noted that this, too, raises ethical and aesthetic 
concerns.
Although the heated discussions in this group produced limited con-
sensus, there was general agreement that it is acceptable under conditions 
where animals do not experience great suffering, to use animals for human 
use—whether for food production, as “bioreactors,” or as research models 
for improving human and animal health.
The intensity of discussions in the group was evident to all meeting par-
ticipants and issues of animal well-being wound up being raised (sometimes 
briefly) in every workshop. In the shadow of such lively dialogue, the work-
shop group examining links to human health felt itself to be too homoge-
neous with few issues on which participants opinions diverged. The group 
invited a participant from the animal well-being workshop to a session to 
learn, at least, what the hubbub was about. Although the agenda was broader,
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and the consensus achievements occurred in other areas, the 1992 meeting 
will undoubtedly be remembered as the “animal welfare” meeting of the Na-
tional Agricultural Biotechnology Council.
Links to Human Health
Recombinant DNA research on farm animals conducted in animal science 
departments of agricultural universities and in colleges of veterinary medi-
cine, has begun to bring the scientists in these areas into the prospects and 
controversies that have traditionally been associated with biomedical re-
search. As highlighted by keynote speaker Neal First, Professor of Animal 
Science at the University of Wisconsin, animal biotechnology continues to 
establish breakthroughs in reproductive technology, enhance genetic 
changes in animals and improve animal health. He conveyed to the partici-
pants some of the excitement felt by researchers, himself included, as they 
push the frontiers of animal science forward. It was noted that basic research 
aimed at disease control in animals often spills over to human applications. 
Fuller Bazer, Animal Science Department, Texas A&M University, asserted 
that “When human and animals have diseases with common etiology and ge-
netic markers of the disease, genetic or therapeutic solutions will favorably 
impact both human and animal health.” What is more, Clifton Baile, Direc-
tor of Research and Development at Monsanto, suggested that intensive pub-
lic and private funding for research in biomedical applications such as gene 
mapping and pharmaceuticals will produce techniques, methods and models 
that will shorten the time for product development for those working on 
farm animals.
The workshop participants actively discussed the need for connections, 
or “new linkages,” between human medicine, animal medicine and animal 
agriculture. They saw a major potential for expanding the dialogue and re-
search interaction among these groups, suggesting that soon the justification 
for animal biotechnology may be its great benefits to human health, not just 
animal productivity.
It was, however, noted that as agricultural researchers expand their re-
search and interact directly, or even indirectly, with biomedical researchers, 
they can expect to face some of the problems that have existed in public 
health and the biomedical research policy arena for some time. These include 
an intense public interest in reproductive technologies, in part because of 
their relevance to the abortion issue, and also a level of public concern for 
the well-being of animals exceeding that hitherto experienced in connection 
with food animals. As such, the workshop on animal well-being experienced 
an overlap with the workshop on animal biotechnology links to human 
health that meeting organizers had not anticipated. When continuing discus-
sions on food safety and regulatory policy were added into the mix, the two- 
plus days of the meeting proved stimulating.
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REVISITED THEMES 
Communication and Open Dialogue
The only issue that could rival animal well-being as a main current at the 
1992 meeting was the continued call from participants for open communica-
tion and the need for all stakeholders to be involved early and continuously 
in the dialogue on biotechnology. The highly publicized White House an-
nouncement of the FDA’s policy for evaluating the safety of foods of plant 
origin made on May 26, 1992, the day before the meeting began, resulted in 
several diverse groups in attendance at NABC 4 openly expressing concern 
that if biotechnology is to gain public acceptance, policies must be developed 
within an open framework with opportunity for input by all interested stake-
holders. While most in attendance were not against the announced policy per 
se, participants on “both” sides of other biotechnology issues followed press 
coverage of the announcement all week, expressing the view that the an-
nouncement reflected little understanding of how public concerns and ques-
tions about biotechnology can be addressed in a manner that inspires confi-
dence in the regulatory process.
At the final plenary session, in response to a recommendation by the 
participants in the Regulatory Issues workshop, several participants spoke 
forcefully in favor (no one spoke in opposition) of NABC corresponding 
with appropriate federal officials urging more open dialogue during future 
deliberations about agricultural biotechnology policies.1
Ironically, the announcement of this policy spoke directly to two of the 
concerns expressed as major themes of the 1991 NABC meeting in California. 
There, U.S. competitiveness had been linked to a need for clear delineation 
of regulatory procedures for research and product development. The policy 
which was, in fact, being announced for comment, was a response to both 
themes.
The two overarching currents of NABC 4—animal welfare and the call 
for open dialogue—point toward reiteration of a conclusion that was 
reached at the 1990 NABC meeting in New York State: concerned parties in 
the food arena have failed to talk with each other, much less communicate. 
Regrettably, much the same conclusion was reached by the 1992 workshop 
on Meat and Animal Product Safety. Participants were in strong agreement 
that differing groups fail to interact and called on scientists to begin to com-
municate with the public as equal partners.
Defining Food Safety
This failure to interact and communicate became evident in discussions on 
how to define safety. There were those, mostly scientists, responding to the
1 Editor’s note: Letters were sent to Vice President Quayle and the heads of HHS, 
FDA, EPA and USDA expressing NABC’s belief that the acceptance of government 
efforts by the public can be enhanced only when policies are developed and per-
ceived to be developed with appropriate input from all interested parties.
Animal Biotechnology: Opportunities & Challenges
presentations of David Berkowitz, Office of Biotechnology, FDA; Russell 
Cross, Administrator, USDA/FSIS; and John Frydenlund, Deputy Assistant 
Secretary, Marketing and Inspection at USDA, who felt that safety should be 
defined in terms of whether eating a product will cause injury or disease. 
They urged that scientific principles be used to; 1. assess the probability of 
foodborne injury to health; and 2. target foods where alterations associated 
with biotechnology might increase the probability of harm (e.g., allergenicity). 
A second view was represented by Dianna Hunter, a former small farmer and 
member of the Minnesota Food Association, who interpreted safety as “feel-
ing confident about one’s food.” Factors that influence such confidence in-
clude whether the food is being produced and provided through a trustwor-
thy source. Many participants agreed that nonscience factors (e.g., social, 
economic) can influence whether a source is deemed trustworthy and should 
be considered in the assessment of foodborne risk.
The 1992 meeting illustrated the need for biotechnology industries and 
high-level government officials to get behind the goal of increasing two-way 
communication where biotechnologists listen to the nature and shape of 
public and interest group concerns before formulating their messages about 
the safety, efficacy and benefits of biotechnology.
Regulatory Policy
A recurring theme in all the workshops was the need for clear regulatory 
policies for agricultural biotechnology whether for food, pharmaceuticals or 
animal use or release. In the workshop on Regulatory Issues, participants felt 
that pharmaceutical products have been foremost in the thinking of regula-
tors who have concluded that the existing framework for biotechnology 
regulation is adequate and that all forms of regulation should stress product 
over process. Martin Terry, Vice President for Scientific Activities, Animal 
Health Institute, expressed the frustration of industry faced with different 
regulations depending on product classification as a drug or a food. He called 
the groups attention to both the debate on extra-label drug use in animals 
and the crisis in drug availability which currently besets animal agriculture. 
From the environmental perspective Margaret Mellon, Director, National 
Biotechnology Policy Center, National Wildlife Federation, argued a need 
for regulatory action, noting that there are several areas, including fish and 
wildlife, where animal scientists are undertaking biotechnology research in 
the absence of clear regulatory authority.
The group also discussed how process and point of origin have tradi-
tionally been important to consumer acceptance of agricultural products. 
Virtually every state claims that its soils, climate and farmers produce the 
best potatoes, onions, wine, pork or something. Furthermore, it was noted 
that the Food Safety Inspection Service (FSIS) has made decisions based 
on judgements that are not supported by risk-based reasons. For example, 
FSIS does not allow lungs to be used in meat products based on the cultural
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judgement that consumers do not want meat products in which lungs are 
used—in the U.S. lungs are not classified as food. As such, participants felt 
that a decision to consider only risk-based regulatory policies for agricul-
tural biotechnology leaves many questions unanswered, for example, label-
ing and product certification—another continuing theme that emerged in 
each workshop only to be shelved by each noting the need for a future NABC 
forum on the issue of labeling of biotechnology food products.
The 1992 meeting explored new issues and revisited several continuing 
issues. NABC 4 established a series of key understandings that should shape 
the direction of animal biotechnology research, product development, policy 
and administration for the coming decade. There was overwhelming consen-
sus that greater public understanding of biotechnology processes and prod-
ucts and greater public participation in the decision-making process was not 
only desired, but essential, if agricultural biotechnology is, indeed, to be the 
growth industry of the 21st century.
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Workshop Highlights and Recommendations
ABC 4 featured four concurrent workshops focusing on areas of con-
cern in agricultural biotechnology: Animal Well-Being, Links of Animal 
Biotechnology to Human Health, Meat and Animal Product Safety and Regu-
latory Issues. In the workshops, participants were asked to define and 
prioritize national issues, reach consensus where possible, and to develop 
recommendations. The diversity of participants helped to insure that a wide 
variety of issues were raised; at the same time, diverse values and goals often 
made consensus difficult. Consequently, workshops were also charged with 
identifying areas of disagreement both of fact and perception. The following 
highlights are from reports prepared by workshop co-chairs and reviewed by 
all participants in those workshops. Any inaccuracies are the result of editing 
and not the responsibility of the original writers. Full versions of the work-
shop reports and summaries, as well as background presentations, can be 
found in Part II starting on page 23.
he workshop began with a wide-ranging discussion about the concept
of well-being. Participants decided that the discussions should be lim-
ited to the well-being of animals involved in biotechnology: farm animals 
and experimental animals. Many felt that new technologies create new prob-
lems and raised new questions.
Individual participants listed 15 questions about biotechnology and ani-
mal well-being. It was observed that the emergence of biotechnology coin-
cides with greater concerns about animals, increasingly cognitive views of 
animals, increased distance from agricultural and draft uses of animals, and 
urbanization and romanticization of animals. Technology is colliding with 
changing morality. Genetic engineering feeds into these concerns because of the 
general concern that the manipulation of genes could lead to unnatural beings.
By this point in the discussion the participants were quite polarized. To 
move the discussion forward it was suggested that some of the fundamental
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concerns might be identified. Among the 16 listed were: whether it is ever ac-
ceptable to utilize animals for human use, whether animal biotechnology 
poses unique questions about animal well-being and whether biotechnology is 
qualitatively or quantitatively different from what has come before.
Following an intense discussion on the concerns, individual participants 
identified some possible harms and benefits to animal well-being that arise 
in the context of biotechnology. A highly unrepresentative straw poll was then 
done in order to see which of these possible harms and benefits the partici-
pants most wanted to discuss. The four possible harms (1. diverting 
resources away from improving traditional husbandry practices; 2. loss of 
genetic diversity; 3. proliferation of genetically defective animals who suffer 
disease as models; and 4. thinking of domestic animals as human artifacts), 
and the four possible benefits (1. removal of genetic defects from animal 
populations more rapidly; 2. better understanding of animal well-being;
3. permitting increased disease resistance; and 4. more efficient production 
leading to the use of fewer animals) receiving the most support, along with 
the possibility that animal biotechnology may lead to healthier products for both 
humans and animals, formed the basis of much of the remaining discussion.
CONSENSUS STATEMENTS
Weighing the broad spectrum of issues related to biotechnology and animal 
well-being, participants were able to reach agreement on four consensus 
statements:
1. Biotechnology may contribute to animal well-being, but it is not the 
only approach to improving animal well-being.
2. There should be responsible, systematic investigation of the benefits 
and harms to animals that may be associated with biotechnology.
3. It is acceptable under some conditions to use animals for human use.
4. Animal biotechnology has the potential to contribute to the “three Rs” 
in animal experimentation: reduction, refinement and replacement.
RECOMMENDATIONS
1. With respect to animal well-being, criteria should be developed for re-
sponsible research and application of specific biotechnologies in animals. The 
full spectrum of opinion should be represented in the development of these cri-
teria. These criteria should be periodically reconsidered in the light of 
changing circumstances.
2. The benefits and harms noted should be taken into account in develop-
ing these criteria.
3. Animal biotechnology should not be used in ways that impose great 
costs in animal well-being while achieving only minor human or animal ben-
efits. When there is the likelihood that a procedure will cause great suffering 
to animals, alternatives should be sought.
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Links of Animal Biotechnology to Human Health
As a result of the advances made in molecular biology over the last decade, the fields of animal agriculture and human medicine have come to share 
a wide range of techniques and models. These profound changes in the re-
search process have raised a series of issues with respect to the use of both 
farm and traditional laboratory animals in research. The discussions in this 
workshop focused on these issues.
HUMAN HEALTH CONSIDERATIONS DRIVING AGRICULTURAL 
RESEARCH
In recent years, public concern about food safety and nutrition has played an 
increasing role in animal agricultural research. The public is also concerned 
about the disclosure of the contents of food and food products as well as 
about broader marketing issues (e.g., product claims).
In addition, new biotechnologies blur the lines between nutrition and 
pharmacy, making possible the creation of what have been variously called 
“nutraceuticals” and “pharmafoods.” These products, often of animal origin, 
serve a combination of nutritive and therapeutic goals. They raise complex 
issues of regulation, food safety and consumer education.
ETHICAL USE OF ANIMALS
Some argue that the use of animals as food or in research is itself unethical. 
Others argue that humane treatment of animals is the major concern. The 
workshop participants agreed that it was not clear just what is ethical. More-
over, they were concerned with methods used to accommodate the wide 
range of views on the subject found in our diverse society. They also ques-
tioned whether current guidelines on the use of animals in research, often 
written before the advent of the new technologies, are adequate morally.
ANIMALS FOR BIOLOGICS AND THERAPEUTICS
The use of animals for the production of vaccines and therapeutics has a long 
history. Workshop members indicated that the widespread use of animals as 
living “bioreactors” to produce chemicals of value to humans differed from 
other uses of animals, (e.g., in food and fiber production). They expressed 
concern as to what, if any, ethical implications were associated with it. More-
over, the use of animals as bioreactors raises some practical questions. For 
example, there is the problem of what to do with the carcasses of these ani-
mals. Should they be allowed to enter the food chain?
Animal bioreactors also pose problems of containment, welfare and 
management, raising the question of whether it would be more desirable to 
have certain species earmarked for this purpose and not used for food. This, 
in turn, raised the issue of whether whole animals or cell cultures should be 
used for screening of therapeutic products.
Workshop Recommendations
SOCIETAL CONTEXT OF SCIENCE SHARED BY AGRICULTURE AND 
MEDICINE
Research rarely takes place outside a larger social context. That context pro-
vides both the limits and opportunities for research. A central issue in this 
workshop was how (or whether) to integrate private and public research at 
the agriculture-medicine interface. Another key issue was the distributive as-
pects of this type of research.
The group also acknowledged that new linkages between the medical 
and agricultural sciences will be influenced by the current state of food, agri-
cultural and medical policy. At the same time, the discoveries and inventions 
stemming from this research will have a considerable impact on food, agri-
cultural, and medical policies. In addition, workshop participants wondered 
whether the current institutional structures (especially at universities) were 
adequate for the new linkages between agriculture and medicine.
Finally, there was a general consensus that greater public participation 
in the decision-making process was both necessary and desirable.
RECOMMENDATIONS
1. Stronger links need to be developed between agricultural and medical 
research relating to biotechnology. Among mechanisms to do so are centers, in-
centives for joint programs, funding, etc. This will require further integration 
and institutionalization of joint agricultural and medical programs. Such link-
ages will need to include an examination of the ethical, economic, social, insti-
tutional, and legal ramifications of these changes.
2. More resources from molecular biology should be devoted to genome 
and other research in an attempt to ultimately spare animals from direct use 
in research. It should be thereby possible to shift largely from whole animal to 
organ, tissue or cellular systems.
3. Explore the moral implications of the use of animals in medical and ag-
ricultural research. Issues in the area are currently inadequately examined, and 
thus, there is not yet an adequate moral framework for making decisions about 
this type of research.
4. Provide for education of and dialogue among all the participants in the 
debate.
5. Improve the agenda-setting process that insures that resources are 
properly allocated and that all interested parties are involved in the allocation 
process.
6. Improve the guidelines to aid in determining appropriate circum-
stances for patenting animals, tissues, and cell lines.
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Meat and Animal Product Safety
Workshop participants identified some potential safety problems fordiscussion. These included unanswered questions about bovine soma-
totropin (BST), allergenicity and questions about a number of products for 
which there are, as yet, no data bases. Participants also discussed the promise 
for new biotechnologies to produce diagnostic tools for food safety testing of 
animal products.
Finding common ground was more difficult and frustrating once the 
group moved past the fairly narrow, but controllable technical hazards to the 
myriad of intellectual and social elements that people bring to a decision 
about the safety of any entity, food included. At this point, participants 
stepped back to list the major concern of each of the participants about the 
safety of biotechnologically produced meat and animal products. The items 
fell into four different areas. Small groups were formed to discuss these issues 
and bring recommendations back to the total workshop group for discussion.
THE SAFETY OF TRANSGENIC ANIMALS AND ANIMALS ADMINISTERED 
RECOMBINANT DNA PRODUCTS
In the area of use of transgenic animals to produce pharmaceutical agents for 
use by humans, the major safety concern was that these “pharm” animals may 
enter the human food supply, but before they do, their safety must be assured.
1. All workshop participants agreed to the need for a data base on the nu-
trient composition and levels of relevant hormones and residues in these 
animals to reassure scientists and the public that there are no detectable dif-
ferences from levels of these substances in traditional animal products. There 
was not consensus in the group as to how extensive the data base would be 
and what it would contain.
In the area of animals administered recombinant DNA products: 1. hor-
mones; 2. vaccines; and 3. direct-fed microbials; there was consensus that the 
regulations under the National Environmental Protection Act (NEPA) and 
the testing protocols for vaccines were probably adequate. FDA has the au-
thority to regulate direct-fed microbials, but the group felt it has not been 
doing so.
2. FDA should investigate direct-fed microbials more carefully in the fu-
ture when applications for recombinant products are received.
Another concern expressed was about long-term consequences of breed-
ing transgenic animals. The concern here is the unknown potential for 
unexpressed genes to cause other changes in animals that may not be ex-
pressed for several generations.
3. The final recommendation in this area speaks to the need for remain-
ing aware of the possibility of cloning defects in embryo transfer and cloning 
experiments.
Workshop Recommendations
BIOTECHNOLOGICAL TOOLS TO ENHANCE FOOD SAFETY 
AND QUALITY
4. Recognizing that animal products are the major source of microbial 
contamination in the food supply, the use o f  D N A  probe assays and immu-
noassays for the detection of pathogens is to be strongly encouraged.
Biotechnology is the most promising source of tools that can yield rapid, 
sensitive, specific and cost-effective diagnostic tests for the presence of mi-
crobiological pathogens, antigens, toxins and other compounds of interest to 
improve food safety. New diagnostic capabilities can also be used to detect 
adulterated foods and as a screening method for allergens in the food supply. 
The group also discussed how genetic markers offer the potential to improve 
the healthfulness and safety of the food supply.
5. Research and application of these tools should move ahead rapidly. 
They endorse continued research on the use of the genetic makers techniques.
DEFINING FOOD SAFETY
Some participants argued the present definition of “safe,” relative to foods, is 
too narrow, ignoring quality issues as well as the fact that food safety is a so-
cial construct. They felt that social, economic and political issues should be 
evaluated concurrently with the evaluation of efficacy and human and ani-
mal safety. Others disagreed with all of these ideas and argued for main-
taining the present system of relying solely on technical data for safety deci-
sions. The latter participants did recognize that social, economic and polit-
ical issues should be discussed, but there was no agreement about whether 
the mechanism should be separate from, or integral to, the present system.
6. The larger issue here is how to define food safety.
COMMUNICATING WITH THE PUBLIC
This section of the report and recommendations are premised on a consensus 
agreement that the public has a stake in maintaining public institutions pro-
vided they are responsive to public needs. Many (but not all) scientists have 
perceptions and biases that are quite different from the various perceptions 
and biases of public groups which makes it difficult for scientists to be good 
communicators. There is also the serious problem of lack of support for these 
activities in the reward structures of institutions and of an imbalance in 
funding going to high technology research versus research in policy and com-
munications. These were all considered in the following set of recommen-
dations which were endorsed by all workshop participants.
7. There is a body of knowledge about communications that scientists 
should use to improve the dialogue with the public.
8. Regional research projects should be promoted and funded, and the 
National Research Initiative should be encouraged to put more funding into 
its policy and marketing line item to promote public understanding of agricul-
tural biotechnology.
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9. Interdisciplinary work between the biological and social sciences 
should be promoted and recognized as critical if serious progress in this area is 
expected.
10. In all grant proposals, the technical significance and relevance of re-
search should be communicated in terms the general public (or anyone outside 
the particular discipline) can understand.
11. Continuing education programs should be developed for scientists to 
teach them how to more effectively facilitate two-way communication be-
tween scientists and the general public.
12. The public, starting at the elementary school level, would be well 
served by educational programs on the social, moral, economic, political and 
scientific issues surrounding biotechnology.
In order to accomplish any wide-ranging change in faculty behavior in 
these areas the group suggested that it will be necessary to re-envision the 
mission of the land-grant colleges to serve all their publics and recognize that the 
responsibility for this is shared by all institutions of higher education. This will 
change the weight given to public service or extension activities in promotion de-
cisions and bring this area into better balance with research and teaching.
Regulatory Issues
The charge to the workshop participants was to identify and examine issues arising in regulatory treatment of animal biotechnology. Free-ranging dis-
cussion among individuals with different perspectives followed. While 
consensus was not sought nor achieved on the specific issues identified, these 
issues were deemed worthy of consideration by one, some, or many of the 
members of the group, and as such help to illustrate the range of concerns in 
the regulatory arena. Common themes of agreement did emerge and these 
were captured in the form of four issue statements or recommendations at 
the end.
The following issues and gaps have been identified in the regulatory process: 
—At the research stage, there are no mandated guidelines/regulations 
for industrial research of animal biotechnology.
—In field testing, there are no regulations for release of fish, wildlife, in-
sects or pets; for micro-organisms in livestock feeds or for zoonotic pathogens 
of animals and humans. Also there is no mechanism to deregulate similar ge-
netically modified organisms that have been proven to be safe based upon 
previous case studies;
—Implementation of the ABRAC developed guidelines should govern 
agricultural research in the area of field testing;
—There is an inability to gain access to some information on health and 
safety of products because of “confidential business information” designation.
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—In the food safety area there are gaps that are currently not covered by 
any regulations including disposition of transgenic animals and whether fish, 
seafood and wildlife should be included.
—In efficacy testing, the issue of whether transgenic animals used as 
pharmacoreactors should receive special attention from FDA was raised.
Recognizing there should be representation of broad interest, the public’s 
role in regulatory debate was discussed. Possible mechanisms identified for 
improved public access included: 1. legislation regarding public participa-
tion in regulating decisions across the board; 2. publication beyond the 
Federal Register; 3. improved representation in decision-making processes;
4. open forums; 5. research on opening up scientific decision-making 
process; and 6. rebuilding public trust and regulatory transparency.
Other issues considered were the role of states and industry in the de-
bates, public education, and communication. Consideration was given by the 
group to the level of information available for consumer choice.
Workshop participants also considered technically based regulations vs 
social/ethical/economic impact considerations. They noted that regulations 
can impact not only in the U.S., but also on international trade, as well as 
trade relationships with Third World countries.
RECOMMENDATIONS
1. The regulatory gaps delineated deserve serious investigation. NABC 
may wish to establish a committee or other mechanism to assist this investigation.
2. A more acceptable policy-making process for rules of broad applicabil-
ity would be clearly understood or known (not ad hoc), transparent, and 
participatory. The group viewed the process by the Council on Competitiveness 
in the Office of the Vice President, leading to the May 26, 1992 FDA food safety 
decision, as falling short of the goals for an acceptable process. (Editor’s note: At 
the final plenary session, a recommendation was made by those present (no op-
position was voiced) that NABC respond urging future processes of policy 
development be open and include all interested stakeholders. NABC sent letters 
to Vice President Dan Quayle and the heads of HHS, FDA, EPA and USDA.)
3. Social, economic and ethical questions need to be explored. What role 
do/should these issues have in research, development and approval processes for 
commercial use of new products? When should these factors be considered, rela-
tive to, but not necessarily as a part of, the regulatory process?
4. With broader representation, (such as food processors and consumer 
groups), NABC should conduct further exploration of the relationship be-
tween the government’s regulatory role, particularly the safety statutes and 
issues of choice, such as labeling provisions.
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NABC 4: Opportunities and Challenges
We, the participants in NABC 4, have been presented with a tremendousamount of information—facts, perceptions, views, values and impacts on 
animal biotechnology. It has been a stimulating, mind-stretching and, yes at 
times, a stressful experience. In this meeting, we have not all really “heard” the 
same things even when we were in the same sessions listening to the same speak-
ers Certainly, we have developed individual impressions. We leave this meeting 
with many of us feeling a little uncomfortable—business representatives feeling 
as if they were at times considered the “bad guys.” Ditto for government repre-
sentatives and scientists, animal rights proponents and those with environmental 
interests. Let me suggest that NABC must be doing something right when partici-
pants do feel a bit uncomfortable, a little bit less sure after actually listening and 
hearing views different from their own; when representatives of different groups 
have had to articulate their positions to fellow participants who are unfamiliar 
with, and even disapprove of, their positions and actions. This forces communi-
cation, perhaps for the first time, with one another rather that at one another. If 
you are feeling just a bit less sure, if you have a bit more insight to the perspective 
of a different group, if you now know someone “from the opposition,” I declare 
NABC 4 a success.
Let me just review with you some of the opportunities and challenges we en-
countered as participants in this meeting. First, we need to examine some of the 
“specs” of the meeting that we are pull together here. As a benchmark, NABC 
Chair Ralph W. F. Hardy, in his charge to the meeting made several key points:
1. We are living in an era of biology with rapid change; 2. Yesterday’s science is 
perhaps but dreams; 3. Today’s science represents possibilities; 4. Tomorrow’s 
science will bring realities; 5. Dr. Hardy implored us to recognize that “risk” is 
product-based, not process-based; 6. Furthermore, he pointed out that we now 
have the knowledge base to allow a thorough look at risk; and 7. Finally, Dr. 
Hardy reminded us that the mission of NABC is that of “providing an open fo-
rum for exploring issues in agricultural biotechnology.” In conducting that open 
forum we come together to speak, to listen, to learn and to participate in mean-
ingful dialogue and evaluation of potential impacts of agricultural biotechnology. 
As I reflect on how well we responded to the charge, I note both some rewarding 
opportunities we have taken and others we left untouched as well as several chal-
lenges we, as individual participants, will take from this meeting.
OPPORTUNITIES
With this assemblage of diverse views and interests, I can only wish we had had 
more time to discuss more of the opportunities placed before us. Let me share my 
views about a few opportunities we missed.
The issue of patenting came up several times. As keynote speaker Dorothy 
Nelkin put it, “Patenting of animals has become a lightning rod.” I was disappoin-
ted that we did not take the opportunity to dissect the patenting issue and to exam-
ine the components. (I realize there is a special optional seminar that will place ad-
ditional emphasis on patenting, but not all participants will be at that activity.1 
There is a general perception that patents (in any field) inherently mean: 1. secrecy 
and 2. making money. I have learned, after having spoken to various university 
patent officers, that they support my own experiences which suggests the following: 
1. Most patents do not return many dollars in royalties; 2. The patent process makes 
information known to the public. One of the requirements for issuing a patent is 
that the details be disclosed; 3. The main reason why universities patent things is to 
encourage commercialization. Most products coming out of university research 
that may be patentable still require further research and development before be-
coming available to users. That means that some business organization must make 
additional investment of likelihood of the business getting a financial return on 
their own funds to bring the patented discovery to commercialization. There usu-
ally is significant risk about the investment; 4. It seems to me that licensing is the 
key issue that really should be addressed under the protection of intellectual prop-
erty by a university or other public sector entity. If a university owns the patent they 
can control the release for the best benefit to those who should be receiving the ben-
efit. In many cases, patents are licensed by the public sector to the private sector on 
a nonexclusive basis. However, sometimes it may be necessary to provide an exclu-
sive license so that a company can have sufficient incentive to cover the additional 
costs to complete the research and development and then test the marketability of 
the product or idea. There are times when an exclusive license may be the most appro-
priate way to proceed.
Another point about licensing is that the intellectual property can be licensed 
for less than the life of a patent. Thus, even if a university decided that it was in the 
best public interest to give an exclusive license, that would not have to be done for 
the life of the patent. It could be made available exclusively for a particular com-
pany’s use for, let us say, five years and after that then, the university may be in a 
position to license it to other companies. This sort of arrangement provides the ini-
tial company the lead time to complete the necessary development and have some 
headstart in the marketing area as an incentive for potential return on that upfront 
investment. If the university has not patented intellectual property in the first place, 
they would not have the option to control the route to commercialization.
I also noted that Dorothy Nelkin made an observation of a general nature: bio-
technology is not the cause of the decline of family farms and banning of patents 
would not likely reverse the trend in decline in the number of family farms. It was a
1 Editor’s note: NABC Occasional Paper #1, Ethics and Patenting of Transgenic Animals, 
is available from the NABC office.
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challenge that was not picked up by any other speaker, or to any significance, in any 
workshop.
NABC 4 provided an opportunity for fairly rigorous examination of animal 
biotechnology implications. I was surprised that there was not (at least in the ses-
sions I attended) more examination and analysis of issues (or the lack of) related 
specifically to each of the different tools and uses of biotechnology for animals:
1. Of course, artificial insemination has been common for 40 years and the subse-
quent advent of frozen semen represents really an early “biotechnology” that has 
had tremendous positive impact on the dairy industry and on the efficiency of dairy 
food production. At the present time, nearly three-fourths of the dairy cows in the 
U.S. are artificially inseminated using enhanced genetic material; 2. Control of re-
production involving ovulation, super-ovulation and estrous cycle regulation;
3. In vitro fertilization, perhaps with spermatozoan carrying X or Y chromosomes 
thus enabling control of sex of the offspring; 4. Embryo manipulations including di-
visions (cloning) and nuclear transfer; 5. Production of transgenic animals. Al-
though this area of animal biotechnology perhaps attracted the most attention, it is, 
in fact, currently only a very small component of all uses of biotechnology for ani-
mal agriculture; 6. Marker-assisted genetic selection through the use of techniques 
for gene mapping. This technology may turn out to be the most powerful tool 
for the intermediate time range; 7. Vaccines produced through biotechnologies;
8. Diagnostic tests; and 9. DNA probes. Each of these has a different set of advan-
tages and issues. It is unfortunate that we did not take this opportunity to look at 
each of the technologies individually, providing an analysis of the issues and poten-
tial outcomes of various alternatives.
OPPORTUNITIES TAKEN
Next, I would like to examine some of the opportunities taken, or overarching 
themes, which appear to me to at least link, if not tie together, the participants 
of NABC 4.
The first I would identify relates to animal well-being. Workshop participants 
were hard pressed to come up with a precise definition that was acceptable to all. 
While no attempt was made to achieve consensus overall, it seems to me that many 
participants in the workshop were saying: 1. Pain and suffering are no longer the 
only criteria to be considered; 2. Some feel “animal welfare” may be a minimum and 
that “well-being” means something above that in terms of production, reproduc-
tive performance, etc; 3. Animal well-being is important; and 4. Animal well-being 
is an important component of the biotechnology dialogue.
A second theme relates to meat and animal product safety. Again, I heard many 
people saying that healthy transgenic food animals are likely to be just as safe as a 
source of food as that from “traditional animals” from which they are derived. That 
goes along with the concept of looking at “product” and not “process.” I also heard 
many saying they wanted to know when their food was biotechnologically pro-
duced—a concern about labeling. A related theme is the clear need to continually 
examine, and perhaps broaden, our definitions and agendas for issues such as 
food safety, especially where food allergies are a concern.
Concluding Remarks
Finally, I often heard (and yet make no claim that there was an effort to achieve 
consensus) that biotechnology is not inherently, or universally, bad.
CHALLENGES
In addition, there were a few challenges to us as participants. These remind us that 
we all need to continue to listen, learn and share. One challenge to NABC was the 
need to broaden the representation of groups in the audience. It was pointed out 
that we especially need in the future to encourage greater participation of farmers, 
of food processors and, certainly, of consumers (as one individual put it, of “eaters”).
A second challenge: the regulatory process continues to be a concern and one 
for which it is very difficult to meet even an approximation of consensus among all 
of us and the groups we represent here at this meeting. Clearly we need more dia-
logue and meaningful interaction all through the year, not just for a few day once a year.
Perhaps the greatest challenge running through sessions and workshops even 
approaching consensus is two-fold: 1. the public will be more involved in decisions 
about biotechnology whether or not the traditional decision-makers invite them; 
and 2. there is a critical need for enhanced true communication. In discussing the 
public, we were reminded that we should not view public participation as an im-
pediment to change. This meeting reinforces some observations I have made from 
other vantage points, namely that “the public” is showing distrust, confusion and 
frustration not just about biotechnology and science, but also with government, 
legislators, etc.
I believe all of us must be seriously concerned that science may continue to lose 
credibility in the eyes of the public. Because science holds many keys to the future, a 
critical question is, “How are we going to develop and use science (e.g., biotechnol-
ogy) for the public good?” Scientists have a responsibility to provide information 
about science in understandable ways for all of society. “The public” must be in-
vited into the decision-making process as full, and informed, participants.
The second part of the major challenge from this NABC meeting is the need for 
enhanced communication. Participants clearly declared that by communication we 
do not mean “we need to educate the public.” Some of the sub-points in those dis-
cussions, and which I would challenge you to think about, are as follows:
—We must keep talking about issues and be open to compromise.
—Scientists have not done a good job of communicating what is going on.
There is a level of mistrust.
—Real communication is not just reaching someone with your message; it is 
interaction among equals who may not necessarily agree. As someone put it “don’t 
talk only with those who agree with you ... you’ll never learn anything.”
—Consumers are removed from agriculture and the production of food and fi-
ber. Since they do not see the various steps in the process they then have difficulty 
understanding this new animal biotechnology.
—The science community cannot just say that public concerns are unfounded. 
Public perception drives policy.
—And finally, special attention is needed to work with the media.
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I cannot leave this topic of communication without pointing out an old axiom, 
but one worth repeating—“we" must not just talk to our “own kind.” That is true 
whether our own kind means scientists, administrators, regulators, advocate and 
consumer group representatives, or any other segment of society. That is what 
NABC is all about—not talking only to our “own kind.”
I suggest that each of us go back from this meeting to our respective organiza-
tions with some action items. One that strikes me very clearly is about the develop-
ment of public policy. I am reminded that it is said about real estate that three things 
are important—location, location, location. If science is to have a role in the devel-
opment of public policy it seems to me that three things are important—communi-
cation, communication, communication.
I would hope that all of us, regardless of what group we consider ourselves to 
be affiliated with, would seriously consider these steps in communication: 1. Listen 
to a broad segment of society; 2. Listen carefully; 3. Frame a response; 4. Go back to 
our audiences with patience and persistence; 5. Listen to the audience once again; 
and 6. Keep up the cycle. It must become a part of our regular way of doing business.
Throughout this meeting we also heard the need for linkages—for coalitions. 
Each of us has a responsibility for our own organization in terms of seeking linkages 
and coordination. NABC provides a unique opportunity to enhance those efforts 
for appropriate development and use of agricultural biotechnology.
C O N C L U S I O N
In conclusion, let me confess that I have not been able to tie the box representing 
this meeting closed. In fact, I have decided that we do not have a box at all, but 
rather a vehicle. I urge each of you to consider the opportunities and challenges that 
we have shared during this meeting as fuel. It is now up to us to make that vehicle 
move forward. Let me leave you with the urgent plea that you communicate openly 
and fully with all stakeholders in agricultural biotechnology.
On a light note about a serious issue, perhaps it is not biotechnology per se that 
causes things to change. I believe that on his late night show Jay Leno said recently 
“the new McLean burger shows how times have changed. Now you find water and 
sea weed at McDonald’s and oil and grease in the ocean.”
Dr. W. Edwards Deming, (the American who finally gained fame for his suc-
cess in rebuilding Japan’s industry following World War II) repeatedly stresses the 
importance to “optimize the system so everybody wins. The best solution is for ev-
erybody to win.” NABC provides an open forum, a level playing field. Let us all 
work to keep the field level and the vehicle, fueled by this open forum, moving.
Finally a quote by Ralph Waldo Emerson, the American scholar, “This time 
like all times is a very good time, if we but know what to do with it.” I challenge us to 
communicate with each other and all the public. That is what we should do with 
“It” (our time).
Concluding Remarks
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Public Policy and Animal Biotechnology 
in the 1990s:
Challenges and Opportunities+
American agriculture has enjoyed momentous success over the past 50 years as measured by the quantity, quality, variety and cost of food and 
fiber. In the years proceeding World War II, the U.S. agricultural sector has 
experienced a significantly high rate of growth in productivity—a level more 
than three times the magnitude of the nonfarm industrial sector.
Into this agricultural system with all its strengths, complexities and chal-
lenges—both biological and political—comes biotechnology. Because of its 
importance to increased competitiveness in today’s expanding global econ-
omy, biotechnology is viewed as one of the keys to U.S. agriculture’s contin-
ued success in the years ahead. Moreover, it is predicted that the world’s 
population will increase at a rate of approximately 90 million people annu-
ally. At this rate, the current global population of just over five billion is ex-
pected to double during the next century. World hunger and malnutrition 
will not be simply problems of inequitable distribution. Expanded food pro-
duction will be essential to accommodate the nutritional needs of this rapidly 
growing global population. Herein lies one of biotechnology’s most pressing 
demands.
A N  I N D U S T R Y  C O M E S  O F  A G E
After years of speculation and commitment, agricultural biotechnology is 
moving slowly from the research laboratory to the barn, the field and the pro-
cessing plant. The puissance of agro-food biotechnology is no longer fantasy. 
Already, diagnosis of disease using biotechnology tools is a reality which is
* Former Staff Director, U.S. House Agriculture Subcommittee on Livestock,
Dairy and Poultry.
* The views and opinions expressed in this article are the authors and do not
necessarily represent the official policy or interpretations of the U.S. House 
Committee on Agriculture.
changing the face of both human and animal medicine. We are now in what 
some call the age of biology, moving from the age of chemistry.
The U.S. has maintained its preeminence in biotechnology, bolstered 
by strong research programs and well-established foundations in pharma-
ceuticals and agricultural science. For instance, in 1991, sales from biotech-
nologies totaled approximately $5.8 billion, an 18 percent increase over 1990, 
with net exports exceeding $600 million (Burrill and Lee, 1991; Raines, 1991). 
Furthermore, the Council on Competitiveness in the Office of the Vice Presi-
dent (1991) projects that by the year 2000, biotechnology will be a $50 billion 
industry. Currently, private industry spends approximately $2.1 billion an-
nually on technology development (Office of Technology Assessment, 1991a). 
The federal-state agricultural research system spends roughly $1.9 billion 
annually on agro-food biotechnology research and development (Office of 
Technology Assessment, 1991c).
These figures merely underscore the fact that what scientists have come 
to understand thus far about plants and animals is impressive. Moreover, this 
basic knowledge has been rapidly carried forward by a whole host of viable 
applications.
I M P A C T  O F  B I O T E C H N O L O G Y  O N  A N I M A L  A G R I C U L T U R E
Over the next 15 years, American farmers and ranchers will be offered an ex-
tensive array of new technologies that could revolutionize food animal pro-
duction. Ongoing research in the areas of computers, information systems 
and processing, robotics, controlled environments and biotechnology are ex-
pected to provide numerous on-farm practical applications (National Re-
search Council, 1990). Such technologies point to more efficient growth rates, 
less feed per unit of output, improved disease resistance and increased pro-
lificacy (Van der Wal et al., 1991).
Today, biotechnology has provided animal agriculture with safer, more 
efficacious vaccines against viral and bacterial diseases such as pseudorabies, 
enteric colibacillosis, and foot-and-mouth disease. We are beginning to seek 
answers to questions regarding complex systems that only a few years ago we 
could not even think to ask. This increased ability is particularly important 
in light of the fact that food animal products account for approximately one- 
half of all U.S. agricultural revenues on an annual basis. Producing leaner, high 
quality meat and meat products to satisfy today’s health-conscience consumer is 
of paramount importance (Pearson and Dutson, 1990; Kopchick, 1992).
Further, the first few commercialized on-farm animal biotechnology 
products will be of particular significance since: 1. they will heavily influence 
public attitudes about other emerging products and applications; 2. will es-
tablish substantive and procedural precedents in the legislative and regula-
tory arenas; and 3. will impact the future willingness of the corporate com-
munity to invest in like or similar product research and development (Kalter, 
1985; National Research Council, 1987; Office of Technology Assessment, 1991 d).
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Unfortunately, there is a lack of recognition in some circles that biotech-
nological applications complement, rather than replace, the traditional 
methods used to enhance agricultural productivity. In reality, many of the 
so-called “new” biotechnologies involve concepts based on centuries-old ap-
plications (Moses and Cape, 1991). Bovine somatotropin (BST) is an inter-
esting example—a product that elaborates familiar disciplines such as breed-
ing, animal nutrition, animal physiology and veterinary science, supple-
mented with the basic disciplines of molecular genetics, biochemistry, micro-
biology and bioprocess engineering (Office of Technology Assessment, 1991 d).
C U R R E N T  C H A L L E N G E S  F A C I N G  A N I M A L  A G R I C U L T U R E
Meeting the challenges of international competitiveness, sustaining a high 
quality food supply, preserving natural resources and protecting the environ-
ment will require a heightened level of knowledge over and above what was 
required to solve previous problems of years past (National Research Coun-
cil, 1989). In fact, an array of thought-provoking questions are being posed 
from both within and outside the agricultural sector. For example, how can 
the safety of biotechnologies, which may be used in food production or pro-
cessing, be systematically evaluated? Will the release of genetically modified 
organisms into the environment pose threats to human health or to natural 
ecosystems? Is new legislation necessary to regulate the agro-food and fiber 
products that are likely to be developed utilizing biotechnologies? These and 
other intricate questions are being voiced with a heightened urgency.
Clearly, the issues and strategies have become increasingly complex. 
Legislative authority and jurisdiction have become widely dispersed among 
several congressional committees and subcommittees with differing and like 
perspectives. Nonetheless, in the end, an effective biotechnology policy must 
knit several dimensions into a coherent framework—including basic re-
search, development and application, marketing and economic competitive-
ness, effective regulation, ethics and public policy (Office of Technology As-
sessment, 1991a).
O V E R C O M I N G  O B S T A C L E S  T O  C H A N G E
Worldwide, biotechnology is debated on three fundamental planes. The risks 
and benefits are disputed on scientific grounds, socioeconomic grounds and 
on the basis of public perception (von Oehsen, 1988; Wald, 1992). As with 
any other new technology, many questions of adjustment to change are posed. 
Concern about the effects of technological change has been a constant in the 
history of industrial development. But how should a democratic society es-
tablish public policies on advanced technical issues like biotechnology?
The primary difficulties inhibiting adoption would appear to lie in the 
provinces of administration, economics, management—and politics. The 
political debate surrounding biotechnology begins at the edge of scientific
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knowledge and lies in the realm of “What if?” Consequently, the barriers are 
both technical and institutional (Ruttan, 1991). Although we live in a society 
where the words of acknowledged experts are often received as gospel, our 
fascination with authority shows some indication of waning. Scientists, in-
dustrialists, politicians and educators have been found to be as fallible as 
other human beings and their “expert” information is greeted with skepticism 
by some, and with open defiance by others.
Today, the agricultural research community, and production agriculture 
in general, face several formidable outside forces. Such influences are fre-
quently referred to as externalities which can either have a positive or nega-
tive effect upon agricultural research and its use—particularly for agro-food 
biotechnology. The ultimate judge of emerging technologies will be the con-
sumer-—whether that be the farmer, homemaker or general public 
(Harlander, 1991). It is they who will appraise the merits of a particular 
product or process and determine its success or failure.
U N D E R S T A N D I N G  C O N S U M E R  C O N C E R N S
Within the past few years the popular press has captured the public’s atten-
tion with the perceived role biotechnology might play in agriculture, citing 
both positive and negative aspects, whether realistic or wildly speculative. 
Further, many of the terms used in current discussions of biotechnology have 
negative overtones. For example, words such as “genetic manipulation” and 
“genetic engineering” have a pernicious ring to the general public, and it is 
significant that those campaigning against BST continually refer to the prod-
uct as “bovine growth hormone.”
Part of the problem surrounding the broad acceptance of biotechnology 
stems from the frequently espoused concern that the processes of scientific 
research, and the applications derived therefrom, seem difficult to access and 
thus opaque, especially to the ordinary citizen. An examination of the testi-
mony received by the U.S. House Committee on Agriculture over the last several 
years would seem to indicate that concerns regarding biotechnology and other 
advancements facing animal agriculture fall into two broad categories—those 
relating to animal and consumer safety issues and those relating to social and 
ethical issues. Furthermore, the testimony submitted by various public inter-
est groups can be summarized under four question headings: 1. Is it natural?
2. Is it right? 3. Is it fair? and 4. Do we need it?
Many characteristics have been identified in the literature that appear to 
influence consumer acceptance of innovation. Among them are relative ad-
vantage, compatibility, complexity, trialability, observability—and risk 
(Herbig and Day, 1992).
Undoubtedly, citizens in the U.S. and around the world are going 
through an often mind-numbing debate about risk and reward in many as-
pects of their lives. Whether it is food safety, car safety, atomic energy, liabil-
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ity laws or even nuclear weapon proliferation, we are in the midst of a debate 
about the “balance” of risk and reward in society. Public attitudes can vary, 
often for reasons beyond the influence of more or better information about 
potential personal, environmental or socioeconomic consequences of a tech-
nology. Moreover, some people may react negatively to the perceived impacts 
associated with anything new or innovative.
What happens if the consumer does not change and refuses to use a tech-
nology? Should one blindly accept the scientists’ opinion of what is best? Do 
the vested interests which exist in a company or industry for an innovation 
mean that consumers must accept their decision? There are a whole host of 
questions and public concerns which must be properly considered and ad-
equately addressed if we are to clearly see what the perspectives are for intro-
ducing biotechnology in farm animal production. The creation and mainte-
nance of the public trust is surely one of the pivotal tasks to be undertaken 
(Harlander, 1991; Stenholm and Waggoner, 1992).
T H E  N E E D  T O  C O M M U N I C A T E
There are those who ask, “Why do we need to understand the consumer’s ac-
ceptance mechanism?” The answer is simple and straightforward: If scientific 
advances are to be allowed to provide an affordable, nutritious and sustain-
ing diet for all, the information gap between science and the lay public must 
be narrowed and the consumer’s perspective understood. Once the public is 
knowledgeable and properly informed, the word “biotechnology” in connec-
tion with food production should not raise a red flag of fear, but rather pre-
sent thoughts of reduced food costs, more nutritious food supplies, a safer 
food supply and a healthier environment in which to raise one’s family.
In an effort to foster the public trust, greater efforts are needed in pro-
viding useful information about the working areas of biotechnology and its 
applications in animal production (Office of Technology Assessment, 199 Id; 
Moses and Cape, 1991). Such information could help support an open and 
balanced public debate, and thus, form a firmer basis for sound decision-
making and sufficient monitoring. We must ensure that our systems of over-
sight, legislative and regulatory, are transparent and open to full participa-
tion by all responsible parties (Stenholm and Waggoner, 1992). At a time 
when more and more of American life is rooted in science and technology 
and when the nation’s economic well-being depends as never before on its 
understanding and utilization, the federal government cannot be complacent 
about the public’s interest and confidence in science. Of course, there will al-
ways be some degree of risk, but as understanding grows the circle of consen-
sus will widen.
A sure prescription for disaster is for each of the many sides of the dis-
cussion to treat the others with contempt. Sincere understanding of the ob-
structions, and a mutual willingness to confront them, is a critical first step 
toward positive conflict resolution.
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F L E X I B I L I T Y  I S  T H E  K E Y
A competitive and profitable agriculture will depend on flexibility—on the 
industry’s ability to respond to, and operate within, an uncertain and rapidly 
changing environment. This means we must learn to view agriculture as a 
system. We cannot be “smart in the parts” and “dumb in the whole.”
Today’s current federal meat inspection scheme is a useful example where 
flexibility and science-driven decisions are presently in short supply. After vis-
iting numerous modern meat processing facilities operating all across 
America, one should recognize that meat hygiene is a complex subject involv-
ing aspects of animal husbandry and physiology as well as food technology 
and microbiology. Growing scientific consensus supports the view that the 
allocation of inspection resources in modern meat and poultry production 
and processing enterprises should reflect a distribution according to risk 
rather than a distribution according to the classical rules of meat inspection 
which rely heavily upon human organoleptic methods of detection (General 
Accounting Office, 1992). Unfortunately, resistance from the inspector’s labor 
union and ongoing concerns within consumer advocacy groups has so far pre-
vented the full implementation of a truly science-based, risk-oriented scheme.
In protecting the public health, a stable and sound regulatory regime is 
essential. However, since the agro-food industries experience rapid break-
throughs in the discovery of new techniques and products, it is important 
to ensure that regulatory systems do not lag behind emerging, proven devel-
opments (Office of Technology Assessment, 1988; Council on Competitive-
ness, 1991).
The key to improved competitiveness will lie in a relatively more flexible 
industrial structure and social organization capable of quickly taking advan-
tage of new technological advances (Office of Technology Assessment, 1991b). 
Further, industry should not rely on the regulatory process as the only mech-
anism to influence public opinion. The biotechnology and food industries 
need to strengthen and promote their own credibility to reduce the burden 
on, and necessity of, the review and inspection processes.
T H E  I N T E R N A T I O N A L  D I M E N S I O N
Biotechnology knows no international boundaries. A number of nations have 
targeted biotechnology as being critical for future economic growth—giving 
rise to several nationally based research and development programs (Office 
of Technology Assessment, 1991a). As a result, agricultural systems through-
out the world continue to adopt new and advanced technologies that enable 
them to become more efficient and competitive in developing new markets 
and capturing old markets for their agricultural products (National Research 
Council, 1987). The Japanese government, in particular, has organized re-
search consortia among companies, has sponsored research into biotechnol-
ogy by industry, and has greatly enlarged its overall funding of biotechnology
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research (Yuan and Dibner, 1990). Consequently, the speed in which innova-
tions are adapted to commercial purposes is a critical factor in achieving and 
maintaining America’s own international competitiveness.
In many critical, high-technology sectors such as biotechnology, Ameri-
can firms are facing competitors whose business risks are shared by their gov-
ernments (Office of Technology Assessment, 1991b). The U.S. approach to 
promoting particular industries has been one of refrain and “hands-off,” the 
underlying belief being that the national economic interest is best served by 
free and fair competition in the marketplace—at home and abroad. Does this 
approach still make sense in a world where governments in most advanced in-
dustrial nations, including those of our most able competitors, are cooperat-
ing with private business to promote critically important industries? Main-
taining the productivity and competitiveness of U.S. agriculture in the public 
interest requires a proper balance between public and private sector support 
for technological change. To move agriculture toward new market opportu-
nities, government must not only support worthy research endeavors, it must 
also be a partner with industry in moving promising ideas and applications 
from the lab to the farm (National Research Council, 1989). Further, in such 
a research-intensive industry, the need to protect innovation is crucial. Many 
researchers and industry leaders cite protection of intellectual property as 
being of paramount importance to preserving competitiveness in biotech-
nology (Office of Technology Assessment, 1991a).
Patenting, licensing and regulatory issues are all areas that affect the rate 
and cost of technology transfer. They play necessary roles in advancing tech-
nology transfer and facilitating the commercialization of research results, es-
pecially in capital-intensive fields such as biotechnology. Consequently, ef-
forts should be continued to harmonize and improve intellectual property 
protection procedures throughout the world (Office of Technology Assess-
ment, 1989; Council on Competitiveness, 1991).
M A R K E T  S T R A T E G Y  E S S E N T I A L S
Will the United States retain its preeminence in biotechnology or will prod-
ucts and services derived from biotechnology be more successfully commer-
cialized in other nations? Acceptance of a new agricultural product seems 
deceptively simple. Our most superficial experiences tell us that good ideas 
should work and fittingly render a tidy profit to the innovator. However, all 
too often the marketing mechanism employed is not marketing pull, but 
technological push (Herbig and Day, 1992). Marketers often presume that 
since the technology exists and an innovation has been created, its diffusion 
is inevitable—a fait accompli. As we have seen in the past, successful innova-
tions are often those which pay more attention to market demand than to 
technological opportunity.
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A product or service must be relevant, have demonstrated value and 
meet specific needs in order to prosper. Therefore, the ultimate objective of 
any commercial research and development program should be to secure a 
better match between the production of resources and their utilization by in-
dustry and consumers. As eluded to earlier, public reaction will be vital in 
determining overall market impacts of animal biotechnology. Consequently, 
greater effort must be focused toward cost-reducing and environmentally 
friendly innovations. While there are many promising applications of bio-
technology on the horizon, biotechnology is neither a panacea nor a com-
plete replacement for established tools. It provides an additional approach to 
agricultural problems.
Recent studies have shown, among other things, that emerging products 
of biotechnology will require considerable management expertise on the part 
of producers (National Research Council, 1990; Office of Technology Assess-
ment, 199Id; Van der Wal et al., 1991). As with many other technological ad-
vances, the farmers that will benefit most will be the more efficient managers 
and early adopters. Furthermore, price support programs, marketing orders, 
grading systems and regulatory mechanisms will all need to adapt to 
tomorrow’s dynamic production systems.
L O O K I N G  T O  T H E  F U T U R E
Leadership in technology development and utilization is the role the U.S. 
has, can, and seeks to assert for the rest of the world. As noted earlier, the 
U.S. federal investment in biological research of the past 30 years has laid the 
foundation for a strong biotechnology enterprise. Because the field is moving 
rapidly, historical leadership does not ensure continued superiority (Federal 
Coordinating Council for Science, Engineering, and Technology, 1992).
Looking toward the future, what elements could present a positive sum 
strategy for animal biotechnology in the 1990s? What will be the challenges 
that influence animal agriculture in the years to come?
First of all, a sound national strategy for biotechnology in agriculture 
must focus on solving pivotal scientific and agricultural problems, effectively 
utilizing the funds and institutional structures available to support research, 
training researchers in advanced scientific areas, and efficiently transferring 
technology (National Research Council, 1987). Both industry and govern-
ment have appropriate roles to play in this process (Council on Competitive-
ness, 1991). There is a need to construct institutional infrastructures that fa-
cilitate more effective collaboration among animal scientists, engineers, 
agronomists and health scientists to deal with issues of production, environ-
mental change and the health of producers and consumers (Ruttan, 1991).
The Cooperative Extension Service and educational institutions must 
keep pace with ongoing change to be relevant to the future competitiveness 
and profitability of American agriculture. Producers of the future will need,
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and desire, a new menu of technologies that recognize contemporary goals 
such as enhanced profitability, increased environmental stewardship, rural 
revitalization and development, and global competitiveness (National Re-
search Council, 1987). Further, there is a need to increase the involvement of 
farmers, researchers and allied industry in developmental partnerships. 
These challenges will demand a correspondingly higher level of vision and 
sophistication on the part of government policymakers, regulators and in-
dustry leaders.
Crucial to all the various points discussed previously is the effectiveness 
of our world trading system. A global approach to the regulation and accept-
ability aspects of biotechnology is worth pursuing in order to create an im-
proved atmosphere of mutual confidence between producers, manufacturers 
and consumers. Moreover, the removal of nontariff trade barriers between 
the world’s trading partners and the development of a common reference 
point is of vital importance while at the same time providing the flexibility to 
accommodate unforeseen and justifiably unique national considerations.
C O N C L U S I O N S
World agriculture stands at the threshold of new scientific and technical de-
velopments in animal science, biology, chemistry, genetics, agricultural engi-
neering, information technology and many other fields. In most of the world, 
the transition from a resource-based to a science-based system of agriculture 
is occurring within a single century (Ruttan, 1991).
Emerging technologies, industry economics and public policy will play 
critical roles in shaping U.S. animal agriculture in the decade of the 1990s. 
Advances in health maintenance, reproduction efficiency and information 
technology will all affect the industry. Additional research is needed to gain 
an increased understanding of the factors influencing animal growth, envi-
ronmental adaptation and well-being, and disease resistance (National Re-
search Council, 1989).
Legislative and regulatory activities that occur in Washington are having 
a greater effect on animal agriculture each year. A simple statement of need is 
no longer enough to justify the allocation of funds for new programs, new fa-
cilities or new research efforts (Waggoner et al., 1989). Consultancies, affili-
ate programs, consortia, research parks and other forms of partnership be-
tween the public and private sectors that foster communication and technol-
ogy transfer should be promoted (National Research Council, 1987).
Certainly, we must not overlook or push aside the legitimate concerns of 
the public and work to establish those principles which govern the safe envi-
ronmental use of emerging products. In such a fast-moving technological 
environment, it will be necessary to regularly review the appropriateness of 
the scientific basis of existing regulation and to make any required adjust-
ments in either the technology or the statutory framework.
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There are, of course, numerous scientific and technological bottlenecks 
and data gaps that still have to be overcome, as can be expected of a technol-
ogy that has been expanding so swiftly and in so many directions. Granted, 
the outcome of the best science can be unpredictable. The obstacles to craft-
ing an effective strategy to support competitiveness in animal biotechnology 
are formidable. However, the potential payoffs are abounding.
The genius that has driven America’s prosperity throughout its history 
has been the ability to combine collective vision with diversity and individu-
alism—to unite grand ideals with arduous pragmatism. As U.S. agriculture 
enters the 21st century, this genius will be put to its most strident test.
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Animal Biotechnologies:
Potential Impact on Animal Products 
and Their Production
Biotechnologies being developed for use in animal agriculture include the commonly practiced technologies of artificial insemination and embryo 
transfer, as well as the developing technologies associated with in vitro produc-
tion of embryos, the splitting and cloning of embryos, marker-assisted selection 
including sexing of the embryo, and the transfer of new genes into an embryo. 
Each technology should be considered separately when assessing the benefits and 
risks of each to animals and humans because each is distinctly different and only 
one, gene transfer, involves recombinant DNA technology.
Genetic improvement of farm animals by traditional parent selection has 
been slow, especially for traits of low heritability. Nevertheless, the rate of in-
crease in milk production has been greatly accelerated by artificial insemination 
of cows with semen from highly-selected, performance-tested bulls. In a limited 
way, the valuable genetics of a few very high production cows has been extended 
several-fold by the use of superovulation and embryo transfer. Conventional 
mating, artificial insemination and embryo transfer all have the disadvantage of 
propagating undesirable genes of a high-performance male or female along with 
the selected genes. Exciting new developments in animal biotechnology offer 
hope for modeling and designing animals to fit market and environmental needs 
and for rapidly propagating or identifying the animals of superior performance. 
This review will focus on each of these biotechnologies, their development status, 
use or potential use in animal agriculture, benefits and risks to the consumer of 
animal products and risks to animals.
A R T I F I C I A L  I N S E M I N A T I O N
Use of artificial insemination developed rapidly in dairy cattle beginning in 
the late 1940s and 1950s when it was realized that bull sperm could be stored 
frozen and that 2-4 ejaculates per week from a bull could provide sufficient 
sperm after frozen storage to inseminate at least 2,000 cows. This allowed ex-
treme selection of the sires, resulting in a more than two-fold increase in ge-
netic ability for milk production of dairy cows. At present the pregnancy
rates are 60-65 percent and most dairy cows are mated by artificial insemina-
tion (70 percent U.S., greater than 90 percent Europe). While this technology 
has been developed for use in other domestic animals, the cost-benefit ratio 
has been favorable in the U.S. only for wide-scale use in dairy cattle or use by 
breeders at the top of the breeding stock pyramid for beef cattle, sheep and 
swine. It is a common practice in poultry breeding. The benefit to consumers 
has been low cost and availability of dairy products of high quality. The risks 
to the animals are essentially none. While it is sometimes argued that high 
milk production could reduce cow longevity, older cows declining in milk 
production are usually slaughtered for meat before becoming aged. For re-
view of artificial insemination see Hafez, 1987.
EMBRYO TRANSFER
Embryo transfer (Figure 1) is being used primarily in dairy cattle and the top 
seedstock herds of beef cattle. It has the advantage of genetic improvement 
through both sire and dam rather than the sire alone, as with artificial in -
semination. There are approximately 250,000 calves born annually in the 
U.S. from embryo transfer. Its use has been limited because the technology of 
superovulation and embryo transfer has allowed only 20-30 calves per year 
from a cow and because it is more expensive than artificial insemination.
FIGURE 1
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Application of Biotechnology to Beef 
Production
F I G U R E  2
One commercial use for ‘in vitro’ production of embryos is illustrated above (Schaefer el al., un-
published). This breeding plan is used to eliminate maintenance of a beef brood cow. Other uses 
when oocytes are recovered by transvaginal laparoscopy from valuable cows include the produc-
tion of large numbers of offspring from a valuable cow, or old or incapacitated cows.
Embryos can, and are, being frozen, and in a few cases sexed or split to 
double the number of embryos. Procedures for superovulation and embryo 
transfer are nonsurgical and present little risk to the cow donating the em-
bryo or the recipient receiving it and cows can be successfully superovulated 
or bred at the second estrus cycle after superovulation. The animal risk is low 
and the benefit to consumers is manifest as more abundant, lower cost, 
higher quality milk and meat products. For review of embryo transfer see 
First, 1991; Seidel, 1991; and Wilmut et al., 1992. Artificial insemination and 
especially embryo transfer are the delivery mechanisms by which the new re-
productive and genetic biotechnologies now under development will be de-
livered to animals for propagation.
IN VITRO P R O D U C T I O N  O F  E M B R Y O S
In vitro production of embryos depends on efficient systems for culture of 
oocytes and sperm, fertilization and embryo culture. This technology is be-
ing developed for all food-producing animals and is presently best developed 
for cattle where it is beginning to be applied. Parts of this technology are es-
sential for cloning of embryos and for gene transfer. Several breeding compa-
nies are applying this technology commercially. Its application has been in 
two forms. In field trials in the U.S., Japan and Great Britain, embryos are 
produced in vitro from abattoir-recovered oocytes of selected breeds that are 
fertilized with semen of highly selected bulls. This is done with the objective
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to replace the brood cow in beef production with in vitro produced embryos 
(Schaefer et al., unpublished) as shown in Figure 2. Each group has used this 
approach for a different genetic purpose. The application in Japan is to use, 
for both reproduction and valuable beef, the young Wagyu females that pro-
duce expensive Kobi beef. In Britain, the use is to produce valuable beef from 
dairy cows; while the use in the U.S. is to produce both embryo transfer re-
cipient females and beef from young females derived from in vitro produc-
tion of embryos, as shown in Figure 2 (Schaefer et al., unpublished). Cattle 
oocytes can also be recovered from follicles matured in vivo by recovery using 
ultrasound-guided vaginal laparoscopy. Recovery of these oocytes from ge-
netically valuable cows provides a supply of oocytes of high genetic value for 
use in gene transfer and production of oocytes and embryos for cloning. Re-
cent estimates indicate that one genetically valuable cow could produce 10 
oocytes every 2-3 days throughout the year (Krimpenfort et al., 1991; Van 
der Schans et al., 1991) or approximately 100 calves per year, a big increase 
from that achieved by superovulation. Several embryo transfer companies 
are preparing to offer this in vitro embryo production service. The major 
challenge to researchers is to harvest and mature the thousands of growing 
oocytes and small follicles of domestic species. This would further increase 
the pool of oocytes available from genetically valuable animals. Application 
of this technique to fetal ovaries would allow rapid genetic progress through 
marker-assisted selection and velogenesis (Georges, 1991). The second part 
of producing embryos in vitro is the sperm capacitation and fertilization sys-
tem. In general, any agent that causes Ca+* entry into the sperm acrosome 
and a pH increase within the sperm causes capacitation. Numerous capacita-
tion systems have been developed including high ionic strength media, gly- 
cosaminoglycans (such as heparin), aging, pH shift, calcium ionophores, caf-
feine and oviduct fluid. With appropriate sperm capacitation and incubation 
in serum-free medium at body temperature, in vitro fertilization rates have 
been reported as high as 70-80 percent in cattle, sheep, swine and goats 
(Parrish, 1990; First, 1991). Embryos of domestic animals can be successfully 
cultured in surrogate oocytes of rabbits and sheep or cultured with oviduct 
cells or oviduct cell conditioned media and recently successfully cultured in a 
defined media (Rosenkrans and First, 1990; First, 1991). While investigators 
are still searching for uterine factors and growth factors that may further in-
crease the survival and development of cultured embryos, present methods 
are satisfactory for commercial use. The in vitro production of embryos as 
now practiced presents several benefits to society other than a lower-cost, 
more-abundant food product. This technology is economical to the environ-
ment and food supply as it eliminates beef brood cows. It permits use of ga-
metes, cells and embryos in research rather than use of animals. To the live-
stock producer it could allow cost-effective genetic improvement. The risks 
are minimal when oocytes are recovered transvaginally and none when they 
are recovered as an abattoir by-product. Pregnancy rates are approximately
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Donor embryos are obtained by flushing the uterus ofa genetically superior cow after superovu-
lation and insemination with sperm from a genetically superior bull. Each cell of each 30 to 60 
cell stage embryo is transferred into an enucleated oocyte. The embryos produced by this process 
can be used to supply donor cells to further increase the number of cloned embryos by recloning.
60 percent and offspring are normal (Monson et al., 1992). For a review of 
this technology, see Leibfried-Rutledge el al., 1989; Gordon and Lu, 1990; 
First, 1991; Flansel and Godke, 1992. These same methods for in vitro pro-
duction of embryos are also beginning to be used to propagate zoo animals 
and to save endangered species (Wildt et al., 1992).
C L O N I N G  O F  D O M E S T I C  A N I M A L S
Twins are presently being produced with good efficiency by bisection of em-
bryos and a few cells left on the bisection knife have been used to sex the bi-
sected embryos. The most promising method for production of large num-
bers of offspring is nuclear transplantation. This procedure has successfully 
produced viable embryos and offspring in cattle, sheep, rabbits and swine. 
The procedure (Figure 3) involves transfer of a blastomere or nucleus from 
the valuable embryo at a multicellular stage (usually 20-120 or more cells) 
into an enucleated metaphase II oocyte. The oocyte then develops to a multi-
cellular stage and is used as a donor in a serial recloning (First and Prather, 
1991; Stice, 1992). Nuclear transplantation is being developed in private in-
dustry as well as by university research. Thus far, nuclear transplantation in 
cattle has been successfully performed using low-cost, in vitro matured oocytes 
from abattoir-recovered ovaries and with serial nuclear transfers. However, 
the efficiency is less than desired with approximately 20-25 percent of the 
nuclear transplantations resulting in transferable embryos and approximately
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30 percent of the embryos transferred into the cows resulting in completed 
pregnancies. Throughout the U.S. and Canada, several hundred pregnancies 
have been produced in cattle by this procedure and recloning has been per-
formed. To date, the largest number of calves cloned from one embryo has 
been 11 calves born at Granada Genetics in 1990 (First and Prather, 1991). 
The keys to a successful cloning system for a livestock industry are the ability 
to use donor embryos of larger cell numbers to produce many offspring and 
the capacity to use cells from cloned embryos as the donor nuclei for another 
generation of clones. In sheep embryos, the frequency of development to 
blastocysts after use of donor cells from the blastocyst inner cell mass was 57 
percent and pregnancies resulted. In rabbits, blastocysts have been produced 
from inner cell mass cells but at a lower frequency than from the 32-cell 
morula stage blastomeres. In cattle, embryos at the stages of morula or the 
inner cell mass of blastocysts have produced good results as donors in clon-
ing. This is approximately the stage where embryonic stem cells can be recov-
ered and multiplied in culture in a mouse. If similar stem cell isolation and 
multiplication were done in domestic animals and if stem cells should prove 
useful in cloning by nuclear transplantation, the number of possible clones is 
unlimited (First, 1991). When developed to high efficiency, cloning provides 
a nearly phenotypic selection and propagation system for replicating valu-
able animals. For example, traits with heritabilities of approximately 30 per-
cent are expected to increase to nearly 70 percent. It will also be used for 
rapid propagation of precious transgenic animals. The benefits of nuclear 
transfer include a nearly phenotypic selection, accelerated genetic improve-
ment or environmental adaptation and characterized and predictable pro-
duction performance, nutrient requirements, disease resistance and exten-
sive screening of clonal lines for genetic defects, disease resistance and envi-
ronmental adaptation before multiplication and release for use. The risks are 
low to none for the animals supplying donor embryo cells or the recipient 
oocytes, but the process at the present state of the art results in less than nor-
mal embryo survival before embryo transfer and less than normal pregnancy 
rates and calving rates. Also, some of the calves are born larger than normal 
and require assisted delivery. It is expected that with time and continued re-
search these problems will be understood and corrected. For reviews of clon-
ing of domestic animals, see First and Prather, 1991; Bondioli, 1992; Prather 
et al., 1992; and Seidel, 1992.
G E N E  T R A N S F E R
Successful production of transgenic food-producing animals requires the 
ability to efficiently achieve development of the transgenic embryo and ge-
nome integration of the transgene. Precise genetic modeling and appropriate 
promoter sequences to achieve expression at a high level in a tissue of choice 
and of the trait desired are necessary. Transgenic cattle, sheep, swine and rab-
bits have been made by microinjection of DNA into a pronucleus of a one-
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Microinjection of concentrated DNA (a gene) into a pronucleus of a bovine egg. Note the egg is 
first centrifuged to concentrate the cytoplasm against one side such that the pronuclei can be visualized 
in the cleared area.
cell zygote (Figure 4), transgenic fish by injection of DNA into oocytes and 
chickens by infection of genes into eggs (Hansel and Weir, 1990; First and 
Haseltine, 1991; Rexroad, 1992). Principle genes introduced into fish have 
been growth hormone genes resulting in production of fish that grow 2-3 
times faster than normal. Genes imparting cold resistance to warm water 
species have also been expressed by transgenic fish. Transgenic chickens have 
been made which express increased growth from a growth hormone 
transgene and increased viral resistance from interference with cell receptors 
for avian viruses. Cattle, sheep and swine have been made transgenic for 
various growth hormones without significant increases in growth, but with 
decreased fat in the carcass. Use of tissue-specific promoter sequences and 
appropriate promoter control of the level of gene expression should improve 
growth responses. The SKI oncogene is an example of a gene that enhances 
muscle growth in mice and swine. Other genes may be identified that in-
crease muscle tenderness. When appropriate disease resistance genes are 
identified, it should be possible to engineer high-producing animals for sur-
vival in high-disease environments. Genes for expanding the MHC complex 
and globins have been introduced into mice and sheep. Cells of animals have 
been genetically modified to resist the entire herpes family and defective vi-
ruses have been used in chickens to promote receptor resistance to patho-
genic viruses (Hansel and Weir, 1990; First and Haseltine, 1991; Rexroad, 
1992). The ability to target gene expression exclusively to the mammary 
gland will allow modification of milk composition to make novel cheeses, 
remove milk fat, lactose or allergenic proteins and increase protein content. 
Thus far, transgenic mice have been made which express new caseins or no 
milk fat. It is likely that some cows will be designed to produce milk for
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specialty dairy products while most cows may be engineered to produce little 
or no fat in their milk. It is also expected that pharmaceutical products will 
be produced from milk of cows expressing pharmaceutical transgenes in their 
mammary glands. Already transgenic mice, sheep, goats and pigs have been 
produced which expressed either the pharmaceutical proteins of tissue plas-
minogen activator clotting factor 9, alpha-l-antitrypsin, lactoferrin, euro- 
kynase, follicle-stimulating hormone, protein C, human growth hormone or 
interleukin 2 in their milk (First et al., 1991; Rexroad, 1992). Gene transfer 
usually results in one or two transgenic animals forming the beginning of a 
transgenic line. It, therefore, does not initially impact a large part of a popu-
lation and requires artificial insemination, or in vitro production of em-
bryos, or cloning or combinations of the above to produce animals or fish 
which are commercially useful. Gene transfer is most useful for introduction 
of genes not found in a population or deletion of genes not wanted, whereas 
marker-assisted selection is considered to be much more efficient in chang-
ing a population if the gene in question exists in the population. The benefits 
from gene transfer other than increasing the efficiency of animal production 
include the development of animals better fit for specific environments, in-
cluding disease resistance; the production of new animal products and higher 
quality products, for example more digestible milk; removal of allergenic 
compounds from milk; etc. The technique of gene transfer imposes no direct 
animal risk. However, a greater than normal early loss of embryos occurs.
The cost of gene transfer and use of animals can be considerably reduced 
by transfer of genes into in vitro produced embryos (First et al., 1991; 
Krimpenfort et al., 1991). Faulty modeling of the gene and promoter con-
struct can result in insertion of the transgene at an inappropriate site with 
disturbance of expression of another gene or expression in other than the tis-
sue or cell targeted in the modeling of the transgene, or expression at an in-
appropriate time in animal development. In the future, these risks will likely 
be reduced or eliminated by advances in several areas. These include the in-
troduction of DNA into cultured cells that can be sampled and screened for 
appropriate expression before use in nuclear transfer to make embryos for 
transfer into cows. The use of cultured cells to make animals also allows site 
specific gene transfer or deletion through homologous recombination, 
thereby eliminating inappropriate sites of integration. Improved modeling of 
the desired outcome of the transfer gene will occur as gene mapping projects 
provide genome knowledge sufficient to allow accurate modeling of the ge-
nome and the gene construct. Perhaps the greatest challenge will be the de-
velopment of consumer confidence that specific genetically engineered ani-
mals may not be at risk and that engineered products are safe whereas other 
transgenics may be rejected because animals are at risk. For review of gene 
transfer see Rexroad, 1992; First et al., 1991; First and Haseltine, 1991; 
Wilmut et al., 1990; and Hansel and Godke, 1992.
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M A R K E R - A S S I S T E D  S E L E C T I O N
Efforts to map the genomes of domestic animals and similarities with the 
mapped human genome have resulted in DNA markers that are beginning to 
be associated with desired or undesired productivity traits. For example, a 
restriction fragment linked polymorphism (RFLP) in at least one family of 
Holstein cattle has been associated with high milk production. Several artifi-
cial breeding companies now use this DNA marker to select for higher milk 
production. Markers for K-casein that relates to protein content of the milk 
and markers for selection against a neurological defect in Brown Swiss cattle 
are also in use (Georges, 1991). Rapid development of markers for use in 
phenotypic and genetic selection is expected as more of the genome and spe-
cific linkages to production traits are understood. Because the genomes of 
higher mammals are similar and gene mapping efforts across species are co-
ordinated, we are rapidly increasing our knowledge of the genome. The ap-
plied value of gene mapping and genetic markers is primarily through asso-
ciation of markers with productivity, disease resistance and product quality: 
traits of interest. But marker-assisted selection has several other advantages. 
Markers can be used to perform early genetic selection on gametes, embryos 
or newborn animals. Markers can be used for DNA fingerprinting and accu-
rate animal identification or association of product with animal, herd or pro-
cessing plant. Markers are used to screen for genetic defects and when genes 
are introduced from other populations, markers can be used to track their 
segregation in the population. Because marker-assisted selection imposes 
little to no risk to the animals donating blood, sperm, or embryos for assay 
and imposes no risk to the consumer, marker-assisted selection is expected 
in the short term to be the most commonly used of the above animal biotech-
nologies. For review of marker-assisted selection see Dentine, 1992; Georges, 
1991; Fries et al., 1989; and Massey and Georges, 1992. Several other biotech-
nologies impact animal agriculture, but also are expected to impose no risk 
to animal or consumer. These include the use of DNA fingerprinting for di-
agnosis of disease microorganisms, the development of new vaccines using 
recombinant technology and the use of engineered colostrums to protect ani-
mals and humans from disease.
S U M M A R Y
In summary, it is apparent that every biotechnology is different. Each gene 
construct is different and each must be examined for its individual benefits 
and risks. Some biotechnologies reduce the need for animals in research or 
reduce the numbers needed for food production. Some protect the health of 
the animal or make it more fit for a changed environment and some allow for 
the preservation and rapid repopulation of an endangered species. Most im-
portantly, biotechnology is a series of tools to be used intelligently or care-
lessly by humans as a choice of humans. We must choose wisely, but avoid
Biotechnologies
condemnation and rejection of the tool. Like fire, clothing and the wheel, we
may someday need it and be wise enough to use it.
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The New Creation:
An Update on Animal Gene Engineering
here have been several new developments in genetic engineering that
show how this new industry is applying biotechnology in agriculture 
and medicine. How valuable these new developments are—in terms of real 
progress in improving agricultural practices and human health—remains to 
be seen. The following examples clearly reveal that the “New Creation” and 
new world order of the biotechnology industry is far from any utopian dream 
of a world made perfect for humankind. One can read between the lines of 
the new patent applications, news releases and scientific reports concerning 
the latest feats of genetic engineering and glimpse into the future. The won-
der-world of the New Creation is not quite here today, but it may be upon us 
sooner than we expect. A whole new generation of genetically engineered 
(so-called transgenic) animals is on the horizon. These will carry genes taken 
from humans and other species. In the world of trade and commerce, they 
will be regarded as “new” species—unique, patentable commodities of the 
new world order.
T R A N S G E N I C  A N I M A L S
Scientists in the U.S., Japan, Europe and Australia have created a number of 
transgenic animals—pigs, lambs, calves and fish—containing the genes of 
other species like the human and bovine growth hormone genes. Success 
rates of gene insertion are extremely low and the entire process is time con-
suming and costly. Much of the funding in this area of biotechnology comes 
from the public via government tax revenues.
Some researchers have recently opted to put extra growth-regulating 
genes of sheep origin into lambs rather than human genes because they felt 
that “transgenes composed entirely of sheep gene sequences would be more 
acceptable to lay persons, in particular consumers” (Murray and Rexroad, 
1991). However, even though these lambs were leaner, they did not have in-
creased feed efficiency. They were diabetic and had such severe health prob-
lems that they died before reaching puberty. “The cause of death has varied, 
but there are clear data that the over-expression of GH (growth hormone)
adversely affects liver, kidney and cardiac function” (Murray and Rexroad, 
1991).
Merck & Co., the European-based pharmaceutical company, has applied 
for a patent in Europe on its super chicken, or Macro-Chicken (Holden, 
1991). They have developed a line of broiler chickens that carry the growth 
gene of cows with the hopes of cornering the market with a highly feed-effi-
cient, fast-growing bird.
It is likely that Merck’s Macro-Chickens will have a variety of health 
problems too. But if the birds eat well and grow quickly, they will be ready for 
slaughter before severe health problems ever develop. But what of the breed-
ing stock of transgenic chickens that will not be raised for slaughter? Will 
they suffer? Because such information is proprietary, corporations are not 
likely to reveal the limitations and risks of their new patentable creations. 
Trade secrets notwithstanding, the social and economic consequences—to 
farmers, to the practice and structure of agriculture and to consumers—of 
creating transgenic farm animals have been given scant attention.
Critics of the genetic engineering of farm animals question the use of 
public funds to make these animals produce more meat (even if it is lean) 
when the short- and long-term costs of such research are not considered and 
when a major problem of contemporary intensive animal agriculture is over-
production, meat and milk surpluses being a chronic problem. It is unlikely 
that the creation of transgenic farm animals will help feed the hungry world 
since meat production efficiency has built-in limitations and inevitable envi-
ronmental costs (Durning and Brough, 1991; Fox, 1990).
Genetic engineering technology is being used in an attempt to alter 
sheep’s and cows’ milk so that it can be consumed by a large percent of the 
world population that is lactose-intolerant (Mercier, 1987). This may be a 
more fruitful approach to helping feed the hungry, since milk production is 
far more efficient, ecologically sound and cost-effective than meat produc-
tion, with or without biotechnology.
Human genes responsible for the production of proteins in mothers’ 
milk are being inserted into calf embryos with the hope of creating a new 
generation of cows that produce “humanized” milk (Phelps, 1989).
Australian government scientists are using genetic engineering to make 
sheep produce more wool by inserting genes into their developing embryos. 
The sheep’s body chemistry is altered to convert sulfur-bearing compounds 
into methionine, an amino acid that increases wool growth (Ford, 1988). 
Australian scientists are also trying to genetically engineer a hormone that 
can be injected into sheep that will make them shed their fleece, thus cutting 
down costs of shearing. Tests to date have caused pregnant sheep to abort 
(Scherer, 1992; New Scientist, 1992). They also plan to genetically engineer 
sheep that secrete insect repellent from their hair follicles to ward off blow-
flies. Blowflies cost the sheep industry $85 million per year in losses. As a 
spinoff, the sheep will also have the world’s first moth-proof wool.
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It should be emphasized that most genetic engineering research in farm 
animals has focused on increasing productivity, while research on increasing 
resistance to disease through genetic engineering (Slater, 1990; Kraemer and 
Templeton, 1990) is still very much in its infancy. This latter area of research 
should be questioned since improvements in farm animal husbandry are 
surely more cost-effective ways of improving animal health and well-being.
T R A N S G E N I C  “ M O L E C U L A R  P H A R M I N G ”
Human genes are being inserted into farm animals so that they produce vari-
ous pharmaceutical products in their milk, such as blood clotting factors and 
other substances of possible medical application (Clark et al., 1987; Watts, 
1990; Schanbacher, 1990; Bialy, 1991). Harvey Bialy, editor of Bio/Technology, 
has extolled the virtues of what he terms “molecular pharming technologies,” 
as exemplified by research teams from the UK, U.S. and The Netherlands, 
who have produced transgenic sheep whose milk contains human alpha-1- 
antitrypsin, transgenic goats that secrete tPA into their milk and the first 
transgenic dairy cattle. “Taken together,” he writes, “their results provide a 
convincing demonstration of the feasibility of using animals as commercial 
bioreactors” (Bialy, 1991). It will be many years before these new animal cre-
ations provide any medical benefits to humans, but venture capitalists are in-
vesting in this speculative line of research and development. Recently, a bio-
technology company, DNX Inc., of Princeton, New Jersey, reported that it has 
developed a line of transgenic pigs that produce human hemoglobin. But they 
are still a long way from having hog farmers raise pigs to be human blood do-
nors (Moffat, 1991a).
O T H E R  I N N O V A T I O N S
Other developments in farm animal biotechnology (which do not entail gene 
transfer) that can have profound social and economic ramifications include 
the development of cow clones (Schmickly, 1991) and a technique to preselect 
the sex of offspring (Federal Register, January 10, 1991). Scientists are baffled 
over the fact that some 25 percent of calves produced by cloning are almost 
twice the normal size at the time of birth and must therefore be delivered by 
Caesarian section.
While no plant genes have been inserted into animals, animal genes have 
been successfully incorporated into the genetic structure of various plants. 
Tobacco plants have been successfully implanted to produce functional hu-
man antibodies, which may be used for diagnosing and treating human dis-
eases. The “antifreeze” gene of the flounder that produces a protein to stop the 
fish from freezing, has been cloned and inserted into tomatoes and tobacco; crops 
may be protected from frost in the future by fish genes (Moffat, 1991b).
Since fish farming is on the increase, biotechnologists have been busy de-
veloping “superfish,” by inserting growth hormone genes from humans, 
cattle, chickens, mice and other fish into a variety of commercially raised fish,
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such as carp, rainbow trout, catfish, Atlantic salmon, walleye and northern 
pike. The antifreeze gene of the winter flounder is also being inserted into 
other fish species to expand commercial fish production in cold regions and 
seasons (New York Times, November 27, 1990; Manci, 1989; Biotechnology 
and Development Monitor, 1991; Fischetti, 1991).
A biotechnologist at the Army Research Laboratory in Natick, Massa-
chusetts, has cloned the silk-producing gene of the Golden Orb weaver spi-
der and spliced it into bacteria that in turn produce large quantities of spider 
silk protein. Stronger than silkworm silk and even steel, this new product 
may have wide commercial use, especially to develop new fabric for bullet 
proof vests, helmets, parachute cords and other strong, light equipment 
(AP news release,.February 27,1990).
On the brave new world frontier of medicine, scientists have created a 
variety of transgenic mice. Some thirty or more strains of mice have been 
created that develop various kinds of cancers that affect the mammary 
glands, pancreas, liver, stomach, bones, brain, eyes and kidneys (Adams and 
Cory, 1992). Another line of mice have been created that carry human genes 
that result in deformed red blood cells, providing a new model for sickle-cell 
anemia (Genetic Engineering News, June, 1991), and a line of rats have been 
developed that carry the defective human gene HLA-B27 that causes a pain-
fully crippling form of arthritis (Fackelmann, 1990). The clinical relevance of 
these new creations has yet to be demonstrated. Making them transgenic pro-
vides no foreseeable benefit to the animals themselves, except perhaps for en-
dangered and genetically “fragile” or defective species, like the cheetah and 
South American maned wolf.
Research is continuing on the identification of genes responsible for 
various inherited diseases, especially in purebred dogs and livestock and on 
genes that play a role in development, growth, milk and egg production, dis-
ease resistance and other physiological processes. The results of such costly 
research may eventually be of benefit to animals in terms of their health and 
overall well-being. But the benefits will be limited if this approach becomes 
overly reductionistic and utilitarian and is not integrated with a more holis-
tic, if not traditional, approach to improving animal health and well-being. 
And especially if it is focused primarily on enhancing the exploitative value 
of animals.
The human genome is being sequenced and genetic defects and strengths 
identified. Next will be the cow, the pig and the dog. All to what end? New 
medical and veterinary products and services will certainly result, including 
varieties of more productive and disease-resistant livestock. But genetic de-
terminism can lead ultimately to eugenics. And eugenics means genetic im-
perialism and a new world order for a New Creation. Do we really want or 
need a Creation made over into a human image of perfect utility?
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N E W  A N I M A L  D R U G S
One potential benefit of biotechnology to animals is in the development of 
genetically engineered vaccines (including birth-control vaccines), hormones, 
immune system enhancers and diagnostic and screening tests. However, this 
new generation of veterinary products and services may be a mixed blessing. 
It is not without potentially adverse animal health, socioeconomic and eco-
logical consequences-as with BST or bovine growth hormone (Wheale and 
McNally, 1990; Gendel, 1990). Many of these products are no substitute for 
humane animal husbandry, sound breeding and good nutrition. There is also 
some evidence that genetically engineered, modified live virus vaccines may 
play a role in the development of autoimmune diseases, especially in pure-
bred dogs (Dodds, 1990).
P U B L I C  A T T I T U D E S
While private industry and government-funded research centers push for-
ward to create genetically engineered animals that may prove profitable 
to agribusiness and the medical-industrial complex, the public’s attitude 
toward such developments is noteworthy. In a recent poll across Europe:
fewer than half thought biotechnological research on farm 
animals “to make them resistant to disease, or grow faster” 
should be encouraged. A third thought, applying biotechnology 
to animals “to develop life-saving drugs or study human dis-
eases” was morally acceptable, “provided the animals’ wel-
fare is safeguarded,” but 20 percent said it was morally wrong 
and 27 percent said government should decide each case. Only 
13percent thought such work justified“some animal suffering” 
(Mackenzie, 1991).
A national survey in Japan revealed that 67 percent of people polled were 
opposed to research that could lead to new forms of plant or animal life 
(Holden, 1988). Opinion polls in the U.S. show that in 1985, 34 percent of 
the attentive (informed) public wished to prohibit the creation of new forms 
of animal and plant life (Feinstein and Miller, 1991). A recent survey in The 
Netherlands finds that consumers “are very unhappy about eating meat from 
genetically engineered animals. They are either afraid it will harm them or 
worried about it on ethical grounds” (Coghan, 1991).
A N I M A L  P A T E N T I N G
The controversy over the patenting of genetically engineered animals began 
after the U.S. Patent and Trademark Office ruled on April 7, 1987, that such 
animals, provided they were nonnaturally occurring “manufactures” and 
“compositions of matter” could be included under Section 101 of the Patent
The New Creation
Act as patentable subject matter. The patenting of animals was vigorously 
opposed by The Humane Society of the United States (HSUS) and a coalition 
of concerned organizations. On August 5, 1987, Representative Charles Rose 
introduced legislation (HR 3119) to impose a moratorium on the patenting 
of animals so that the potential adverse implications of such patenting could 
be carefully studied. And on February 29, 1988, Senator Mark Hatfield intro-
duced moratorium bill S 2111 in the Senate. But on April 13,1988, the U.S. 
Patent Office and Trademark Office issued Patent Number 4,736,866 on 
Harvard University’s, DuPont Chemical Co. funded, new creation—the 
“Onco Mouse,” a genetically engineered, cancer-prone mouse (Hubbard and 
Krimsky, 1991).
Since this time, there have been no further animal patents awarded, even 
though the U.S. government and U.S.-based multinational corporations have 
been pushing for changes in European patent law that currently prohibits the 
patenting of animals (Watts, 1991); and even though the State Department 
effectively squashed the Rose and Hatfield bills on the grounds that they 
would weaken U.S. economic competitiveness in the world marketplace.
Some 145 patent applications are now awaiting approval at the U.S. 
Patent and Trademark Office. Approximately 80 percent of these have medi-
cal utility while the remainder involve agricultural animals (Congressional 
Record-Senate, June 13, 1991). One explanation for the fact that no new ani-
mal patents have been awarded is that there is as yet no clear regulatory 
structure set up for the commercial marketing of transgenic animals 
(Charles, 1991; Fox, 1991).
A new bill was introduced in the Senate (S 1291) by Senator Hatfield on 
June 13,1991, to impose a 5-year moratorium on the granting of patents on 
invertebrate and vertebrate animals including those that have been geneti-
cally engineered. HSUS supported this bill with the following statement pub-
lished in the Congressional Record on that day;
In order for society to reap the full benefits of advances in 
genetic engineering biotechnology, the social, economic, 
environmental and ethical ramifications and consequences 
of such advances need to be fully assessed. Considering the 
rapid pace of developments in this field, which will be spurred 
on by the granting of patents on genetically altered animals, 
a 5-year moratorium on the granting of such patents is a wise 
and necessary decision. A moratorium will enable Congress 
to fully assess, consider and respond to the economic, envi-
ronmental and ethical issues raised by the patenting of such 
animals and in the process, establish the United States as the 
world leader in the safe, appropriate and ethical applications 
of genetic engineering biotechnology for the benefit of so-
ciety and for generations to come (pp. 7818-19).
It is very likely that the Council on Competitiveness, chaired by Vice Presi-
dent Dan Quayle, will attempt to block this bill. This same Council has been
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actively working to deregulate the entire biotechnology industry. Its pro-
posed administrative and regulatory guidelines for the Environmental Pro-
tection Agency and U.S. Department of Agriculture are such that the risks 
and costs of new biotechnologies—socially, economically, environmentally 
and in terms of animal-welfare—will be virtually ignored (Charles, 1991;
Fox, 1991).
Clearly, while the genetic engineering of animals is not likely to be 
stopped, increasing public awareness and censure of the biotechnology in-
dustry and its political allies is essential. A 5-year moratorium on the patent-
ing of “new” animal creations would be prudent and timely, especially since 
we are moving into a new world order of free trade, which should be condi-
tional upon effective international regulations and the adoption of the most 
stringent controls and regulations over biotechnology by all nations. Other-
wise, the privatization of the world’s resources and of the genetic material of 
life itself, coupled with the misapplication of genetic engineering biotechnol-
ogy in agriculture and medicine, will be against the public interest and the 
good of generations to come.
C O N C L U S I O N
There are several interrelated dimensions to fully evaluating the costs and 
consequences, risk and benefits of new developments in science, technology 
and industry, especially in genetic engineering biotechnology; and of the pat-
enting of both processes and products. These dimensions are as follows: 
ethical and religious, legal and political, social and economic, environmental 
and cultural. Generally these dimensions of concern, constraint and direc-
tion have been virtually ignored by policy-makers and even seen as obstacles 
to economic growth and industrial expansion. As a consequence, the gap has 
widened between private (corporate) and public interests. We are witness to 
a widening of this gap with the rise of a global industrial biotechnocracy, the 
costs and consequences, risks and benefits of which need to be rigorously 
evaluated. To voice such concern should not be misjudged as anti-science, 
anti-progress. Rather, it should be recognized that with greater involvement 
of an informed public in the policy decision-making process, advances in 
science and technology and in biotechnology in particular, will be more 
likely to serve the public good and to help enhance the quality of life and en-
vironment alike. Current attempts by the U.S. government to deregulate the 
biotechnology industry (Phelps, 1991) and by the EEC’s Commission on Bio-
technology to eliminate socio-economic considerations in the licensing of 
new animal drugs (Phelps, 1991) support the conclusion that the direction 
being taken by the biotechnocracy of the industrialized world is neither prudent 
nor appropriate.
Some proponents of genetic engineering feel “more comfortable” (from 
a not fully articulated moral/ethical perspective) with the patenting of the 
techniques of biotechnology, rather than with its products, including transgenic
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animals. However, the unconditional acceptance of creating transgenic ani-
mals for any and all purposes (from the perspective that it is not a moral/ 
ethical issue to create such animals) is as unreasonable as the unrealistic abo-
litionist position that would prohibit all such research and development 
(because it is immoral/unethical).
Our power over the genes of life is a recent acquisition, as significant a 
notch in human evolution as the discovery of pyrotechnology and atomic en-
ergy. But this power does not give U.S. the absolute right to transform ani-
mals to further satisfy our myriad needs and wants. Rather, it places U.S. on a 
critical threshold of moral/ethical choice and responsibility. This means that 
we must choose wisely and compassionately, case by case. We must not forget 
the history of science, technology and industry. In the past, we have made 
many wrong choices for selfish reasons, the consequences of which have been 
as harmful to our own kind as to the rest of Creation, especially to the animal 
kingdom and to the natural biodiversity of our fragile planetary ecosystem.
A D D E N D U M
First Creation-First:
Protecting the First Creation from Further 
Desecration and Transformation
The kinds of plants and animals that are being genetically engineered for agriculture (along with a host of other agribiotechnology products) are 
primarily those kinds that are being designed for adoption by conventional 
agriculture. Their adoption and incorporation into our food production sys-
tem should be contingent upon them quickly helping make industrial agri-
culture humane and sustainable.
The appropriate use of agribiotechnologies in ecological farming, in ho-
listic resource management and in the development of alternative, socially 
just agriculture is possible and attainable. It should not be used as another 
technological fix to compensate for the effects of agricultural degradation, 
but at the same time aggravate that degradation, necessitating even more 
costly “fixes.” It is surely absurd to use this technology to boost productivity 
of agricultural commodities that are already in oversupply, like milk.
Genetically engineered bovine growth hormone (BGH)—which is an af-
front to the science and ethics of good dairy cow husbandry—is the first 
product that the biotechnology industry has yet to recognize as their own 
Ford Edsel: And selling it to good dairy farmers is like convincing Eskimos 
that they need refrigerators.
Increased dependence upon biotechnology will put us on the treadmill 
of economic competitiveness accelerating the transformation of life into 
profitable commodities, with the emergence of genetic imperialism and an
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increasingly p arasitic relationship with the rest of Earth’s creation, as exem-
plified by turning farm animals into bioreactors to produce pharmaceuticals.
Another example of gross misapplication of biotechnology would be to 
develop a vaccine to make African cattle resistant to Trypanosomiasis rather 
than using this new technology to increase overall herd health and productiv-
ity and indirectly reduce herd size. Such a vaccine would lead to an expansion 
of livestock into wildlife areas (where wild animals possess natural immu-
nity) and will mean the end of the wild.
While the benefits to animals of making them transgenic are unclear, 
there are clear benefits of other biotechnologies to enhancing their overall 
well-being. These include: rapid identification and elimination of genetic 
diseases; increased disease resistance; protection of endangered species; hu-
mane population control of feral and wild species; preservation of genetic di-
versity; selecting farm animals better adapted to traditional, and alternative, 
humane husbandry systems; increased efficiency/productivity of farm ani-
mals, which will mean fewer animals, more efficient resource utilization and 
more land being freed up for wildlife habitat recovery.
Appropriate uses of biotechnology in animals should follow the “3R’s” of 
refinement, reduction and replacement in the utilization of animals by society 
today. We need to not only decrease the suffering and enhance the well-being 
of animals utilized by society today, we also need to decrease and not increase 
our dependence upon them for a host of reasons—economical, ethical, envi-
ronmental, etc. For detailed discussion see Fox, 1992.
Gene mapping and marker-assisted selection to identify useful genes in 
cattle, hogs and poultry should not be focused primarily on making these 
animals more productive under conventional husbandry conditions. Over-
production is a chronic and unacceptable problem, lowering farmers’ profits 
and forcing them to get bigger or get out. Better to seek genes that will help 
livestock and poultry be healthier and better adapted to more ecologically 
sound farming practices, like rotational grazing of dairy cows and pasture 
feeding of hogs and helping the livestock population in the Third World cease 
to expand and to become healthier and more productive. Better still, per-
haps, to conserve and propagate rare breeds for such purposes than to create 
patented transgenic animals derived from narrow utility stock genetically se-
lected for generations to be used under intensive factory systems of produc-
tion that are gaining widespread societal disapproval.
Above all, new developments in biotechnology should not create barriers 
that would prevent or delay the adoption of alternatives, such as more hu-
mane sustainable animal husbandry practices and greater advances in public 
health, education and nutrition instead of creating ever more transgenic 
mice. With these considerations and caveats, the appropriate application of 
biotechnology in animals will be more reasonably assured and objectively 
determined.
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The biotechnology explosion has resulted, over the past decade, in the 
creation of over 10,000 new lines of transgenic mice; in farm animals with 
human genes producing milk with new health promises to offer genetically 
impaired and immune-compromised people; in genetically engineered 
plants secreting spider venom. Human disease antigen injected into cows to 
provide day care infants and others with protection from the diseases that are 
spread and potentiated by their situation may soon be marketed. Milk con-
tains a natural opiate, which may help calm some kids down. Selecting cows 
to produce opiate-rich “Sleepy Time” milk may be on the horizon soon. Al-
ready there is a company developing a transgenic pig industry to provide “xe-
nografts”—genetically humanized swine hearts, livers and kidneys—for hu-
mans in need of such organ transplants.
These new directions and applications of biotechnology make one won-
der when there will be a concerted effort to develop and distribute a safe and 
effective, if not also a reversible, genetically engineered contraceptive. That it 
will be developed and marketed for women first should not be an obstacle to 
its widespread adoption. The Catholic Church could help by embracing the 
view that such an application of biotechnology is to use our God-given 
power over the gene for reasons of compassion and to further the greater 
good and future security of all Creation.
We must stop multiplying our numbers, needs and wants. And we must 
learn to live gently and simply so that others may simply live. We need to stop 
regarding technological progress as unstoppable. It is change that we cannot 
stop; and it is up to us to direct progress, to take charge of the direction new 
technologies might take in order to maximize their benefits and minimize 
their costs and risks to all concerned. We need to constantly redefine what true 
progress is in order to implement correctives and preventatives where needed.
The mutant “monster” creation of genetic engineering we all feared has 
already been created and released into the world. It is not some insulation-
eating superbug, AIDS-like virus, mind-altering transgenic pollen, or Iowa 
corn plant that eats Texas beef. This monster seeks to use biotechnology for 
purely materialistic and consumptive ends and is preparing to remake cre-
ation into its own image of how the natural world can best serve its myriad 
consumptive needs.
The primary purpose behind the genetic engineering of Second Creation 
products is their profitability to their makers: the remakers of the First Cre-
ation. The mythic image of this mutant monster that connects us to a fate far 
more terrible than that of a Midas, Icarus, Prometheus or Marsyas, is so be-
cause it consumes itself as it destroys the Earth’s natural resources.
After the carnage, the pestilence, the long drought, the ozone hole, 
Chernobyl, pesticide rain and shores reeking with dead seals and dolphins, what 
will there be? What is coming is what we see, unfolding before our very eyes.
Genetic engineering and all applicable technologies should first and 
foremost be directed at these kinds of issues and with the vision and ethics of
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organic, if not sacred, unity rather than at developing new biotechnology 
products to help boost a non-sustainable agricultural system and an unethi-
cal biomedical research industry. The so-called health industry fights cancer 
with tons of profitable treatment, but not an ounce of prevention and justi-
fies untold animal suffering in the name of medical progress.
How can we have a government with health and agricultural agencies 
that are not in concert, but in kahoots? For them to prohibit the wholesale 
application of thousands of potential carcinogenic chemical pesticides and 
the millions of tons of petrochemical fertilizers by the feed and food industry 
would be in the public interest. So why has this not been done and countless 
other social and ethical issues addressed by industrial world governments? 
Perhaps not until we all confront our own personal monsters and demons 
and discover that we are all related.
We cannot continue to be blind to the irony that there are many publicly 
supported corporations that are distributing pesticides, as well as processing 
and marketing various crops and factory-farmed animals; developing and 
patenting genetically engineered mice and selling x-ray film for nationwide, 
annual mammograms.
The monster on this planet is a product of biotechnology because in 
breaking the DNA code, it became addicted to changing the codes of life to 
serve its own industriously Earth-transforming and all-consuming existence.
The male of this monstrous product of biotechnological skill and arro-
gance likes those of its opposite sex to have large firm breasts. It even sells 
them breast implants when their natural breasts become cancerous with the 
poisons of industrial indifference, ignorance and greed.
The entire immune system within the monster body-human, the corpus 
of industrial civilization, is beginning to break down. It is creating thousands 
of varieties of transgenic mice to find ways to help its failing immune system 
adapt to an increasingly dysfunctional and hazardous society and environ-
ment. The monster’s name is Nemesis. His mate, more ignorant than Eve and 
not so loving and alive, is a modern Pandora with perfect silicone breasts.
Where nature is the least defiled, humans still go to rest, dream, heal, 
play and pray. But some still come to these sacred places—the dying rem-
nants of the First Creation—simply to take. They must be stopped by all and 
every means for our children’s sake and for all other creatures great and small.
To conclude, from an ethical and spiritual perspective, the future of the 
natural world or First Creation will only be secure if this new technology is 
applied like no other before it. Otherwise, the Second Creation will mean a 
wholly unnatural, humanized world as we transform the First Creation into a 
bioindustrial system remade into our own self-serving materialistic image of 
utility and productive efficiency.
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This presentation will provide an overview of the broad set of publicconcerns about animal biotechnology that have been expressed both in 
the U.S. and in the European Community (EC). I will also assess the mean-
ing of biotechnology disputes for recent policy decisions concerning regulation.
The Bush Administration policy on regulating biotechnology defined 
and limited the scope of statutory authority of federal agencies. To facilitate 
federal approval of new products and, thereby, to enhance the competitive-
ness of the American biotechnology industry, the Council on Competitiveness 
in the Office of the Vice President limited regulatory authority to the issue 
of “reasonably foreseeable risk to health or the environment.” The Council’s 
policies for biotechnology for the 1990s would focus on encouraging eco-
nomic competitiveness over other concerns.
Limiting regulation to narrow questions of risk was welcomed by some 
for its economic benefits, but it was promptly attacked by others for ignor-
ing the troublesome implications of creating genetically engineered organ-
isms. These implications have been the source of continuing disputes over 
issues extending far beyond the question of “reasonably foreseeable risk.” 
The range of these issues suggests that the narrowly focused Bush adminis-
tration policy and its arguments for the urgency of economic competitive-
ness are unlikely to ease the growing tensions over biotechnology develop-
ments and, indeed, may increase the “intuitive mistrust” that has long 
marked public attitudes towards genetic manipulation.
T H E  P U B L I C  A N I M A L  P A T E N T I N G  D I S P U T E S
The patenting of living organisms has become an important focus of these 
tensions in both the U.S. and in Western Europe. A 1987 decision by the U.S. 
Patent and Trademark Office held that animals altered by genetic engineer-
ing were patentable. However, the European Patent Office decided, in 1989, 
that it could not grant patents on animals under the terms of the European *
* Developed from her paper: Living Inventions: Animal Patents in the United States 
and Western Europe. Stanford Law and Policy Review Vol IV. 1992.
Patent Convention. Currently the issue is the focus of intense debate in sev-
eral European countries. It is also the subject of debate in the European Par-
liament as it responds to a legal appeal against the patenting of a genetically 
engineered human hormone called Relaxid, and considers legislation on the 
legal protection of biotechnological inventions.
Normally business in a patent office is viewed as technical and hardly 
a subject for public debate, but the granting of patents to living inventions 
has spurred a storm of protest from a broad range of interests. The outraged 
response reveals the complex set of concerns that has more broadly marked 
public attitudes towards genetic engineering and raises questions about the 
viability of limiting the scope of regulation.
The debate over the patenting of genetically engineered animals offers 
a window on the range of concerns that have followed the diffusion of new 
biotechnology developments since the 1970s when recombinant DNA re-
search evoked fears of the escape of lethal organisms into the environment. 
Subsequently, critics have mobilized to oppose the field testing of geneti-
cally engineered bacteria designed to inhibit frost damage, the creation of 
genetically altered fish, the development of disease-resistant crops, the use 
of bovine growth hormones and many other biotechnology applications. 
Such disputes are likely to amplify in response to advances in human genet-
ics, especially as scientists seek to patent human genetic material.
To explore the nature and diversity of these concerns, I find it useful to 
present the views expressed by participants in a Congressional hearing and 
by the literature disseminated by several European Green groups. From 
there, I am able to provide suggestions regarding the kinds of strategies that 
may help to develop acceptable policies concerning a technology with sig-
nificant economic and ethical implications.
Disputes over genetic manipulation of animals have been smoldering 
in both the U.S. and Western Europe since the 1980 Supreme Court ruling 
on patenting living organisms. Researchers in both academia and industry 
have maintained that patent protection of transgenic animals is essential for 
the development and diffusion of promising medical and agricultural ben-
efits to society and, in its 1987 decision, the U.S. Patent and Trademark Of-
fice concurred. After this decision, applications flooded the Office, but so 
too did protests—from farmers, religious leaders, environmentalists and 
animal rights activists who were concerned about the consequences of this 
technology. Farmers believe that the high cost of raising, breeding and own-
ing genetically altered livestock would cause small farm foreclosures. Others 
believe that patenting animals is immoral because it defines complex, living 
organisms as profit-making machines. Still others worry that the institu-
tional collaborations between industry and universities involved in the de-
velopment of biotechnology will compromise the quality and integrity of 
research.
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These issues were played out in the U.S. at Congressional hearings and in 
Europe in appeals against the European Economic Community (EEC) di-
rective on biological patents. These animal patent disputes aired a set of 
controversial questions: Would the effects of biotechnology on agricultural 
production destroy small farms unable to pay royalties? What does patent-
ing imply for the integrity of species and the moral obligation to preserve 
nature? What would be the effect of patenting on scientific research? The 
decision to patent transgenic animals has generated economic speculations 
about the current pace of research in internationally competitive scientific 
fields and the impact of new technology on the traditional farm sector. Bio-
technology and pharmaceutical firms regard patent protection as essential 
to fueling invention by the private sector, particularly because federal sup-
port for agricultural research has declined steadily since the second World War.
American corporate interests, for example, view patenting as necessary 
if the U.S. is to effectively compete worldwide for the products emerging 
from biotechnology research. In the Congressional hearings of 1988, Rich-
ard Godown, president of the Industrial Biotechnology Association (IBA) 
pointed out that: “A Japanese company has genetically engineered silk-
worms to produce a hepatitis vaccine” and “the United Kingdom and Ire-
land may be in the lead in animal biotechnology.” Even China, he observed, 
is already test marketing low-fat pigs produced by growth hormone injec-
tion. Another scientist asked the Congress: “How are our farmers going to 
feel when that ham, which is 70 percent fat-free, comes here in cans and is 
sold in the United States?”
Farmers, however, are deeply divided on the issue. The American Farm 
Bureau Federation, representing 3.5 million member families, has long fa-
vored free market policies and innovation in farming technology, and em-
phasizes the potential benefits of genetic engineering. They anticipate that 
new biotechnologies will reduce farm costs and expand the utilization of 
farm products—transgenic livestock would grow faster and be brought to 
market sooner than conventional breeds; genetically lean and disease-resis-
tant animals would provide healthier meat to consumers than the fatty live-
stock injected with antibiotics sold today. According to the Farm Bureau, 
patents and exclusive licensing to the private sector were the only ways to en-
sure the development of biotechnology discoveries and the commercialization 
of new agricultural products.
Other farmers’ groups, however, oppose animal patents on the grounds 
that large corporations would usurp the ownership of livestock—a resource 
presently controlled by the farmers themselves. These farmers predict dire 
consequences for traditional breeding techniques and they worry about the 
continued demise of the small family farm. “Will animal patenting result in 
greater concentration in those who produce breeding stock as it has created 
in the seed industry in recent years? ...We are an industry that has seen our
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numbers drop drastically in the past two years and there are not enough of 
us left to take chances on a major mistake,” said the president of the Na-
tional Farmers Union (NFU) in his testimony at the hearings. Representing 
about 300,000 farming families, this organization believes that “The small 
business structure of the family farm is the nation’s bulwark against com-
munism and fascism. It is essential to the democratic way of life.” This has 
frequently translated into opposition to technological changes that would 
harm the small farmer.
The National Farmers Organization, the American Agriculture Move-
ment, the Coalition to Save the Family and the League of Rural Voters 
joined the NFU in its concerns about the economic implications of genetic 
engineering. They played on the popular myth of the family farm as a foun-
dation of American values and the fear that patents would force further cor-
porate concentration of agriculture. European groups, for example, the 
UK’s Compassion in World Farming, oppose patenting for similar reasons. 
“The losers would be the smaller plant and animal breeders who are not 
able to embark on research or pay the royalties....This makes the farmer 
more dependent on the chemical industry that currently controls biotech-
nology.” It would further divide the farming community into winners 
(those who can afford to adopt these expensive technologies) and losers 
(those who cannot). In Europe, as in the U.S., opposition focused on issues 
of equity, drawing from the growing concern about monopolistic practices 
in the agribusiness, pharmaceutical and chemical sectors.
While farm interests have focused on the economic consequences of 
animal patenting, an unlikely coalition of religious, environmental and ani-
mal rights groups have raised a set of moral concerns. These groups attack 
the issue from different perspectives reflecting their own moral agendas, 
but they all reject the definition of animals as resources, or, in the language 
of patent law, “compositions of matter.” Jeremy Rifkin, a persistent critic of 
biotechnology research, has accused the U.S. Patent and Trademark Office 
of reducing “the entire animal kingdom of this planet to the lowly status of a 
commercial commodity—a technological product indistinguishable from 
electric toasters, automobiles, tennis balls, or any other patented product.” 
While most visible, Rifkin is not alone; indeed, his influence as a biotech-
nology “gadfly” reflects the wide appeal of his ideas. Representatives from 
an array of citizen’s groups are questioning the moral authority of scientists 
to alter the state of nature.
Although humans have owned and used animals for millennia, the idea 
of patented ownership has invited renewed scrutiny of the human-animal 
relationship. Animal rights group in the U.S. and in Western Europe are en-
joying extraordinary expansion and public visibility. They maintain that 
tinkering with an animal’s genes violated “species integrity” and, in typical 
animal rights language, “the inherent sanctity of every unique being and the
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recognition of the ecological and spiritual interconnectedness of life.” Ex-
pressing these assumptions at the Congressional hearing, John Barnes, a 
veterinarian testifying for the Alliance for Animals, suggested that animal 
ownership has traditionally implied the responsibility of stewardship. This 
responsibility would be lost with corporate ownership.
Animal rightists usually see themselves in conflict with those who es-
pouse a Judeo-Christian ethic supporting human domination over animals, 
but on this issue these groups concur. Reverend Wesley Granberg-Michael- 
son of the National Council of Churches said, “A real shift in how humanity 
relates to the natural environment is occurring when we face this issue.” 
From his religious perspective: “The Judeo-Christian view says that the 
Creation is, in essence, held in trust...We have a responsibility to see that its 
integrity is preserved.”
The notion of “species integrity” has raised the question of what is, or 
is not, natural. Genetic engineering, sanctioned by patents, seems to some a 
profoundly unnatural act. “We are engineering ourselves away from natural 
selection into a mechanical selection of traits," said Representative Charles 
Rose (D-NC), who had introduced legislation for a moratorium on animal 
patents. Granberg-Michaelson stated this idea in graphic terms: “Cows do 
not mate with fish. Humans do not mate with pigs. Fireflies do not mate 
with tobacco plants. These combinations are more than what can be called 
simply‘natural occurrences.’” Similarly, European activists have objected 
to the view of “living factories rather than sentient beings.” They reject the 
very principle of patenting of life as reflecting “a highly questionable rela-
tionship of Humanity to Nature.” It would “undermine any last thread of 
respect for nature in our already artificialized world...forcing upon us a re-
ductionist and materialistic concept of life.” Thus, this dimension of the de-
bate reflects fundamental philosophical differences concerning the essential 
nature of living beings.
Some concerns about biotechnology have focused more concretely on 
the effect of patenting on the research agenda and on the use of government 
supported science. Is it right that private biotechnology companies will 
profit by building on a base of publicly funded research? Will academic sci-
entists, in dealing closely with industry, be appropriately accountable for 
their work?
In the U.S. Congressional hearings, the president of the Farmers’ Milk 
Marketing Cooperative, addressed the issue of profit: “...if most of the re-
search and development costs in the production of some super animal have 
been paid for from public coffers, is it proper to grant a monopoly market 
position for giant corporations for 17 years? Furthermore, is all of this nec-
essary to promote alleged scientific progress?” In fact, current laws deliber-
ately encourage private exploitation of publicly funded research as the most 
effective means of diffusion; but this policy continues to confront opposition
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mainly from groups concerned about the general direction of technological 
change.
Many scientists favor the growing industry-university collaborations 
in commercially useful research. They minimize the risks of such ventures 
based on traditional assumptions about scientific neutrality and the ability 
of scientists to regulate themselves. They do not believe patenting would 
distort the research agenda of scientists which is shaped by intellectual in-
terests and controlled through peer review and the values of their scientific 
disciplines. Others, however, suspect that the profit motive would, indeed, 
affect research. Jack Doyle of the Environmental Policy Institute, suggested 
at the hearings that industry-university collaboration in research and de-
velopment “is worrisome because it blurs the roles of government as regula-
tor and the university as society’s natural arbiter and adviser.” Such col-
laboration would disturb the traditional checks and balances on scientific 
knowledge and its application and shape the direction of future research. 
Critics doubt the ability of scientists to control the direction and use of 
their own research. “Allowing patent protection at this time will sever the 
contact between research and the public interest,” said the Wisconsin Farm 
Unity Alliance. “It will mean that biotech corporations will be able to fi-
nance a much more accelerated level of research and development with little 
concern for the need to build public understanding and support and even 
less concern about meaningful regulation.” This view was especially trou-
bling in Europe where private industry funding of research in public insti-
tutions is a recent practice. Opponents fear the privatization of public re-
search and suspect that patenting would lead to restricted information ex-
change among scientists and further limit public access to scientific infor-
mation. They feel that only private industry would benefit.
E T H I C A L ,  E C O N O M I C  A N D  P O L I T I C A L  C O N C E R N S  
The patenting of animals has become a lightning rod for existing ethical, 
economic and political concerns in both the U.S. and Europe. It takes place 
when the plight of small farmers is a growing problem and technological 
changes in the farm community are a polarizing force. The issue has entered 
the public arena when animal rights groups are questioning the morality of 
vivisection and arguing against the instrumental values that allowed ani-
mals to be used as a resource. The decision also touches on controversial 
and widely publicized possibilities of commercializing human tissue for fe-
tal research and human body parts for organ transplantation. It feeds exist-
ing worries about the effect of proliferating industry-university collabora-
tions in biotechnology with their implications for the values of open scientific 
communication, professional responsibility and academic freedom.
The decision also resonates with the general uneasiness about genetic 
research which relates to vague, yet profound, fears of human genetic engi-
neering. One should not underestimate the depth of public feelings about
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tampering with genes. We have only to look at the long history of popular 
culture—films and science fiction—that play on the fear of radiation muta-
tion and genetic manipulation to discover its archetypal roots. Recall, for 
example, the series of classic horror films in the 1950s (e.g., The Fly, The 
Wasp) and their images of mutant monsters resulting from radiation and 
tampering with genes: ants, wasps, spiders, scorpions mutated into the size 
of 747s. In Europe, the discourse on genetic engineering is colored by im-
ages of Nazi eugenics and human experimentation. These fears contribute 
to the opposition to genetic engineering and its popular image as technol-
ogy out-of-control.
The biotechnology debate must be understood in the context of the 
many other policy controversies over science and technology, for example, 
over the practices of fetal research and animal experimentation, the teach-
ing of evolution in the schools, the burial of nuclear wastes and the effects 
of technology on the environment. Such controversies reflect fundamental, 
and sometimes irreconcilable, values that are not easily resolved. In the case 
of animal patenting disputes, the small farmer, economically committed to 
the family farm and ideologically convinced that it is “essential to the demo-
cratic way of life,” is not likely to be convinced that patenting is beneficial. 
Biotechnology is not the cause of the decline in family farming and a ban on 
animal patents would not reverse the trend. For some, this technology has 
come to symbolize the differential social and economic impacts of techno-
logical change. Similarly, arguments about the usefulness of transgenic ani-
mals for medicine and research are unlikely to stop the opposition of animal 
rights crusaders. Driven by anti-instrumental values and beliefs about the 
sanctity of nature, they are mobilized to oppose all use of animals as tools. 
They are particularly troubled by techniques of biotechnology that have 
blurred the boundaries between inert matter and living objects, techniques 
now recognized in law and reified by the decision to patent animals as living 
inventions.
Even the scientists who deny effects of commercialized research on the 
norms and practices of science base their position on fundamental beliefs 
about academic integrity. Convinced of the moral neutrality of science, they 
assert the ability of scientists to resist the lures of profit and to effectively 
regulate themselves. Though academic engagement in the development and 
diffusion of new technology surely weakens the credibility of the academy 
as an independent source of assessment, industry-university consortia in 
biotechnology have proliferated.
The controversy over biotechnology patents has developed out of a 
fundamental clash of moral values, conflicting visions of progress and com-
peting world views. Based on beliefs about equality and justice and reflect-
ing questions about the meaning of progress, such controversies cannot be 
resolved by simply assessing risk or claiming the necessity of greater com-
petitiveness. Nor, in democratic societies, can they be simply dismissed, for
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underlying protest is a troubling mistrust of the authorities responsible for 
technological development. A national survey conducted by the Office of 
Technology Assessment has indicated broad mistrust of the government’s 
role in regulating biotechnology. In disputes involving statements concern-
ing potential risks, Americans believe environmental groups over federal 
agencies by a margin of 63 percent to 26 percent. The picture is similar in 
Europe where opinion surveys carried out in the 12 member states of the 
EEC showed that 52 percent of the people trust environmental and con-
sumer organizations “to tell the truth about biotechnology and genetic en-
gineering.” Only 20 percent chose public authorities and 6 percent chose in-
dustry as trustworthy guides.
The critical questions, then, have to do with authority. Who should be 
making decisions about a technology with such broad economic, moral and 
political consequences? How can we develop policies for technology assess-
ment that would include broader concerns about new biotechnology prod-
ucts and processes? The critical challenge in both the U.S. and the EC is 
how to develop mechanisms for conflict resolution in the face of intuitive 
mistrust, competing economic visions and philosophical disagreement 
about the costs and benefits of new technologies and their differential effects.
Since the early 1970s, similar challenges have been expressed in dis-
putes over other technologies that present potential risks to health, envi-
ronment or social values. Opposition to nuclear power; protests against the 
siting of airports, toxic waste dumps, chemical plants and other noxious fa-
cilities; and fights over the rules and standards regulating pollution, began 
in the early 1970s—most have persisted for several decades. To resolve these 
disputes, public agencies in both the U.S. and Western Europe during the 
1970s encouraged greater public involvement in technological decisions on 
the assumption that this would foster public acceptance of technology and 
enhance the legitimacy of decision-making institutions. There followed a 
variety of efforts to involve citizens more directly in creating and imple-
menting policies for technological change.
These efforts ranged from broadly participative inquiries to environ-
mental mediation. They included complaint and consultation systems, citi-
zen advisory groups, representation of citizens in review boards and special 
issue referenda. Some were intended to develop consensus among conflict-
ing scientific groups as a means to advise decision-makers (e.g., science 
courts); others to educate the public. The process created depended on how 
the problem of public acceptance was defined. Where lack of public confi-
dence was thought to arise from technical uncertainties (for example, about 
risk), the goal was to develop a scientific consensus among dissenting 
groups in order to improve the advice available to decision-makers. Where 
problems of acceptance were attributed to lack of public understanding, the 
task became one of public education. Where controversy was defined in
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terms of alienation and mistrust, more participatory and consultative sys-
tems evolved.
The 1970s experiments had mixed success, depending in part on how 
realistically they defined the source of public opposition to technology poli-
cies. However, they helped to avoid the polarization and mistrust that is so 
evident in biotechnology disputes today. This polarization reflects, in part, 
the insistent focus on economic competitiveness as the central value over-
shadowing all other concerns—a focus that necessarily defines public par-
ticipation as an impediment to technological change. This attitude, how-
ever, has only served to exclude issues of public concern and increase public 
resentment. European groups, for example, feel that “the public is being 
kept out of the discussion, as if it were merely a technical matter. This must 
stop! The patenting of life is too important to leave up to a handful of ex-
perts and corporate lobbyists.”
C O N C L U S I O N
I conclude by extracting some principles from the 1970s struggles to estab-
lish effective negotiations for the resolution of technological disputes. We 
learned from these struggles that:
—Negotiations must deal directly with issues of public concern includ-
ing questions of ethics and equity as well as economics and risk. Thus, con-
troversial issues must be defined in terms of problems to be solved rather 
than solutions to be accepted. Proponents of a technology, determined to 
implement preconceived decisions, try to deal with protest by co-opting pub-
lic support rather than by expanding choice. Leaving little room for compro-
mise, these attitudes often resulted in the transfer of conflict from public 
hearings to the courts and sometimes to the streets.
—We learned that effective negotiation requires that participants have a 
sense of political efficacy and choice over the issues that most concern them. 
Establishing political efficacy rests on widely distributed knowledge and ac-
cess to expertise. High quality educational materials should be designed, not 
to promote the technology, but to open frank discussion and understanding 
of both benefits and costs. Thus, efforts to enhance the competence (and to 
avoid manipulation) of journalists is essential, for the media play a signifi-
cant role in informing the public.
—Finally, developing trust is a long-term process built on evidence of 
reliability and openness established over time. The emerging field of biotech-
nology offers opportunities for policy negotiation early in the development 
of the technology, before significant choices are made. These choices should 
not, at this early stage, be limited to narrow, short-term questions of risk.
The dispute over animal patents suggests that evaluation of the products and 
processes emerging from biotechnology must be developed with an eye to 
their differential social and economic impacts. The institutional procedures
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for assessing these impacts must also involve those who are affected and con-
cerned. The history of participatory procedures suggests this may not pro-
duce consensus; when technologies embody highly controversial political 
and social values, consensus is not a feasible goal. By sorting out conflicting 
values, they may reduce public mistrust of administrative institutions and, in 
the long run, encourage the development of equitable decisions.
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his topic brings together two issues which have been much on the minds
of livestock producers in recent years. Animal welfare and biotechnology 
are important, not only because the politics of the issues could affect agricul-
ture, but also because producers are good citizens concerned about doing 
what is right.
A workable definition of biotechnology can be derived by examining the 
two parts of the word. “Bio” stands for biology, the science of life that in-
cludes all living things. “Technology” is collectively tools and techniques 
which include animal breeding, embryo transfer, genetic engineering, fer-
mentation, tissue culture and so forth. Biotechnology is applying these tools 
to living organisms to get them to do what you want them to (Witt, 1990).
Biotechnology offers the potential of incredible benefits for society with 
very little risk, such as a whole generation of safer, more effective drugs. 
Hundreds are in development including 50 new cancer drugs and 15 new 
AIDS drugs now being clinically tested (Gorner, 1992). Nearly 8,000 com-
mercial processes which use genetic engineering principles are in the process 
of being patented. Disease-resistant crops and livestock, more efficient food 
production, lower fat meat and biotechnology-aided processes can help 
make significant gains in feeding the world higher quality food. Society has 
an obligation to develop these techniques.
Biotechnology is playing an increasing role in nearly all scientific fields. 
To choose not to implement these tools in any one industry or country would 
leave that industry or country noncompetitive. The application of biotech-
nology to agriculture has lagged behind human health applications due to a 
lack of investment which would yield needed basic knowledge in animal 
physiology, biochemistry and microbiology (National Agricultural Research 
and Extension Users Advisory Board, 1990).
With all of the intense research efforts to date, not one industrial acci-
dent or disaster has befallen society because of biotechnology. This is not to 
say that food safety, environmental protection and animal welfare issues 
should not be addressed. They should be addressed, but in an appropriate 
perspective.
R E G U L A T I O N
The Bush administration announced in 1992 that no special regulations were 
needed for gene therapies and genetically engineered drugs and pesticides. 
This was good news for the biotechnology industry and for society. The same 
logic should be applied to the issue of animal well-being in biotechnology.
Biotechnology should be considered as one more in a long line of tools 
developed for the betterment of human life. Once human and environmental 
safety are proven for biotechnological procedures and products, their use 
should be allowed. Additional regulations pertaining to animal well-being in 
a society utilizing biotechnology are not needed.
It is human nature to develop a system of ideals, practices and prohibi-
tions to both protect us from nature and from ourselves (Kaye, 1992). There 
are many reasons for society to have regulations and to vigorously enforce 
them. However, regulations are not always the best way to affect human be-
havior. Regulatory activity should be focused on the priorities of protecting 
and enhancing human life. It is not practical, possible, or cost-effective to 
regulate every aspect of industry and research.
Additional regulations on industries and people who are willing and ca-
pable of doing what is right are a waste of time and effort. Unnecessary regu-
lations stifle competitiveness by burdening industries with unproductive pa-
perwork, delays and bureaucracy. The key is to give people involved in pro-
duction and experimentation the training and information to act responsi-
bly. A more humane, enlightened and compassionate regard for all life, in-
cluding human life, is a mindset that cannot effectively be legislated. People 
continue to be bound by a moral obligation to minimize pain and suffering 
of animals while advancing important interests of their fellow human beings.
A N I M A L  R I G H T S  A N D  A N I M A L  W E L F A R E :  A N  O V E R V I E W
Philosophical conflicts about whether or not animals have rights dates back 
to early civilization. The Greek scholar, Pythagoras, was a vegetarian who be-
lieved human souls migrate to animals after death. On the other side was 
Aristotle, who believed that animals existed to serve humanity. The 17th 
Century French scientist, Descartes, believed that humans alone have souls 
and on this basis he categorized humans separately from all other matter. He 
considered animals as machines with no capacity for pain.
Judeo-Christian traditions and teachings support the concept that ani-
mals and humans do not have similar interests or rights. Old Testament writ-
ings described humans as having dominion over all creatures. The use of ani-
mals was permitted for food, service, protection and even sacrifice. New Tes-
tament concepts generally support Old Testament descriptions of humanity’s 
dominion over animals, but stopped the practice of animal sacrifice. Some 
biblical passages encourage kindness to animals. Of course, other religions, 
such as Buddhism, have very different perspectives on human-animal rela-
tionships.
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Howard Kaye (1992) wrote, in an essay lamenting the reductive and de-
terministic view of human life accompanying the Human Genome Project, 
that more than the categories of heredity and environment are required for 
understanding human life. He said that humans are moral and cultural be-
ings with the elements of will, choice and responsibility contributing to the 
essence of their being. He wrote, “Our capacities for reason, symbolic expres-
sion and imagination; our aspirations for esteem and respect; and our quali-
ties of curiosity and self-consciousness all may have evolutionary origins and 
may have contributed to our species’ biological success.” While Kaye uses 
these arguments to say that humans should be seen in much more than just a 
biological sense, it also follows that human beings are, in many respects, very 
different than animals.
While most people and most farmers believe that animals have no rights, 
they do believe that animals (and humans) should be spared unnecessary suf-
fering through neglect, deprivation or willful abuse. There is a great differ-
ence between the humane treatment of animals and humanizing animals.
This important difference between animal welfare and animal rights seems to 
be inherent in the thinking of most people. But as society becomes more af-
fluent and more well-fed, there are more resources available for social move-
ments and philosophical thinking about topics such as humans’ relationships 
with animals. That society dwells on questions of animal rights and animal 
welfare when problems of human welfare, human rights and world hunger 
abound should make us stop and examine our priorities. The truth is that 
farm animals are treated reasonably well and that the use of animals in medi-
cal research greatly benefits people. The use of biotechnology does not 
change the basic responsibilities that humans already have toward animals as 
they farm or do research.
A N I M A L  R I G H T S  A N D  A N I M A L  W E L F A R E :  A  C L O S E R  L O O K
Rare are discussions of animal rights/animal welfare and the use of animals 
by humans which are objective, scientific and cogent. Two writings which are 
particularly useful in sorting out the complexities are: The Ethics of Meat 
Production by Kauffman and Rutgers (1991) and Interspecific Justice by Van de 
Veer (1979).
Kauffman and Rutgers reason that animals do not have rights since they 
cannot exercise or respond to moral claims. Beings with rights must balance 
their own interests with what is just. Therefore, humans have a moral obliga-
tion to treat animals with compassion, prohibit cruelty, prevent extinction of 
species and respect animals’ basic interests. Basic interests of animals include 
freedom from pain and suffering, nourishment, freedom of movement, com-
panionship of other animals and protection from predators. The “five free-
doms” of the UK guidelines for animal welfare in agriculture could also be 
taken to define farm animals’ basic interests.
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Kauffman and Rutgers admit that most professionals in meat, animal 
and veterinary sciences have not taken time to thoroughly examine the moral 
justifications or ethical decision-making on these philosophical issues. They 
write in detail about the definitions of philosophy, ethics and rights. Ethical 
principles are presented as guides in making decisions and exercising judg-
ments about how we think about and treat humans and animals. These au-
thors emphasize that before animal-human relationship issues can be re-
solved responsibly, people must think through all the major issues. Each per-
son should make his or her own decision independently before collective so-
cietal decisions can be established. They conclude that the use of animals for 
food or for experimentation to provide for humans’ right to live healthy lives 
is justified, but that the well-being of those animals should not be ignored.
Van de Veer (1979) cites five ways that humans can relate ethical prin-
ciples to animals:
—Radical Speciesism (RS) is the extreme view held by Descartes, but few 
people presently believe that animals are objects having no interests. This 
view would allow people to use animals in any conceivable way without any 
regard for animal well-being.
—Extreme Speciesism (ES) maintains that an animal does have certain 
interests and needs and is more than an object at the disposal of man. ES 
would, however, permit subordination of basic interests of animals for even 
peripheral interests of humans. Most people would reject ES as well as RS be-
cause it would allow animal suffering as long as some peripheral human in-
terest was being served.
—Interest Sensitive Speciesism (ISS) is the view that when there is a con-
flict of interests between an animal and a human being, it is morally permis-
sible to subordinate animal interests to promote basic interests of humans. 
However, one may not subordinate basic interests of animals in promoting 
peripheral human interests. ISS would permit the sacrifice of a dog to save a 
human life, but would not permit animal suffering for frivolous reasons. A 
majority of people would subscribe to this ethical principle, though classify-
ing various interests as basic or peripheral could be a problem, especially 
among species at different stages of the evolutionary ladder.
—Species Egalitarianism (SE) gives animals equal status to humans when 
interests are considered. It holds that when there is a conflict of interests be-
tween an animal and a human it is morally permissible to subordinate the 
more peripheral to the more basic interest and not otherwise, regardless of 
which one is jeopardized. Few people would subscribe to SE.
—Two-Factor Egalitarianism (TFE) holds that interests and psychologi-
cal capacities are both important factors as conflicts of interests between two 
beings are considered. Many people would subscribe to TFE along with ISS. 
TFE would allow the sacrifice of an interest of a species with less developed 
psychological capabilities to promote a like interest of a more developed spe-
cies. Basic interests of the lower species could be sacrificed for promotion of 
serious interests of the higher species. TFE attempts to take into account
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both the kind of interests at stake and the psychological traits of the beings in 
question. As in ISS, there is difficulty in objectively assessing these interests 
and capacities.
Since most people would subscribe to the ISS and TFE approaches described 
by Van de Veer, humans must consider animals’ interests and psychological 
capacities. Research should continue on animals’ perception of pain, stress 
quantification, healthy physiology, behavioral characterization and the inter-
action of productivity with these factors.
The degree of morally acceptable animal suffering is higher for medical 
experimentation than it is for animal agriculture. Biotechnology can likely 
produce better animal models to study human disease. The potential for 
great human benefit from these genetically engineered animal models out-
weighs the fact that animal well-being may be decreased. Biotechnological 
advances such as genetic engineering may also make it possible to increase 
the well-being of disease-model animals by making them more able to cope 
with their surroundings, less susceptible to stress and less sensitive to pain.
E U R O P E A N  A N I M A L  P R O T E C T I O N
In 1964, Ruth Harrison’s book Animal Machines was published. Conse-
quently, the UK government set up a Technical Committee to examine ani-
mal welfare in intensive livestock systems. The 1965 report of the Brambell 
Committee led to the establishment of legal definitions of behavioral needs. 
The Farm Animal Welfare Committee of the UK has articulated criteria to as-
sess animal welfare in agriculture. These so called “five freedoms” are:
1. freedom from thirst and hunger;
2. comfort and shelter;
3. prevention/rapid treatment of disease;
4. freedom to display most normal patterns of behavior;
5. freedom from fear.
In 1976, a European Convention for the Protection of Animals kept for farm-
ing purposes was elaborated by an ad hoc committee comprising delegations 
from most of the member states of the Council of Europe. Ingvar Ekesbo 
(1991) urged this convention to include some basic rules that limit humans’ 
right to manipulate animals kept for farming purposes. However, he adds 
that such rules should not limit the possibility to do research in biotechnol-
ogy. The rules suggested by Ekesbo regarding biotechnology are:
—Animals produced as a result of genetic manipulation procedures shall 
not be kept for farming purposes unless, through scientific evidence, it is 
shown that their health and welfare will not suffer;
—No substance shall be administered to an animal kept for farming pur-
poses unless it has been demonstrated by scientific studies of animal welfare 
that the ultimate effect of the substances is not detrimental to the health and 
welfare of the animal;
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—The animals used, at present, for farming purposes should be pre-
served in a way that makes it possible to again start breeding a variety that 
may not have been bred for several years, should this be judged desirable.
Ekesbo concludes, “Man [sic] has always had ethical rules, written or unwrit-
ten, for animal husbandry. In our time with rapid scientific achievements, 
international agreement on ethical rules are necessary for the protection of 
the animals, the farmers and the society.” While Ekesbo’s proposal for ethical 
rules regarding biotechnology in farm animals seems reasonable, the rules 
and criteria are still subject to different interpretations depending on one’s 
viewpoint. Unregulated ethical guidelines would be preferable to written 
rules in animal agriculture and in research, except for the most basic re-
search. Anti-animal cruelty statutes, humane slaughter regulations and ani-
mal use guidelines for research already in existence are sufficient.
C O N C L U S I O N
Animal agriculture contributes to the quality of human life by providing 
high-quality, nutrient-dense foods. Farmers have a moral obligation to pro-
duce this food as efficiently as possible. This will provide the maximum 
amount of human food while minimizing the consumption of natural re-
sources and effects on the environment. Biotechnology should be used like 
any other tool to help achieve this goal. As the world population approaches 
six billion people, these persons’ basic interest in being fed certainly takes 
precedence over the peripheral interests of animals served by over-regulation 
of animal production.
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“Models” for Human Genetic Disease
Perhaps the greatest socio-ethical challenges associated with the develop-ment and use of transgenic animals in biomedical research are the prob-
lems associated with animal welfare. Whereas the issue of biosafety does, in-
deed, represent a major concern, the minimization of such risk is as much a 
prudential concern as an ethical one for investigators, as they themselves are 
put at risk by failure to provide adequate safeguards against the dangers of 
transgenic animal research. Animal welfare concerns, on the other hand, rep-
resent a far greater moral challenge, for concern about animal welfare often 
does not coincide with perceived self-interest and, indeed, can exact costs in 
terms of self-interest, in the form of money, time, extra personnel, delay 
in research, etc. In other words, many researchers have traditionally not 
equated concern for animal welfare with self-interest and are, thus, unlikely 
to do the right thing for reasons of self-interest. Somewhat mitigating this 
blanket statement is the relatively recent acknowledgement of the fact that 
failure to assure animal welfare can skew variables relevant to research and 
actually compromise research (Rollin, 1990), but nonetheless, the coinci-
dence of the two is far from perfect. As we shall see, certain aspects of trans-
genic animal research do represent an area where welfare could be ignored 
without obviously jeopardizing the work in question. Thus moral concern 
must take up the slack left after prudential considerations are exhausted.
The emergence of a systematic social ethic whose purview extends to the 
treatment of laboratory animals is a relatively recent phenomenon, as evi-
denced by the fact that researchers basically enjoyed carte blanche in the use 
of animals until the mid 1980s (Rollin, 1991). For most of the 19th and 20th 
centuries, the only consensus ethical principle extant in society for the treat-
ment of animals was a prohibition against overt, willful, intentional, need-
less, wanton cruelty, as expressed in anti-cruelty legislation. Concerned as 
much with ferreting out sadistic individuals who might begin with animals 
and move to humans as with protecting animals, these laws, therefore, did 
not address “normal,” “necessary” or “beneficial” sources of animal suffering
such as agriculture, research, hunting, trapping or education; these are typi-
cally exempted from the anti-cruelty laws by statute, or else have been ex-
cluded by judicial decision. Rather, the laws focused on deviant behavior 
leading to “unnecessary” animal suffering. It is only in the past decade that 
society has begun to realize that a mere fraction of animal suffering is a result 
of overt cruelty—the vast majority of animal suffering at human hands, in 
fact, grows out of such decent motivations as increasing knowledge, curing 
disease, increasing efficiency of food production, protecting humans against 
toxic substances and so on. Correlative with this realization has come a de-
mand for the control of suffering in areas of animal use which previously en-
joyed laissez faire, notably toxicity testing, animal research and animal agri-
culture. First to be directly affected by this demand was animal research, with 
two major pieces of federal legislation designed to assure the welfare of re-
search animals passed in the U.S. in 1985.
Perhaps the main feature of this legislation, which I have discussed at 
length elsewhere (Rollin, 1989; 1991), is a mandate to control pain, suffering 
and distress in research animals except where scientifically necessary, as in 
the study of pain, and even there, to minimize it as far as possible. Second, 
the legislation is designed to assure “enforced self-regulation” of animal re-
search and dialogue about animal welfare concerns, through the vehicle of 
protocol and facilities review by animal care committees. Third, the legisla-
tion suggests that welfare concerns are not limited to controlling overt pain 
and suffering, but actually points towards providing some positive opportu-
nity for animals to express their biological and behavioral natures—this is 
exemplified by the requirements of exercise for dogs and provision of an en-
vironment conducive to the psychological well-being of primates. This legis-
lation has already had many salubrious effects on the welfare of laboratory 
animals, perhaps the most dramatic being the focusing of scientific attention 
on recognizing, characterizing and alleviating animal pain. It has also led re-
searchers to far greater awareness of ethical questions in research, something 
which was traditionally stifled by widespread belief that science is and ought 
to be, “value-free” (Rollin, 1989).
Thus, we see the emergence of a new ethic for animals demanding, in es-
sence, maximization of the interests of animals while they are being used for 
human benefit. The most articulate expression of this ethic thus far, has been 
the demand for the control of animal pain and suffering in research.
For certain aspects of transgenic animal use, this demand will be rela-
tively easy to satisfy. Consider, for example, the patented Harvard mouse 
which is disposed to the development of tumors. In the words of the patent, 
this is “an animal whose germ cells and somatic cells contain an activated 
oncogene sequence introduced into the animal...which increases the prob-
ability of the development of neoplasms (particularly malignant tumors) in 
the animal” (U.S. Patent Number 4,873,191). Minimizing pain and suffering
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for such an animal is, in principle and in fact, no different from minimizing 
pain and suffering in nontransgenic animals in whom tumors are induced by 
other means: the establishment of endpoints for euthanasia, in terms of tu-
mor size, so that the animal does not suffer, and the judicious use of anesthet-
ics, analgesics and tranquilizers during operative or other procedures.
Similarly, there is no reason the second major thrust of the new social 
ethic cannot be applied to these transgenic animals—namely the provision of 
enriched environments and husbandry systems for these animals which allow 
them to actualize their behavioral and biological natures. In the case of trans-
genic mice, for instance, one should look to the recommendations outlined 
in literature on care of mice; for example, a recent article described a caging 
system for rodents that is meant to accommodate their behavioral needs 
(Sharmann, 1991). Indeed, the characterization of such environments and 
systems for a variety of animals is a primary purpose of the chapters in a 
book I am currently editing (Rollin and Kesel, in press). Thus, the vast ma-
jority of transgenic animals developed so far raise no additional welfare is-
sues beyond those concerning nontransgenic laboratory animals.
Indeed, those welfare issues which are raised dramatically by transgenic 
animals are also continuous with analogous nontransgenic cases. I am refer-
ring to the creation and maintenance of seriously defective animals which are 
developed and propagated to model some human disease. This was tradition-
ally accomplished through identification of adventitious mutations and se-
lective breeding. Transgenic technology allows for accomplishing the same 
goal far more quickly and in a far wider range of areas. One can essentially 
replicate, in principle, any human genetic disease in animals—and therein 
lies the major ethical concern growing out of transgenic technology.
A recent chapter in a book devoted to transgenic animals helps to focus 
the concern:
There are over 3,000 known genetic diseases. The medical costs 
as well as the social and emotional costs of genetic disease 
are enormous. Monogenic diseases account for 10% of all ad-
missions to pediatric hospitals in North America... and 8.5% 
of all pediatric deaths.. .. They affect 1% of all liveborn in-
fants. .. and they cause 7% of stillbirths and neonatal deaths.
... Those survivors with genetic diseases frequently have sig-
nificant physical, developmental, or social impairment. . . .
At present, medical intervention provides complete relief in 
only about 12% of Mendelian single-gene diseases; in nearly 
half of all cases, attempts at therapy provide no help at all 
(Karson, 1991.)
This is the context in which one needs to think about the animal welfare is-
sues growing out of the use of transgenic animals in biomedical research.
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On one hand, it is dear that researchers will embrace the creation of animal 
models of human genetic disease as soon as it is technically feasible to do so. 
Such models, which introduce the defective human genetic machinery into 
the animal genome, appear to researchers to provide convenient, inexpensive 
and—most importantly—high fidelity models for the study of the gruesome 
panoply of human genetic diseases outlined in the over three thousand pages 
of text comprising the sixth edition of the standard work on genetic disease, 
The Metabolic Basis of Inherited Disease (Scriver et al., 1989). Such “high fi-
delity models” may well reduce the numbers of animals used in research, a 
major consideration for animal welfare, but are more likely to increase the 
numbers as more researchers engage in hitherto impossible animal research. 
On the other hand, the creation of such animals can generate inestimable 
amounts of pain and suffering for these animals since genetic diseases, as 
mentioned above, often involve symptoms of great severity. The obvious 
question then becomes the following: Given that such animals will surely be 
developed wherever possible for the full range of human genetic disease, how 
can one assure that vast numbers of these animals do not live lives of constant 
pain and distress? Such a concern is directly in keeping with the emerging 
social ethic for the treatment of animals; as we said, one can plausibly argue 
that minimizing pain and distress is the core of recent federal legislation con-
cerning animal use in research.
The very first attempt to produce an animal “model” for human genetic 
disease by transgenic means, as mentioned earlier, was the development, by 
embryonic stem cell technology, of a mouse which was designed to replicate 
Lesch-Nyhan’s disease, or hypoxanthine-guanine-phosphororibosyl trans-
ferase (HRPT) deficiency (Hooper et al., 1987; Keuhn et al., 1987). Lesch- 
Nyhan’s disease is a particularly horrible genetic disease, leading to a “devas-
tating and untreatable neurologic and behavioral disorder” (Kelley and 
Wyngaarden, 1983). Patients rarely live beyond their third decade and suffer 
from spasticity, mental retardation and choreoathetosis. The most unforget-
table and striking aspect of the disease, however, is an irresistible compulsion 
to self-mutilate, usually manifesting itself as biting fingers and lips. The fol-
lowing clinical description conveys the terrible nature of the disease:
The most striking neurologic feature of the Lesch-Nyhan syn - 
drome is compulsive self-destructive behavior—between 2 and 
16 years of age, affected children begin to bite their fingers, 
lips and buccal mucosa. This compulsion for self-mutilation 
becomes so extreme that it may be necessary to keep the el-
bows in extension with splints, or to wrap the hands with gauze 
or restrain them in some other manner. In several patients, mu-
tilation of lips could only be controlled by extraction of teeth.
The compulsive urge to inflict painful wounds appears 
to grip the patient irresistibly. Often he [sic] will be content
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until one begins to remove an arm splint. At this point a com-
municative patient will plead that the restraints be left alone.
If one continues in freeing the arm, the patient will become 
extremely agitated and upset. When completely unrestrained, 
he will begin to put the fingers into his mouth. An older pa-
tient will plead for help and if one then takes hold of the arm 
that has previously been freed, the patient will show obvious 
relief. If help is not forthcoming, a painful and often severe 
injury may be inflicted. The apparent urge to bite fingers is 
often not symmetrical. In many patients it is possible to leave 
one arm unrestrained without concern, even though freeing the 
other would result in an immediate attempt at self-mutilation.
These patients also attempt to injure themselves in other 
ways, by hitting their heads against inanimate objects or by 
placing their extremities in dangerous places, such as in be-
tween the spokes of a wheelchair. If the hands are unrestrained, 
their mutilation becomes the patient’s main concern and effort 
to inflict injury in some other manner seems to be sublimated 
(Kelley and Wyngaarden, 1983).
At the present, “there is no effective therapy for the neurologic complications 
of the Lesch-Nyhan’s syndrome”(Stout and Caskey, 1988). Thus Kelley and 
Wyngaarden, in their chapter on HRPT-deficiency diseases, boldly suggest 
that “the preferred form of therapy for complete HRPT-deficiency (Lesch- 
Nyhan’s syndrome) at the present time is prevention,” i.e. “therapeutic abor-
tion” (Kelley and Wyngaarden, 1983). This disease is so dramatic that I pre-
dicted almost a decade ago that it would probably be the first disease for which 
genetic researchers would attempt to create a model by genetic engineering.
Researchers have sought animal models for this syndrome for decades 
and have created rats and monkeys that will self-mutilate by administration 
of caffeine and other drugs (Boyd et al., 1965). Thus, it is not surprising that 
the first disease genetically engineered by embryonic stem cell technology 
was, indeed, Lesch-Nyhan’s disease (Hooper et al., 1987; Keuhn et al., 1987). 
However, these animals were phenotypically normal and displayed none of 
the metabolic or neurologic symptoms characteristic of the disease in hu-
mans. The reasons for this are unknown (Stout and Caskey, 1988).
This case provides us with an interesting context for our animal welfare 
discussion. Although the animals were, in fact, asymptomatic, presumably at 
some point in the future researchers will be able to generate a symptomatic 
model transgenically. Let us at least assume that this can occur—if it cannot, 
there is no animal welfare issue to concern us! Whether one ought to create 
such animals is a question I have addressed elsewhere (Rollin, 1986). The prac-
tical moral question that arises is clear: Given that researchers will certainly 
generate such animals as quickly as they are able to do so, how can one assure
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that the animals live lives that are not characterized by the same pain and dis-
tress which they are created to model?
Again, this question does not differ in kind from the moral questions as-
sociated with developing traditional chronic animal models of human dis-
ease, be it by breeding, pharmacological manipulation or tissue destruction. 
The difference is in degree—transgenics provides the potential for generat-
ing vast numbers of animals modeling genetic diseases with devastating 
symptoms. A second difference lies in the fact that transgenic technology is 
developing at precisely the same time that social/ethical demand for control-
ling pain and suffering in research animals is at its historical peak and seems 
to be increasing.
Regrettably, researchers in the past have been cavalier in controlling 
pain and suffering in animals used as chronic disease models. Though many 
of the animals have required extraordinary amounts of care and husbandry, 
such efforts have been directed, for the most part, at keeping the animals 
alive and scientifically functional rather than at controlling pain and suffer-
ing. Given our current social ethic, it is increasingly imperative that pain and 
suffering be controlled in all animals used for research. Thus, concern for 
this dimension of animal care needs to be a fundamental principle which 
guides those contemplating the transgenic creation of animals which repli-
cate human genetic disease. Such an issue is a true moral challenge for re-
searchers, as concern for the animals’ quality of life will undoubtedly make 
things more difficult and expensive for researchers. At the same time, it is 
patent that such concern is both morally and socially obligatory. Further-
more, failure to assure the public that animal suffering is being minimized 
could well accelerate major political constraints on all areas of biotechnology 
(Rollin, 1986).
Unfortunately, because the research community traditionally ignored 
this moral component of animal research, there is no vast literature on con-
trolling pain and suffering in chronically defective animals. There has prob-
ably been more scientific attention to such questions during the six years fol-
lowing the passage of the aforementioned federal legislation than in the en-
tire previous history of animal research (Rollin, 1989). Doubtless such atten-
tion will continue to grow at a significant rate. Researchers undertaking work 
with animals which model human genetic disease should, therefore, vector 
these concerns into protocol planning and budgeting; funding agencies 
should demand such planning, and animal care and use committees should 
not approve projects until they have evidenced that pain, suffering and dis-
tress are controlled.
In many cases—perhaps in a symptomatic Lesch-Nyhan’s animal—man-
agement of suffering may require a far more radical approach than the stan-
dard uses of anesthesia, analgesia and tranquilization, which are, by and
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large, used for short periods of time. If a defective animal is to be kept alive 
for long periods and is likely to experience pain and suffering during that pe-
riod, researchers should consider the possibility of effecting total elimination 
of consciousness. One such approach could involve surgically rendering an 
animal decerebrate, so that, while vegetative functions are extant, the animal’s 
subjective experience has been shut down. Alternatively, and perhaps more 
viably, one could render an animal irreversibly comatose so that it was effec-
tively anesthetized throughout its life. Unfortunately, virtually no literature 
exists on induction of coma.
I have galvanized a team of researchers at Colorado State University to 
explore this drastic possibility. We utilize animals scheduled to be euthanized 
for other reasons and attempt to induce irreversible coma in these animals by 
induction of cerebral hypoxia. We hope to find a clear EEG criterion which 
signals coma. If the method is successful, perhaps the method could be taught 
to veterinarians at institutions planning to utilize animal models of genetic 
disease so that the animals will not needlessly suffer.
Obviously, such methods of controlling pain and suffering are very dras-
tic and their effective application is fraught with difficulties. For example, 
they could, presumably, only be employed where higher brain function is es-
sentially irrelevant to the study of the disease. Whether this is the case or not 
with Lesch-Nyhan’s disease, for example, once it was established that the trans-
genic animal, indeed, showed all signs of the disease, is unclear. I believe it is. 
Certainly, at least some metabolic genetic diseases could be studied in this way.
Equally significant, there is something aesthetically, at least and perhaps 
morally as well (I am not clear on this), about deliberately creating such ani-
mals. At the very least, it dramatically perpetuates the notion that society is 
seeking to transcend—that animals are simply tools for human expedient 
use. It is, in my view, the lesser of two evils.
The key point is that this dimension of genetic engineering of animals 
cannot be ignored. There is, as we saw, every reason to believe that transgenic 
animals will be created to study human genetic disease as soon as the techno-
logical capability exists to do so. Extant laws permit such animals to be cre-
ated. The mindset of the research community makes it inevitable. It is also 
clear that such diseases can cause enormous amounts of pain and suffering.
In the face of this development, responsible researchers need to explore all 
possible avenues for controlling such pain and suffering. These approaches 
should include such established methods as the liberal use of anesthetics, an-
algesics and tranquilizers, and by making as much of the research as possible 
acute. But these methods are unlikely to be effective in the case of those dis-
eases where suffering begins at birth or is chronic after a certain stage of de-
velopment. (Lesch-Nyhan’s patients, as we mentioned, do not show symp-
toms from birth, but do exhibit them chronically after their onset.) Thus,
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methodologies need to be developed which will control pain and suffering 
over extended periods of time. There is, thus far, no reason to believe that the 
research community has yet engaged this issue vis d vis animals used in other 
chronically painful work, let alone in genetically engineered animals. The 
development of such methodologies for controlling pain and suffering is 
likely to be exportable to numerous areas of animal research, not only trans-
genic creation of disease. Only in this way can research attempt to stay in har-
mony with the ethical stance of the society which allows and supports it.
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Workshop Report
The workshop began with a wide-ranging discussion about the concept of well-being. To what extent does it overlap with productivity? Does it take 
into account the sentience of the animal, the exercise of its cognitive capaci-
ties and its ability to cope with its environment? It was asserted that at the 
least, well-being involves an ability to express a range of normal behaviors. It was 
remarked that well-being is not a single, precisely defined state. The indica-
tors of well-being are not linear. In some cases, more of something may be 
better, but-in other cases there may be thresholds such as optimal body 
weight. Perhaps well-being should be defined negatively rather than posi-
tively: the failure of some system may imply a lack of well-being, but the 
presence of something (e.g., normal blood glucose levels) may not indicate 
an acceptable level of well-being. Productivity (e.g., growth, milk produc-
tion, reproduction) has been used as one measure of well-being for agricul-
tural animals although it was noted that such measures often will be inappro-
priate for determining the well-being of pets and research animals. It was 
also remarked that the notion of well-being applies to individuals, but indi-
ces of well-being are relative to populations.
Participants, faced with a vast scope of issues in animal well-being, de-
cided that the discussions should be limited to the well-being of animals in-
volved in biotechnology: farm animals and experimental animals. What are 
the factors that we should look for to measure well-being in transgenic ani-
mals? What about the integrity or intrinsic value of the animal? It was sug-
gested that there were two problems in proceeding this way. First, not all con-
cerns about the use of animals involve inadequate well-being during these 
uses. Rather, some individuals object to specific uses of animals. Perhaps 
harms that animals may suffer as a result of biotechnology should be consid-
ered. Discussion could focus on whether infliction of these harms can be jus-
tified, or whether there are alternative procedures. Secondly, it was pointed 
out that biotechnology involves much more than just transgenic procedures. 
Selective breeding, artificial insemination and embryo transplantation are 
other examples. Different forms of biotechnology may raise different issues. 
Animals may be harmed deliberately in order to create disease models for
research purposes, whereas any harms animals suffer in production are inci-
dental and usually not intended.
These points led to a discussion of why older forms of biotechnology did 
not stimulate as much public concern as newer forms. Selective breeding has 
been going on for centuries without serious well-being objections. Many 
people feel that new technologies create new problems. Furthermore, societal 
views of animals are changing. Technology is colliding with changing moral-
ity. In addition, lay people are increasingly skeptical of scientific ethics, due 
in part to recent negative publicity associated with a few famous scientists.
Some people are upset about biotechnology because it is perceived as 
“unnatural.” This connects to general cultural attitudes about the human re-
lationship to nature. Against this it was suggested that people are part of na-
ture, so everything we do is natural. The objection to this, however, is that 
this concept eludes the distinction between the natural and unnatural.
It was suggested that one new thing about contemporary biotechnology 
is that we can create animals who may have no potential for “happy” lives.
Can we be said to have wronged such animals?
Some participants suggested that biotechnology gives us the capability 
to create animals that are adapted to a closed-confinement system in which 
they cannot move or otherwise express some movement-related behaviors. 
We may be able to imagine creating animals that would delight in confine-
ment—to some extent this has been done already. Some thought that it 
would be wrong to do this because it would be exploiting the animals, al-
though it was remarked that this objection was not an objection on grounds 
of animal well-being.
QUESTIONS RAISED ABOUT BIOTECHNOLOGY 
AND ANIMAL WELL-BEING
Individual participants listed questions about biotechnology and animal 
well-being during the workshop. In no specific order they are:
—Will the farm community compensate for bad environments by creating 
new animals?
—Will genetic engineering arbitrarily be singled out from other forms of ge-
netic manipulation (e.g., pet breeding, spaying, castration)?
—Will biotechnology be used to reduce and replace animals used in painful 
and invasive research?
—Are we changing our attitude and relationship towards nature, e.g., from 
the standpoint of mastering nature?
—Will a concern with animal well-being lead us to overlook the important 
human issues involved in the use of biotechnology?
—Whose interests are being served by biotechnology?
—Does biotechnology raise new issues about animal well-being? How much 
has the technology changed and how much have we changed?
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—Are societal needs or scientific needs driving the development of biotech-
nology?
—What do we want the future animal production system to be like and how 
can biotechnology be used to forward our vision?
—Why is it difficult to pose fundamental questions about biotechnology?
—Why do people respond so strongly to biotechnology?
—Are there nonbiotechnological alternatives to what we want to do?
—Is biotechnology different in kind from what we have been doing?
—How does money flavor the issue?
—What are the larger beliefs about the relations between humans and ani-
mals that drive the differences in opinion about biotechnology? (It was ob-
served that the emergence of biotechnology coincides with greater concerns 
about animals, increasingly cognitive views of animals, increased distance 
from agricultural and draft uses of animals, and urbanization and romantici- 
zation of animals. Genetic engineering feeds into these concerns because of the 
general concern that the manipulation of genes could lead to unnatural beings).
CONCERNS ABOUT BIOTECHNOLOGY AND ANIMAL WELL BEING
Individual workshop participants had concerns which were then listed as follows 
(again in no special order):
—Some of the public believe that there are more costs than benefits to biotech-
nology;
—Biotechnology could increasingly depersonalize the relationship between 
people and animals;
—Everything we do to animals biotechnologically could eventually be done to 
humans (and thought to be acceptable because of the previous animal work); 
—Politicians frequently do not understand the social ramifications of their ac-
tions;
—Scientists and farmers want to make decisions about the use of biotechnology 
(even though they do not always understand the implications of their deci-
sions) and some resent the intrusion of lay people into routine decision-
making;
—People like us (well-educated, predominantly urban, well-placed) are making 
certain decisions for rural farmers and there is little they can do about it. Bio-
technology and its regulation are being driven by intellectual power rather 
than by people who work with animals on a daily basis;
—Uncertain, and by some interpretations frivolous, restrictions may be imposed 
that will prevent society from reaping the benefits of biotechnology;
—Uncertain, and by some interpretations frivolous, use of biotechnology may 
limit the options of society to have a just and sustainable future;
—There is a risk that biotechnologists will defend the use of animals so avidly 
that they will evoke a huge counter-reaction;
—Some critics of biotechnology want to stop all human uses of animals;
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—The rate of change goes beyond our ability to anticipate it and to respond 
to it;
—People do not understand that animal biotechnology could eventually lead to 
the elimination of animal food production (through fermentation tech-
nologies, etc.);
—There is a lack of effective communication between science and the public;
—Genetic engineering may eventually make the discussion of animal well-being 
a nonissue;
—The failure to use animals in genetic engineering will deprive people of the 
benefits of medical pharmaceuticals;
—If we cannot predict the impacts of genetic engineering on animal well-being, 
should we still undertake it?
By this point in the discussion the participants were quite polarized and it 
was remarked that some people who hold very strong views were not even 
represented. It was suggested that some of the fundamental questions might 
concern whether it is ever acceptable to utilize animals for human use, 
whether animal biotechnology poses unique questions about animal well-
being and whether biotechnology is qualitatively or quantitatively different 
from what has come before.
POSSIBLE HARMS OF BIOTECHNOLOGY TO ANIMAL WELL-BEING
Participants decided to identify some possible harms and benefits to animal 
well-being that arise in the context of biotechnology. Possible harms elicited 
from participants were:
—Loss of genetic diversity;
—Proliferation of genetically defective animals who suffer as disease models;
—Thinking of domestic animals as human artifacts;
—Diverting resources away from improving traditional husbandry practices;
—Leading us away from sustainable agriculture which might be better for 
animals;
—Leading to ecological devastation through the introduction of genetically al-
tered animals;
—Narrowing the concept of well-being to merely biological health;
—Strengthening corporate agribusiness with long-term negative consequences 
for animal well-being;
—Creating animals who do not feel pain and may still damage themselves.
POSSIBLE BENEFITS OF BIOTECHNOLOGY TO ANIMAL WELL-BEING
Following a listing of harms to animal well-being, workshop participants 
then listed possible benefits biotechnology could bring to animal well-being:
—Removal of genetic defects from animal populations more rapidly;
—Permitting increased disease resistance;
—More efficient production leading to the use of fewer animals;
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—Better understanding of animal well-being;
—Better well-being through the creation of animals less susceptible to environ-
mental conditions;
—Creating animals so existing resources can be used as food;
—Using fewer animals both in research and in farming;
—Increasing genetic diversity;
—Increasing understanding of and solutions to the medical problems of both hu-
mans and nonhumans;
—Enhancement of wildlife management and growth of nonhuman populations 
as hunting becomes obsolete;
—The end of factory farming through the redesign of farm animals;
—Driving small producers out of business who mistreat animals.
A highly unrepresentative straw poll was then done in order to see which of 
these possible harms and benefits the participants most wanted to discuss. As 
listed, the first four possible harms and the first four possible benefits re-
ceived the most support along with the possibility that animal biotechnology 
may lead to healthier products for both humans and animals. They formed 
the basis of much of the remaining discussions.
CONSENSUS STATEMENTS
Weighing the broad spectrum of issues related to biotechnology and animal 
well-being, participants were able to reach agreement on four consensus 
statements:
1. Biotechnology may contribute to animal well-being, but it is not the 
only approach to improving animal well-being.
2. There should be responsible, systematic investigation of the benefits 
and harms to animals that may be associated with biotechnology.
3. It is acceptable under some conditions to use animals for human use.
4. Animal biotechnology has the potential to contribute to the “three Rs” 
in animal experimentation: reduction, refinement and replacement.
RECOMMENDATIONS
1. With respect to animal well-being, criteria should be developed for re-
sponsible research and application of specific biotechnologies in animals. The 
full spectrum of opinion should be represented in the development of these cri-
teria. These criteria should be periodically reconsidered in the light of chang-
ing circumstances.
2. The benefits and harms noted should be taken into account in develop-
ing these criteria.
3. Animal biotechnology should not be used in ways that impose great 
costs in animal well-being, while achieving only minor human or animal ben-
efits. When there is the likelihood that a procedure will cause great suffering 
to animals, alternatives should be sought.
Animal Well-Being
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The Potential Spinoff of Advances in Human 
Medicine to Animal Research and Agriculture
BIOTECHNOLOGY AS A GROWTH INDUSTRY
The discoveries of biotechnology will soon be approaching 20 years of age. Several of the key discoveries—restriction enzymes (Kelly and 
Smith, 1970), DNA ligases (Weiss et al., 1968), etc. led to the first trans-
formed microbe in 1973 (Cohen et al., 1973). These initial discoveries led to 
an extended discussion, in 1976, in a San Francisco tavern between a venture 
capitalist Robert A. Swanson and Herbert W. Boyer of the University of Cali-
fornia in San Francisco. The first biotechnology-based “boutique,” Genentech, 
was thus soon formed. Genentech’s success led the way to the creation of 
hundreds of other small companies specializing in applications of an emerg-
ing technology—genetic engineering. The excitement, dreams and specula-
tion generated by this technology attracted billions of dollars of venture 
capital, primarily for human medical interests. By January 1, 1992, Amgen, 
one company of these origins, joined the Standard & Poor’s 500 and was 
given a $10 billion market evaluation.
The growing market of biotechnology-based protein drugs is now well- 
over $2 billion annually. In the late 1970s, interest in animal applications of 
biotechnology started to attract investments. Bovine somatotropin (BST) 
product development was the first direct spinoff of this early drug research 
activity. Many other applications of biotechnology for animals and plants 
have subsequently been the basis of the formation of small companies. Fed-
eral agencies directed close to $4 billion to support biotechnology research 
in 1992; this is of special interest to those of us interested in animal produc-
tion and the development of improved methods for enhancing the efficiency 
of production. Even more than that is being spent by hundreds of companies 
to develop further scientific bases and applications of biotechnology. Of tre- 
menendous potential for broadening the horizons for many aspects of biological 
research is the 15-year, $3 billion federal support of the Human Genome Project.
BIOTECHNOLOGY ADVANCES IN HUMAN MEDICINE AND SPINOFFS 
TO ANIMAL AGRICULTURE
Others in this conference will undoubtedly discuss the numerous and essen-
tial contributions of animal models to the development of human drugs and
treatment strategies for even the most intractable of the human disease con-
ditions. The following discussion will deal with certain aspects of the appli-
cations of biotechnology to animal research and agriculture.
In Table 1 is a list of protein drugs approved by the Food and Drug Ad-
ministration (FDA)since 1982, starting with Humulin®, a biosynthetic insu-
lin (Genetic Engineering News, January, 1992). Momentum in protein drugs is 
growing—5 of the 30 products approved by the FDA in 1991 were of this 
type. This rate may be duplicated in 1992 and possibly 100 more biotechnol-
TABLE i: BIOTECHNOLOGY-BASED DRUGS APPROVED BY FDA
Product Company Indication Year
Actimmune Genentech management of chronic 1990
granulomatous disease
Activase Genentech acute myocardial infarction 1987
acute pulmonary embolism 1990
Alferon Interferon Sciences genital warts 1989
Engenix SmithKlineBeechamhepatitis B 1989
Epogen Amgen 2 treatment of anemia associated with 1989
chronic renal failure, including 
patients on dialysis & not on 
dialysis, and anemia in Retrovir- 
trated HIV-infected patients
Procrit Ortho Biotech treatment of anemia associated with 1990
chronic renal failure, including 
patients on dialysis & not on 
dialysis, and anemia in Retrovir- 
trated HIV-infected pa lients
Humatrope Eli Lilly human growth hormone deficiency in 1987
children
Humulin Eli Lilly diabetes 1982
Intron Schering-Plough hairy cell leukemia 1986
genital warts 1988
AIDS-related Kaposi's sarcoma 1988
non-A, non-B hepatitis 1991
Leukine Immunex autologous bone marrow 1991
tranplantation
Prokine Hoechst-Rooussel autologous bone marrow transplan- 1991
tation
Neupogen Amgen chemotherapy-induced neutropenia 1991
Orthoclone OKT3 Ortho Biotech reversal of acute kidney transplant 1986
rejection
Protropin Genentech human growth hormone deficiency in 1985
children
Recombovax HB Merck hepatitis B prevention 1986
Roferon-A Hoffman-LaRoche hairy cell leukemia 1986
AIDS-related Kaposi’s sarcoma 1988
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ogy-based drugs are now in clinical trials. Applications of identical or similar 
products for animals are bound to follow all of this activity. A major advan-
tage of this is that human drug development leads to initial reagents and test 
probes for studies both in vitro and in vivo in other animals.
Of longer-term consequence is the development of a large number of 
products resulting in significant production process developments and asso-
ciated discoveries which lead to reduced costs of drug production. In many 
cases, this alone permits consideration of new animal product concepts. Ad-
ditionally, some of these biosynthetic proteins are likely to have desirable ef-
fects during certain physiological states of animals not predicted from their 
names or the initial basis for their discovery.
The rapid development of genetic engineering has made it possible for a 
soaring rate of new discoveries. Proteins present in minute quantities, but 
occasionally of immense importance to animal physiology, can be predicted 
from messenger RNA. Thus, the existence of previously unknown proteins 
can be demonstrated by isolation and multiplication of very specific genetic 
codes. This has led to the discovery of numerous important proteins (i.e., 
hormones, receptors, enzymes) that otherwise would have been impossible 
to discover by classical endocrinology-based techniques, even before know-
ing the function of these proteins.
Within the lifetimes of many of us, the understanding of receptors on 
cells have evolved from essentially a concept to a specific protein or a family 
of proteins. These advances have, in many cases, replaced the need for phar-
macological classifications for receptor types such as the adrenergic recep-
tors which are subdivided according to their pharmacological response to 
epinephrine and non-epinephrine (Ahlquist, 1948). The genetic expression 
of a hormone receptor and binding characteristics of each of a family of re-
ceptor proteins can now be studied for cell type specificity, etc. (Laird et al., 
1991). The diversity of protein receptors has led to new strategies for drug 
design including the utilization of very powerful chemical tertiary structure 
software for predicting specific drug analogs with highly selective activity.
In some cases, possession of quantities of a specific receptor protein allows 
screening for specific binding by peptides or other chemicals to develop spe-
cific blockers.
As recently reported (Gibbons, 1992), second generation products from 
biotechnology will include other specific means of modifying selected pro-
tein expression. The expression of specific proteins which either inhibit 
growth enhancement or cause disease conditions may be reduced or elimi-
nated by blocking the transcription of DNA into the specific protein messen-
ger RNA. Another method of obtaining similar responses is to develop short 
oligonucleotides that recognize and bind to specific messenger RNAs and 
thus block protein synthesis. These and other means provide opportunities 
for developing drugs that enhance animal production and health.
Links to Human Health
SUMMARY
Human health-related research is leading the way to new technological 
breakthroughs, reagents, probes and general understanding of biological sys-
tems at a molecular level. An additional benefit will be the generation of 
many opportunities for enhancing animal production. In many cases, species 
specificities may be engineered into the developing strategies to ensure that 
human health concerns are met even at a molecular level. At the present time 
there are more opportunities for improving the efficiency and endproduct 
quality (e.g., nutritional value), than can be funded by most major compa-
nies. The many exciting advances in biotechnology are steadily making the 
discovery process more affordable and allowing the backlog of opportunities 
to build. Recognition and acceptance of how to safely apply biotechnolgically 
based productivity enhancers and health aids will surely result in much 
greater investment in animal drug development in the near future. All of this 
activity, plus the advances in animal science, will assure the world new meth-
ods of increasing the abundance, quality and variety of foods. Given the pre-
diction that 10 billion people may be on earth within the first half of the 21st 
century, this is an issue of great importance. These future products will be 
cheaper and safer to produce and will lead to superior, safer and environ-
mentally friendly management options for animal agriculture. All of these 
qualities should make these innovations available to more of the world’s food 
producers including those in developing countries.
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Reproductive Biology of Domestic Animals: 
Linkages with Veterinary 
and Human Medicine
This paper will discuss opportunities for linkages between research in animal agriculture and research directly related to human medicine. 
Results of research in animal agriculture have affected certain aspects of clin-
ical medicine for many years. The application of biotechnology to human and 
veterinary medicine involves many techniques used in reproductive biology 
and applied in animal agriculture. Among these are embryo transfer, gene in-
jection, use of embryonic stem cells for introduction of genes and cloning of 
embryos. Gene transfer in animals is being used to evaluate the value of trans-
genic animals in animal agriculture. Transgenic animals are also being used 
for the study of specific genetic defects. Production of transgenic animals 
has received much attention recently. This technique represents only one ap-
proach which can be used not only to examine questions of interest to the 
biomedical community, but will also help establish linkages between animal 
agriculture, veterinary medicine and human medicine. Naturally occurring 
diseases in livestock must be examined for their value as models for human 
disease. Regulatory proteins normally secreted by the conceptus (embryo/fe- 
tus and associated membranes) may have unique therapeutic value for cer-
tain diseases. In addition, regulatory proteins secreted in significant amounts 
may be associated with normal development of the conceptus, but with vari-
ous disease states in adults. Although it may be useful to create transgenic 
animals as models for specific diseases, we must also focus on naturally oc-
curring diseases affecting animals that are common to humans.
Reproductive biology, in particular the study of pregnancy in livestock, 
provides numerous opportunities to address questions of biology with appli-
cation to both veterinary and human medicine. Pregnancy and associated de-
velopment of the conceptus seems analogous to compressing events of a life-
time into a period of gestation. Because of extremely rapid development of 
the conceptus, basic questions relative to proliferation and differentiation 
of cells, cell-cell interactions and regulation of gene expression can be
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addressed. Results impact our knowledge of wound healing, cancer biology, 
tissue transplantation biology, immunology, developmental^ regulated ex-
pression of genes, endocrine regulation of maternal and fetal-placental ex-
pression of genes, the hematopietic system and so forth. It is not surprising 
that investigators from numerous disciplines have petitioned for the oppor-
tunity to study fetal-placental tissues of humans. Again, understanding nor-
mal events and mechanisms associated with the reproductive process will di-
rectly impact animal agriculture and the biomedical community.
GENE TRANSFER IN HUMAN AND NONHUMAN ANIMALS
It is clear that techniques such as embryo transfer, gene injection, cloning of 
embryos and related technologies have always been done first in animals so 
that proven methods can later be applied to human and veterinary medicine. 
Gene transfer in animals is now being evaluated critically in a number of spe-
cies and with a number of genes. The problems laboratories face in attempt-
ing to produce transgenic animals include poor expression, lack of expres-
sion or over expression of genes of interest, and in some cases, lack of incor-
poration of injected genes. Documentation of these problems in animals and 
development of technologies to overcome them must be through animal ex-
perimentation before these techniques become useful to clinical medicine. In 
some cases, tissue specific expression is essential. This is also being studied 
extensively in animals in which expression of genes are being restricted to the 
mammary gland and the gene products are being harvested from milk. These 
technologies will eventually impact animal agriculture and medicine, but ex-
perimentation with animals will continue to be central to this research.
ALTERNATIVES TO TRANSGENIC ANIMALS
An alternative to development and use of transgenic animals is the identifica-
tion of animal models which have naturally occurring diseases and/or meta-
bolic disorders that provide natural linkages between animal agriculture and 
the biomedical community. Although rodents or other small laboratory ani-
mals are commonly used, domestic animals should be used as models when-
ever possible so that scientific breakthroughs will impact animal health, hu-
man health and production animal agriculture. For example, sheep are used 
extensively as the animal model for studies of basic questions pertaining to 
pregnancy, perinatology and neonatology in humans in departments of pedi-
atrics and departments of obstetrics and gynecology. Results from such re-
search directly impacts the base of knowledge available to clinicians to im-
prove survival and well-being of neonatal humans and animals. Importantly, 
the same information benefits production animal agriculture.
Trophoblast In terferons
Acquired immunodeficiency syndrome (AIDS) is having devastating effects 
on human health throughout the world. Similar lentivirus-induced diseases
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affect cattle, sheep, horses, goats, primates and cats which makes them excel-
lent animal models for studies of the etiology, prevention and treatment of 
human AIDS. A potential therapeutic drug for AIDS is recombinant leuko-
cyte interferon alpha. The trophoblast of conceptuses of some species (e.g., 
ruminants and humans) produce unique interferons which may be especially 
useful for treatment of AIDS and AIDS-like diseases because the trophoblast 
interferons appear to lack the undesirable toxic side effects of leukocyte 
interferons.
Type I trophoblast interferons (tIFN) of sheep, goats and cows are bio-
chemical signals for maternal recognition of pregnancy which may be useful 
for enhancing fertility in animal agriculture; however, they may also have 
therapeutic value in human and veterinary medicine (Bazer and Johnson, 
1991). The tIFNs have high amino acid sequence homology with both inter-
feron alpha I (IFNa j) and interferon alpha II (IFNa jj) or omega interferon 
(IFNq ) which are produced by white blood cells. The tIFNs produced by 
sheep, cow and goat conceptuses are very similar to each other in structure 
and biological activity. A gene for human tIFN (htIFN) that has 85 to 87 per-
cent homology with sheep tIFN (otIFN) has been cloned from a human pla-
cental cDNA library (Whaley et al., 1991).
The tIFNs have potential therapeutic value because they are interferons 
that inhibit cellular proliferation (Pontzer et al., 1991), exert antiviral effects 
(Pontzeret al., 1991) and regulate the immune system (Newton et al., 1989). 
Evaluation of the potential therapeutic value of tIFNs requires sufficient 
amounts of pure protein for clinical studies. A synthetic gene for sheep tIFN 
is being used in yeast and bacterial expression systems to produce recombi-
nant sheep tIFN (rotIFN) that is identical to natural otIFN in terms of its 
amino acid sequence and biological activities (Ott et al., 1991). The antiviral 
activity of this tIFN is as potent as that of known recombinant leukocyte 
interferons from humans (rhIFN) and cattle (rbIFN), but sheep recombinant 
tIFN does not exert cytotoxic effects characteristic of treatment with rhIFNa  
and rbIFNa  (Pontzer et al., 1991; Bazer et al., 1989). Exposure of human and 
feline peripheral lymphocytes infected with human immunodeficiency virus 
(HIV) and feline immunodeficiency virus (FIV) respectively, to sheep tIFN 
inhibited replication of the viruses, but did not exert cytotoxic effects on the 
infected cells when used at concentrations up to 200,000 antiviral units per 
ml. However, rhIFNa  and rbIFNa  exerted significant cytotoxic effects at only 
1,000 to 5,000 antiviral units per ml.
The tIFNs also have antiproliferative effects on cells that is equivalent to 
or greater than that of rbIFNa  and rhIFNa  (Pontzer et al., 1991) and maybe 
useful in the treatment of cancers. When anticellular activities of sheep tIFN, 
rbIFNa  and rhIFNa  were compared using human amnion (WISH) and 
Madin-Darby bovine kidney (MDBK) cells, all inhibited proliferation of the 
cells. However, sheep tIFN was more effective at lower dosages and, at high
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dosages (50,000 antiviral units per ml), otIFN more effectively blocked cell 
proliferation without adverse effects on cell viability. At the same concentra-
tions of antiviral activity, rbIFNa caused substantial cell death (Pontzer et 
al., 1991; Bazer et al., 1989).
Human patients having steroid-dependent mammary tumors respond 
to treatment with ^-interferons because of increased receptors for progester-
one and decreased receptors for estrogen in tumor cells (DeCicco et al.,
1988). In the pregnant uterus of sheep, tIFN stabilizes receptors for progest-
erone while decreasing receptors for estrogen (Ott et al., 1992). The health 
of many women is affected adversely by estrogen-dependent tumors of the 
mammary glands and reproductive tract. Because estrogen-dependent tu-
mor growth depends on the presence of cellular receptors for estrogen, 
tIFNs have potential therapeutic value because they inhibit synthesis of cel-
lular receptors for estrogen which should prevent estrogen-dependent 
growth of the tumors.
Humans suffering from infection with HIV or diseases such as hairy 
cell leukemia are willing to consider lifelong therapy with rhIFN; however, 
chronic treatment with rhIFN results in development of resistance to the ef-
fects of currently available recombinant rhIFN (Tamm et al., 1987). In addi-
tion, high doses of rhIFN produce intolerable fever and chills, anorexia, 
weight loss and fatigue (Oldham, 1985) and may also cause seizures (Janssen 
et al., 1990). Interferons have both immuno-enhancing and cytotoxic effects; 
therefore, therapeutic doses are chosen which favor the immuno-enhancing 
effects. In contrast, tIFNs act through receptors on the uterine epithelium 
which are in direct contact with the conceptus and are exposed to as much as 
40 million units of antiviral activity per 24 hours without cytotoxic effects. 
These tIFNs have unique “cell friendly” properties which may make them es-
pecially desirable therapeutic agents for use in animal agriculture, veterinary 
medicine and human medicine.
A number of diseases affecting livestock result from infections by lenti- 
viruses of the family Retroviridae. These include, ovine progressive pneumo-
nia virus (OPPV), caprine arthritis-encephalitis virus (CAEV), bovine im-
munodeficiency-like virus (BIV), equine infectious anemia (EIA), feline im-
munodeficiency virus (FIV) and simian immunodeficiency virus (SIV) 
(Haase, 1986). Diseases caused by OPPV, CAEV and BIV, for example, are 
uniquely suited for testing the therapeutic value of tIFNs in the control of 
lentivirus-induced diseases because conceptuses of each of these species se-
crete tIFN. These animal models must be studied to assess the therapeutic 
value of tIFNs in preventing or ameliorating vertical transmission of lenti- 
viruses (i.e., via the placenta), and horizontal transmission (i.e., animal to 
animal), as well as the efficacy of tIFNs in treating infected fetuses and adult 
sheep, goats and cattle.
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Hematopoietic System
Another protein isolated from reproductive tissues of domestic farm animals 
which has potential application to veterinary and human medicine is utero- 
ferrin. Uteroferrin is a purple-colored, progesterone-induced glycoprotein 
secreted by uterine endometrial epithelium of pigs (Bazer et al., 1991). Utero-
ferrin can also be purified from human term-placenta. During pregnancy, 
uteroferrin is transported from uterine secretions into the fetal-placental 
circulation and is targeted to reticuloendothelial cells of the fetal liver, the 
major site of hematopoiesis in fetal pigs. Uteroferrin, from pig uterus is a tar-
trate-resistant acid phosphatase with many properties in common with the 
Type 5 tartrate-resistant acid phosphatase in human placenta, chondrocytes 
of osteoclastic bone tumors, spleens of patients with hairy cell leukemia, as 
well as Gaucher’s and Hodgkin’s diseases (Ketcham et al., 1985). In addition, 
uteroferrin has characteristics similar to those for purple acid phosphatases 
from normal bovine, rat, mouse and pig spleen, as well as bovine milk, bo-
vine uterine secretions, equine uterine secretions and rat bone. Uteroferrin 
from pig uterus and human placenta is a hematopoietic growth factor having 
granulocyte-erythrocyte-monocyte/macrophage-megakaryocyte colony 
forming unit (CFU-GEMM) activity that affects differentiation of primitive 
nonadherent hematopoietic stem cells from pig and human bone marrow 
(Bazer et al., 1991).
Uteroferrin from pig uterine endometrium and human placenta 
(Ketcham, 1988), appears to influence hematopoiesis during fetal life. In 
adult humans, however, the presence of the Type 5 tartrate-resistant acid 
phosphatase, which has high amino acid sequence homology with utero-
ferrin, is indicative of abnormal function of cells associated with hematopoi-
etic tissues (Ketcham et al., 1985) in such diseases as hairy cell leukemia. It is 
not clear why there is such abundant secretion of uteroferrin by pig uterus 
and human term-placenta during the course of a normal pregnancy while the 
apparently identical protein is associated with pathological conditions in 
adults, e.g., hairy cell leukemia. An understanding of this paradoxical situa-
tion requires further studies to determine the precise role of uteroferrin in 
hematopoiesis. Animal agriculture, veterinary medicine and human medi-
cine will benefit from collaborative efforts to understand the role of this pro-
tein in health and disease.
Reproductive Management
Research with farm animals has contributed significantly to the development 
and use of clinical methods to enhance fertility through the use of techniques 
for in vitro fertilization, embryo transfer, embryo culture, endocrine therapy, 
cloning of embryos and cryopreservation of sperm, ova and embryos. These 
techniques are used to enhance fertility in human and nonhuman animals. 
Methods for contraception or reducing fertility are also based, in large part,
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on results of experiments with domestic livestock. Functional sterility is de-
sired by many humans to limit family size and in animals it may be used to 
control growth of populations in general or in a specific geographical area. 
Research continues to develop methods which render one functionally ster-
ile, but are reversible. Progress in development of immunological methods 
for achieving fertility control continue and will impact programs designed 
to offer safe and effective alternatives for regulation of fertility in human and 
nonhuman animals.
DEVELOPMENT OF ANIMAL GENETIC MODELS OF DISEASE
Development of animal models to study human disease often raises ethical 
and/or animal welfare issues. However, these issues must be considered in 
light of the tremendous positive impact disease research has had in the past 
and will undoubtedly provide for the future for both human and nonhuman 
animals. Diseases of humans and animals must be understood if the adverse 
impact of those diseases are to be ameliorated or eliminated. The possibility 
of experimentation with naturally occurring or transgenic animal models ex-
pressing diseases, or metabolic disorders, is essential to the biomedical com-
munity. Otherwise, we could not adequately address issues of health, disease 
and reproductive management that our increasingly global society will pre-
sent during the next century.
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Workshop Report
ntil recently, animal agriculture and human medicine were largely distinct
fields of scientific inquiry. However, as a result of the advances made in mo-
lecular biology over the last decade, the two fields have come to share a wide 
range of techniques and models. These profound changes in the research pro-
cess have raised a series of issues with respect to the use of both farm and tra-
ditional laboratory animals in research. The discussions in this workshop ses-
sion focused on these issues and recommendations were developed.
The links between animal agriculture and human medicine led partici-
pants in this workshop to the exploration of various relevant issues. They are 
discussed in depth below.
HUMAN HEALTH CONSIDERATIONS THAT DRIVE AGRICULTURAL 
RESEARCH
In recent years, public concern about food safety and nutrition has played an 
increasing role in animal agricultural research. Often, public concerns and 
scientific perspectives with respect to these issues have differed. Yet, under-
standing public concerns and engaging in genuine dialogue are essential if 
these issues are to be properly addressed.
The public is also concerned about the disclosure of the contents of food 
and food products. One area of concern is the labeling of foods which is cur-
rently being debated both nationally and internationally. In addition, there 
are public concerns about broader marketing issues, e.g., product claims.
Participants asked how one chooses between the various options for re-
solving particular problems or improving situations. For example, reduced 
fat intake could be brought about by: 1. developing lower fat meats through 
molecular biology; 2. cutting excess fat off on meat; 3. reducing marbling of 
meat through conventional technologies and changes in the diet of meat ani-
mals; or 4. urging consumers to consume less meat than they do currently.
In addition, new biotechnologies blur the lines between nutrition and 
pharmacy, making possible the creation of what have been variously called 
“nutraceuticals” and “pharmafoods.” These products, often of animal origin,
serve a combination of nutritive and therapeutic goals. They raise complex 
issues of regulation, food safety and consumer education.
ETHICAL USE OF ANIMALS
Some participants at NABC 4 argue that the use of animals as food or in re-
search is itself unethical. Others argue that humane treatment of animals is 
the major concern. The workshop participants agreed that it was not clear 
just what is ethical. Moreover, they were concerned with methods used to ac-
commodate the wide range of views on the subject found in our diverse society.
A related area of concern was the extent to which human beings should 
be dependent on animals for food, medicine and medical research. Some 
would argue that such dependence should be limited, while others consider 
it unproblematic.
Some of the concern regarding the ethical use of animals in biotechno-
logical research stems from the public perception that biotechnological re-
search differs from other biological research. Without question, venture 
capital firms and research universities seeking new funds have fostered that 
belief. Yet others argue that there are no special concerns about the use of 
animals arising from biotechnology.
The creation of transgenic animals is a case in point. Some persons argue 
that this marks a major departure from earlier animal research. Some ask 
whether it is ethical to transfer genes across species lines in order to serve hu-
man ends. The utilitarian position asserts that such research is acceptable as 
long as the benefits outweigh the costs and risks. Yet some participants sug-
gested that the utilitarian position might have limitations insofar as it pro-
duced side effects for animals. A related issue is how much genetic alteration 
is acceptable and how much is too much.
Finally, participants questioned whether current guidelines on the use of 
animals in research, often written before the advent of the new technologies, 
are adequate morally.
ANIMALS FOR BIOLOGICS AND THERAPEUTICS
The use of animals for the production of vaccines and therapeutics has a long 
history. For example, porcine and bovine insulins, purified from the pan-
creas of these animals, have been used therapeutically for human diabetes. 
Nevertheless, the widespread use of animals as living “bioreactors” to pro-
duce chemicals of value to humans, poses several important issues.
Most obvious of these is the ethics of use. Put differently, to what extent 
do we have a moral right to transform animals in this way? Workshop mem-
bers indicated that this type of use differed from other uses of animals (e.g., 
in food and fiber production) and were concerned as to what, if any, ethical 
implications were associated with it.
Moreover, use of animals as bioreactors raises other questions, both 
ethical and practical. For example, there is the problem of what to do with
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the carcasses of these animals. Should they be allowed to enter the food chain? 
Unlike similar products produced through cell or tissue culture, animal biore-
actors raise special questions of regulatory clearance and quality control, 
since cell lines are produced in a controlled environment, whereas animals 
are in contact with other organisms, including those causing diseases.
Animal bioreactors also pose problems of containment, welfare and man-
agement. Such animals probably would have to be segregated from other 
farm animals, raising the question of whether it would be more desirable to 
have certain species earmarked for this purpose and not used for food, Moreover, 
such animals might require greater care or different methods of livestock 
husbandry than is typical of conventional farm animals.
This, in turn, raised the issue of whether whole animals or cell cultures 
should be used for screening of therapeutic products. While it was generally 
felt that cultures were usually more economical, it was also noted that certain 
cases were likely to require the use of whole animals.
THE SOCIETAL CONTEXT OF SCIENCE SHARED BY AGRICULTURE 
AND MEDICINE
Research rarely takes place outside a larger social context. That context pro-
vides both the limits and opportunities for research. The workshop partici-
pants found a number of contextual issues of relevance.
A central issue was how (or whether) to integrate private and public re-
search at the agriculture-medicine interface. Included here were a multitude 
of issues such as the sharing of information (e.g., genome maps and sequences) 
and access to funds, materials and processes.
Another key issue was the distributive aspects of this type of research.
All research activities tend to disrupt ongoing social and economic arrange-
ments. The group asked who benefits, who pays, and who loses from a re-
search project.
Furthermore, new linkages between the medical and agricultural sci-
ences will be influenced by the current state of food, agricultural and medical 
policy which will, either through their deliberate intent or by unintended 
side effects, encourage certain kinds of linkages with research and discourage 
other kinds. At the same time, the discoveries and inventions stemming from 
this research will have a considerable impact on food, agricultural and medical 
policies. There is a clear need to attempt to foresee some of these impacts now.
The intentional transfer of genetic information between organisms raises 
other issues. In particular, although the public may be willing to accept tran-
sfers of material across species in general, it may be unwilling to accept the 
transfer of human genes to animals, or vice versa, for any purposes.
Workshop participants also wondered whether the current institutional 
structures (especially at universities) were adequate for the new linkages be-
tween agriculture and medicine. It was noted that medical and agriculture 
schools, often even those on the same campus, have little history of cooperation.
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There is probably much duplication of effort occurring in medical schools, 
veterinary medical schools and agriculture schools. Currently, the agricul-
ture and medical research agendas are largely distinct and they are set by dif-
ferent constituencies. There was some concern that we do not know how the 
agenda is currently set, nor will we know who will control the agenda of 
newly linked agricultural and medical research programs. One of the pro-
posed solutions to these sorts of problems is technology assessment in vari-
ous forms. The group felt that it was unclear whether the methods and mod-
els of technology assessment were up to the task of charting this new area of 
research.
Another area of concern was that of public relations, both domestically 
and internationally. Is there a way in which the international issues could be 
correlated?
Finally, there was a general consensus that greater public participation 
in the decision-making process was both necessary and desirable.
RECOMMENDATIONS
1. Stronger links need to be developed between agricultural and medical 
research relating to biotechnology. Among mechanisms to do so are centers, in-
centives for joint programs, funding, etc. This will require further integration 
and institutionalization of joint agricultural and medical programs. Such 
linkages will need to include an examination of the ethical, economic, social, 
institutional and legal ramifications of these changes.
2. More resources from molecular biology should be devoted to genome 
and other research in an attempt to ultimately spare animals from direct use 
in research. It should be thereby possible to shift largely from whole animal to 
organ, tissue or cellular systems.
3. Explore the moral implications of the use of animals in medical and ag-
ricultural research. Issues in the area are currently inadequately examined 
and thus, there is not yet an adequate moral framework for making decisions 
about this type of research.
4. Provide for education of and dialogue among all the participants in the 
debate.
5. Improve the agenda setting process that insures that resources are 
properly allocated and that all interested parties are involved in the allocation 
process.
6. Improve the guidelines to aid in determining appropriate circum-
stances for patenting animals, tissues and cell lines.
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Food Safety Perspectives on 
Animal Biotechnology
Having been involved in meat and food animal research for a good part of my career, I am aware of the opportunities biotechnology provides 
in improving the health of food animals and the safety of the meat supply.
As the new administrator of the U.S. Department of Agriculture, Food Safety 
and Inspection Service (FSIS), I am also aware of the responsibilities we have 
to ensure the safety of food produced through animal biotechnology. In this 
paper I will present my perspectives on animal biotechnology by discussing 
two broad areas. First, the opportunities biotechnology provides in making 
food safer, and second, the regulatory implications of the new technologies 
as they relate to the meat and poultry supply.
OPPORTUNITIES TO PRODUCE SAFER FOODS
The Food Safety Inspection Service is a public health agency dedicated to en-
suring the safety of the meat and poultry supply. For that reason, any new 
technology that offers the opportunity to fulfill that mission more effect-
ively and efficiently is of interest to us. While we are addressing the issue of 
transgenic animals, we are also looking at products such as bioengineered 
vaccines, bioengineered pharmaceuticals and diagnostic tests. All of these 
will have a long-term impact on animal health and food safety. Biotechnol-
ogy offers a number of new tools that will improve the health of food ani-
mals. Genetically engineered vaccines may confer immunity more safely and 
efficaciously than traditional vaccines. With genetically engineered vaccines 
we can differentiate whether the animal is vaccinated or infected—an impor-
tant distinction in the fight to control and eradicate animal diseases.
One North Carolina firm recently developed a method of vaccinating 
chickens inside the shell—even before they hatch. While FSIS does not use 
these vaccines or regulate them, they affect our mission by improving the 
health of animals coming to slaughter.
Other tools, such as improved diagnostic tests, are of direct value to us 
in the meat and poultry inspection program. For instance, researchers with 
USDA’s research arm, the Agricultural Research Service (ARS), are develop-
ing a recombinant antigen for the serodiagnosis of bovine cysticercosis.We 
hope to be able to use this test in the inspection program in the future.
Biotechnology also offers opportunities to improve the microbiological 
safety of meat and poultry products—our number one priority. In our labo-
ratories DNA probes are being used for detection of Salmonella in cooked, 
ready-to-eat meat and poultry products. We are working to integrate similar 
DNA probes for Listeria monocytogenes and Campylobacter into our program 
in the near future. These tests provide advantages in terms of reducing the 
time needed to get results and greater specificity in identifying organisms.
Another way to improve microbial safety is by using recombinant DNA 
to produce a bacteriocin effective against specific foodborne pathogens. The 
bacteriocin could be added to processed foods to reduce spoilage in a manner 
similar to the currently approved use of nisin in cheese spreads. Other devel-
opments are on the horizon. While we are not currently using these technolo-
gies in our microbiology program, certainly the potential is there. For in-
stance, polymerase chain reaction (PCR) technology will allow us to amplify 
the genetic material from pathogens so we can detect these pathogens with-
out enrichment. This technology will also allow us to look for a specific bac-
terial genus or species and even a specific virulence gene.
Biosensors are an even newer avenue of biotechnology research. By at-
taching an antibody, enzyme or nucleic acid to an electrode, these sensors 
can be used to detect a foodborne pathogen or antibiotic. They have the po-
tential to make shelf life predictions for chilled meat by detecting glucose 
(an indicator of microbial spoilage flora) at the surface of the meat. While de-
tection is important, the ultimate goal is to prevent contamination in the 
first place. That is why we hope to see future research directed towards using 
genetic alteration to produce meat and poultry resistant to pathogenic 
microbes such as Salmonella.
While diagnostic tests that are faster and more effective is a great advan-
tage, producing disease-resistant animals is equally important. For instance, 
ARS has demonstrated that it is possible to identify swine with a genotype 
that is resistant to trichinosis. With further research, this genotype could be 
incorporated into domestic swine populations—conferring trichinosis im-
munity to all future generations of swine.
At Texas A&M, site of NABC 4, animal geneticists Jerry Taylor and Scott 
Davis are working on a project funded by the U.S. Agency for International 
Development to determine if individual genes in goats are associated with re-
sistance to Haemonchus contortus, a parasitic disease that affects ruminants 
throughout the world. While this specific study is more applicable to Third 
World countries, it certainly has relevance for domestic animal production.
If a genetic basis for resistance can be incorporated into livestock produc-
tion, we can produce healthier animals and reduce the need for animal drugs.
There are also other possible benefits aside from disease resistance that 
may be realized through genetic modification of animals. Some of these
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possibilities include:
—animals with leaner meat;
—animals that use feed more efficiently;
—animals with better growth features; and
—animals that manufacture biopharmaceuticals for human or animal therapy. 
The potential benefits from genetically modified animals appears to be in-
creasing all the time.
REGULATION OF TRANSGENIC ANIMALS
Certainly, these new products of biotechnology such as vaccines, diagnostic 
tests and disease-resistant animals interest us as ways to make the meat and 
poultry supply safer. We also have another role—to ensure that transgenic 
animals produced through biotechnology are safe for human consumption. 
For purposes of this paper, transgenic animals are animals whose genetic 
composition has been changed by introducing selected genes from other sources 
into the line from which the animal is derived.
Food-producing animals involved in transgenic animal experiments are 
currently considered experimental under existing FSIS regulations that affect 
the meat and poultry industries. The regulations define experimental animals 
as those treated with experimental drugs, chemicals or biologies. We have not 
yet approved the slaughter of any transgenic animals and are still in the pro-
cess of developing our policy. Since the field of biotechnology is changing as 
we speak, we recognize that our regulatory oversight will have to change to keep 
pace with technological advances.
In the Federal Register of June 26, 1986, the USDA, in conjunction with 
the Office of Science and Technology Policy in the Executive Office of the 
President, stated the Department’s intention to regulate foods produced by 
new methods, such as recombinant DNA techniques, within the existing statutory 
and regulatory framework. This policy is in line with President Bush’s federal 
biotechnology policy, announced in February, 1992, which emphasizes that 
federal oversight should be based on risk, not triggered simply by an innovative 
technology.
We believe the existing system will work because we plan to regulate the 
products of biotechnology, not the process itself. Our inspection program is 
now prepared to handle many diverse animals and many different product 
types. Our system can handle transgenic animals as well. Under our planned 
regulatory approach, the investigator must specifically request slaughter of 
any investigational animals involved in transgenic experiments. Whether or 
not genetic material was successfully incorporated, the following information 
must be submitted and reviewed by FSIS before the animals are presented for 
slaughter:
—species;
—genetic changes being attempted or affected;
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—technique used to introduce the genetic material;
—results of appropriate scientific methods for detection of the transgene, 
such as PCR or Southern hybridization; and 
—physical condition and appearance of the animal prior to slaughter.
In addition, for animals that have successfully incorporated the genetic ma-
terial, the following information should also be provided:
—information on the gene product;
—analytical data/results of the gene product analysis; and 
—an assessment of animal health and performance, including a veterin-
arian’s observation and examination, and any clinical laboratory data 
on the overall health of the animal.
If the information meets the criteria under the experimental animal regula-
tions, the animals would be approved for slaughter. A request for slaughter 
of these animals must be made indicating the location of slaughter. Each ani-
mal from transgenic experiments permitted for slaughter would also receive 
the required antemortem and postmortem inspection by an FSIS inspector 
and/or veterinarian. This is important because the way in which an animal 
grows and functions is a reliable indicator that the change was not detrimen-
tal to the safety of these animals. Since we will know ahead of time that the 
trans-genic animals are to be presented for slaughter, we will have the oppor-
tunity to examine their growth and general health before they reach the 
slaughterhouse.
INTERACTION WITH OTHER AGENCIES
In evaluating the food safety of transgenic animals, we would consult with 
the Food and Drug Administration (FDA), USDA’s Animal and Plant Health 
Inspection Service (APHIS), or the Environmental Protection Agency (EPA) 
before making a food safety decision.
The FDA is responsible for assuring food from species other than those 
inspected by FSIS is safe. They are also responsible for assuring that animal 
drugs are safe, effective and properly labeled, particularly with regard to the 
safety of residues remaining in the animal at slaughter. The FDA, along with 
FSIS, is charged with assuring that food additives added to meat and poultry 
products are safe for consumers. The FDA, in cooperation with state authori-
ties, also sets standards for the wholesomeness of milk. Pesticide chemicals, 
used directly on food animals or on animal feed crops, are reviewed prior to 
marketing for safety by the EPA. Finally, biologic products, such as vaccines 
and serums used in animal health programs, are subject to oversight by 
APHIS for potential food safety impacts.
To repeat, FSIS has not approved any transgenic animals for slaughter 
yet. Our policy on these animals is still being developed and will be consid-
ered ready for review as soon as FSIS has come to an understanding with FDA 
regarding jurisdictional responsibilities of the two agencies with regard to
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animal biotechnology. FSIS is planning to publish a paper entitled “Points to 
Consider” by the end of 1992 that will offer more specific guidance on the re-
quirements for slaughter of transgenic animals. In addition, we plan to have 
our entire policy reviewed by USDA’s Agricultural Biotechnology Research 
Advisory Committee (ABRAC).
I also want to emphasize that all federal agencies involved in regulating 
biotechnology are coordinating their efforts in order to secure common 
guidelines and a clear understanding of jurisdictional responsibilities. In the 
near future evidence of this coordination as policies on various biotechnol-
ogy products emerge.
REGULATION OF NONTRANSGENIC ANIMALS FROM BIOTECHNOLOGY 
RESEARCH
Although no transgenic animals have been approved for slaughter yet, FSIS 
has authorized the slaughter of nontransgenic animals in Texas. These ani-
mals were involved in biotechnology experiments, but they were not geneti-
cally modified. These animals were slaughtered after it was ascertained that 
the criteria announced in the Federal Register notice of December 27, 1991, 
“Livestock and Poultry Connected with Biotechnology Research” (Vol 56,
No. 249) was met.
OBSTACLES TO THE USE OF BIOTECHNOLOGY IN 
ANIMAL AGRICULTURE
Progress has been made in the animal biotechnology arena and the benefits 
to animal health and food safety are evident. It will not be smooth sailing all 
the way, however. There are potential obstacles out there that must be brought 
into the open in order to address them in a constructive manner.
Consumer acceptance of the new technology is a prime example. Just 
because it is good technology does not mean consumers will accept it. All of 
us—government, academia and private industry—must work together to ad-
dress consumer concerns. At FSIS, better communication with the public 
about biotechnology as well as all other issues concerning food safety, is one 
of my major priorities. We must not wait until the questions are asked before 
we provide information. We must not wait until we are attacked to respond. 
We must be on the offense, not on the defense.
At USDA, we are developing a strategy to get information about biotech-
nology to the public with the goal of helping the public make informed deci-
sions about the products of biotechnology. Certainly, our agency will have a 
role in informing the public about our regulatory strategy regarding trans-
genic animals, but this is just a small part. We must do much more. This is es-
pecially important because we will be competing with a number of other 
groups for the public’s attention on this issue.
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Short-term, we must focus on educating U.S. policymakers about bio-
technology so they can make informed decisions on legislation and policies 
at the local level. USDA is partially funding pilot studies currently underway 
to educate local county administrators on the risks and benefits of biotech-
nology.
Long-term, we must reach the public. USDA’s Extension Service plans 
to set up focus groups with consumers to determine what types of informa-
tion the public wants and how best to provide them with that information. 
We must know our audience and we must know how to reach them.
The bottom line is this: we must stay in tune with public opinion. I urge 
you to pay close attention to a survey of consumer attitudes about biotech-
nology to be released shortly. It was conducted by North Carolina State Uni-
versity and Colorado State University and funded by USDA’s Extension Ser-
vice and North Carolina State.
While the preliminary results show overall support for the use of bio-
technology in agriculture and food production, apparently the acceptability 
of biotechnology will vary with the specific use. People are much more com-
fortable with the idea of tinkering with plants than with animals, a reflection 
of public concerns regarding the well-being of animals and moral beliefs re-
garding genetic modifications in animals.
It is also apparent that the public wants to be involved in decision-mak-
ing about biotechnology. This interest is a good sign that the public will be 
receptive to biotechnology education. That is one reason I have been so can-
did here. Not only must the public be enlightened to enable them to make in-
formed decisions about biotechnology, but they must have confidence in the 
government’s ability to regulate biotechnology. The public must believe us 
when we say these products are safe. If we do not have their confidence, use 
of the technology is threatened. That is why we must carefully develop our 
policies and involve the public in the decision-making process.
SUMMARY
In summary, biotechnology offers us many opportunities to improve agricul-
ture. I believe biotechnology will have its greatest impact on meat and poul-
try safety in two ways. First, it will provide us with diagnostic tests that can 
help us to quickly and effectively detect contamination during the food pro-
duction process.
Second, biotechnology will enable the production of healthier animals 
through improved vaccines, improved diagnostic tests and the ability to pro-
duce disease-resistant animals. Biotechnology will also potentially provide 
us with animals with leaner meat, animals that are more feed efficient and 
animals with better growth potential.
While ensuring the safety of transgenic animals will have an impact on 
FSIS, I am confident our regulatory structure is equipped to ensure the safety 
of these new animals.
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The Food Safety of Transgenic Animals'
In the last 40 years a number of modern techniques for improving animal lines have been developed. Artificial insemination has already had an enor-
mous impact on the dairy industry. Techniques such as in vitro fertilization, 
embryo cloning, nuclear transplantation and transgenesis are reaching matu-
rity. These techniques and their potential effects on the environment, genetic 
diversity, animal production and society have been discussed by George 
Seidel (1989; 1991).
Introducing food products into the market place requires that the safety 
aspect be fully analyzed and documented so that healthy transgenic animals 
will be at least as safe as the traditional animals from which they were derived.
The classical breeding of familiar food animals has been practiced since 
antiquity and has never resulted in a hereditary trait that made animals un-
safe as food. Traditional breeding is accomplished by focusing on a desirable 
trait, such as milk production or fat content, and breeding only those ani-
mals which best exemplify the trait. If the trait is quantitative, this practice 
moves the population mean in the desired direction. The cause of the impro-
vement is unknown. Theprogeny results from thousands of selections be-
tween paternal and maternal genes and the genes responsible for the im-
provement in the phenotype are rarely, if ever, identified. There is little know-
ledge of the physiological mechanism underlying the phenotypic change. Yet, 
this approach has been safe and successful and is exemplified by the dairy 
industry where selecting semen from bulls with high-producing daughters 
more than doubled the milk output per cow in the twenty years following 
1955. The genetic events associated with traditional breeding are safe; conse-
quently, only the unique features of transgenesis are examined here.
One can organize the unique features of transgenesis into three catego-
ries: the genetic construct (i.e., the DNA introduced), changes resulting 
from the integration of the construct, and the nature of the gene product.
The views expressed are not necessarily those of the Food and Drug Administration.
SAFETY CONSIDERATIONS ASSOCIATED WITH 
THE GENETIC CONSTRUCT
There is little concern about the safety of orally consumed genes. The human 
diet, consisting of bacterial, animal and plant products, include all of the ge-
netic material of those organisms. Digestive enzymes in the human gastro-
intestinal tract degrade DNA in the food and, since a single nick in a gene is 
enough to inactive the production of the gene product, the probability of a 
functional gene sequence surviving intestinal digestion may be considered 
near zero. On the off chance that some DNA does survive, it would only be 
excreted.
The increased purine and pyrimidine content of tissues resulting from 
the extra gene in transgenic animals will be negligible relative to the total tis-
sue purine content. In mammals, the purine from a single gene is on the or-
der of one millionth of the total genomic content of purines. Some plant 
breeds produced by traditional methods have resulted in large percentage in-
creases in the nucleic acid content, i.e., increases in the somatic cell chromo-
some number. These considerations may be more important if the food 
product were a sole source of protein or energy.
The DNA of the construct is of concern only if it is infectious, i.e., if it 
can be propagated in the environment or transmitted by the food to suscep-
tible cells in the gastrointestinal tract. Retroviruses are used to introduce 
genes into some species, particularly poultry. The viruses that come in con-
tact with prospective transgene recipients are defective, likely carrying at 
least one deletion in a transacting gene. Rarely, through recombination with 
endogenous viruses or from functional retroviruses present in nature, could 
fully functional viruses emerge from the helper cell line. The probability of 
functional recombinants arising is small, but they have been observed. New 
helper cell lines with less homology between the defective viruses and the 
provirus will reduce the possibility of recombinant virus production (Miller, 
1990; Temin, 1989). From the food safety perspective, even competent ani-
mal retroviruses pose no threat to human health because of the species speci-
ficity of viral infection.
SAFETY CONSIDERATIONS ASSOCIATED WITH INTEGRATION 
OF THE CONSTRUCT
The insertion of a transgene into a recipient genome is a safety consideration 
because the location and manner of insertion may increase or decrease the 
expression of host genes. The hypothesis is that the insertion process might 
activate latent toxin genes or increase levels of hormones or other substances 
detrimental to human health when the food is eaten. In healthy animals this 
is not a realistic concern. If the transgenic animal is not healthy, the cause 
must be investigated to be certain that the pathology has not resulted from 
something transmissible in the food. However, the possibility of activating a 
toxin gene is insignificant, as discussed below.
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The genetic events causing the modulation of gene expression as a result 
of transgene insertion are not different from genetic events that occur natu-
rally. Modifications of gene expression are caused by the generation of new 
connections between sequences that are not normally juxtaposed or by the 
separation of normally connected sequences. Chromosomal translocations, 
deletions and inversions occur continually in animals in nature as well as in 
food animals. Animals also contain interspersed sequences that transpose to 
new chromosomal locations, though the frequencies of transposition in food 
animals are not known. Written records of animal breeding go back as far as 
Aristotle (Sturtevant, 1965), and animal breeding has never been associated 
with the production of toxic lines of animals. This historical record is strong 
evidence for the food safety of translocations, inversions, deletions and in-
sertions in animal chromosomes.
Toxin genes are rare in animals. Animals are generally safe as food. The 
dangers in eating animal products usually stem from parasites or microbio-
logical contaminants; these are inactivated by cooking. The overwhelming 
majority of animal species can be eaten without harm. There have been re-
ports of dogs being poisoned by eating polar bear liver, but the poisonings 
are caused by high levels of vitamin A in the livers (Russel, 1966). Although 
this is an example of toxicity from the ingestion of animal tissues, the accu-
mulations of high levels of vitamin A in the liver is a complex trait and is not 
induced by a single genetic event. The genomes of the common food animals 
do not carry toxin genes that can be activated.
A classical case of acute “animal” poisoning is the biblical case of quail 
poisoning (brought to my attention by John Kirschman) described in Num-
bers, Chapter 11. During the Exodus the Israelites became tired of eating 
manna and wanted “flesh.”
And there went forth a wind from the Lord, and brought across 
quails from the sea...and the people gathered quail; he that gathered 
the least gathered ten heaps...While the flesh was yet between their 
teeth, ere it was chewed, the anger of the Lord was kindled against 
the people, and the Lord smote the people with a very great plague.
And...they buried the people that lusted.
The investigation of modern cases of quail poisoning have been attributed to 
coniine, the hemlock neurotoxin that killed Socrates. The quail feed on hem-
lock during their migration from Africa to Europe, are resistant to the toxin, 
and are able to consume enough hemlock to poison predators. The toxin it-
self is a plant product, not an animal product.
An important consideration in animals is that toxic genetic effects with 
adverse human health effects, unexpected or otherwise, are likely to produce 
visible signs in the development or growth of the transgenic animal. Trans-
genic animals are themselves an important demonstration of their food safety. 
The fact that an animal has gone through normal intrauterine development,
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birth and growth in the presence of the transgene and its product is a strong 
indication of the safety of the derived food. For the food to be toxic, the ani-
mal would have to produce a species-specific toxin that is inactive in the spe-
cies of origin, but orally active in the species consuming the food. No such 
toxins from land food-animals have been described.
THE SAFETY OF THE GENE PRODUCT
The essence of the safety review of transgenic animals must be an examina-
tion of the gene product. The safety of gene products may be reviewed in the 
same way the safety of drugs or pesticides are classically reviewed, i.e., the 
important food safety matter is the presence of a pharmacologically or toxi- 
cologically active residue. Because the product of the transgene is completely 
characterized, one can use traditional methods to evaluate its safety. This is 
an advantage over traditional breeding because the knowledge of the exact 
genetic change directs the safety inquiry to the correct gene product and its 
effects. Traditional breeding is accomplished empirically by focusing on a de-
sirable trait with little knowledge of the physiological mechanism underlying 
the phenotypic change.
Gene products may have both direct effects resulting from the action of 
the gene products themselves and indirect, secondary or compensatory ef-
fects brought about in response to the direct effects of the gene product. For 
example, somatotropin stimulates the secretion of IGF-1 from the liver and 
other tissues. IGF-1 is responsible for many of the effects formerly attributed 
directly to growth hormone and this was taken into account in evaluating the 
safety of milk from bovine somatotropin-treated cows (Juskevich and Guyer, 
1990). Such reasoning is normally part of the review of the food safety of feed 
additives and new animal drugs. Routine toxicology testing is designed to de-
tect all effects of a compound, direct and indirect.
Once the safety of the transgene product is established, transgenic ani-
mals may be considered as safe as traditional animals. Some of the food 
safety considerations may change as the technology advances. Richa and Lo 
(1989) produced “transomic” mice by introducing chromosome fragments 
dissected from metaphase spreads into fertilized ova. Chromosome frag-
ments known to be associated with desired traits can be used selectively.
Large numbers of genes (10 megabases) are introduced rather than selected 
genes. For intraspecies transfers, the results are likely to be similar to natu-
rally-occurring cases of trisomy. Transomic animals are likely to be safe also, 
but too few have been studied to make conclusions about the food safety con-
siderations.
If we imagine that we are many years in the future when livestock are 
routinely improved by recombinant DNA techniques, traditional breeding, 
in retrospect, will seem far too hazardous. To allow all the genetic changes to 
occur by chance and then never know what genes or genetic changes were re-
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sponsible for the new phenotypes is likely to seem far more risky than 
transgenesis. Cattle have 30 pairs of chromosomes. Thus, in the absence of re-
combination, a single mating has a potential of producing 2^® or 1.07 billion 
genetically different eggs or sperm. Surely the introduction of a single well- 
characterized known gene is less risky!
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To Live as Natives, Free of Fear:
What Citizens Should Require from 
Animal Biotechnology
Floodwood, Minnesota, the little town near my farm, can barely keep a feed store going today, but it led the nation in dairy technology 55 years 
ago. In 1937 at Island Farm, on the flat marsh west of town, technicians per-
formed the first-ever insemination of a dairy cow with frozen semen 
(Goodrich, 1988). Into the early 1960s, the roads around Floodwood were 
lined with dairy farms and Floodwood had three car dealers, two tractor 
dealers and a cooperative creamery owned by local farmers. Today, we have to 
drive 40 miles to buy a new car or tractor and the only cooperative creamery 
left in all of northeastern Minnesota is the Duluth Division of Associated 
Milk Producers, Incorporated—a cooperative owned by farmers from Min-
nesota to Texas. During the Reagan years, half the farmers who shipped milk 
to that last local creamery quit dairying (Hunter, 1989).
Considering America’s agricultural history, it is not surprising that 
farmers and other citizens who follow agricultural events ask hard questions 
and look with cynicism at the promises made for genetically engineered ani-
mal products such as bovine growth hormone and porcine growth hormone, 
and humanly created, patented species. To Floodwood farmers, biotechnol-
ogy looks like one more unit in a long parade of agricultural technologies— 
technologies which were sold to us as benefits, but which led to the displace-
ment of our neighbors and the decline of our towns.
We are wary of new technologies because of our experiences. Besides the 
hurt heaped on family farmers by technology-driven economic upheaval, we 
have witnessed the hurt heaped on everyone by technology-driven environ-
mental upheaval. Jim Davidson, soil scientist and research dean at the Uni-
versity of Florida, did a good job of articulating the reasons nonfarming citi-
zens are wary in his 1989 address to the Agronomy Administrator’s Round 
table. Davidson said:
The distrust on the part of nonagricultural groups is well justified.
With the publication of Rachel Carson’s book entitled Silent Spring,
we in agriculture loudly and in unison stated that pesticides did not 
contaminate the environment. We now admit that they do. When 
confronted with the presence of nitrates in groundwater we resp onded 
that it was not possible for nitrates from commercial fertilizer to reach 
groundwater in excess of 10 parts per million under normal productive 
agricultural systems. We now admit that they do. When questioned 
about the presence of pesticides in food and food quality, we assured 
the public that if a pesticide was applied in compliance with the la-
bel, agricultural products would be free of pesticides. We now admit 
that they’re not (Kirschenmann, 1992).
Since informed citizens have such good reasons to be wary of promises made 
for new technologies, it is a challenge to find avenues of communication be-
tween them and the proponents of animal product biotechnologies. My job 
in this essay is to suggest some possibilities. I am not going to dwell on the 
bovine growth hormone (BGH) experience, but I am going to use it as a 
springboard, an element in a true story that illustrates why citizens have 
learned to require honesty, patience and respect from the proponents of new 
animal biotechnologies.
As a dairy farmer in the midi980s I started following news about BGH in 
farm magazines. In 1988,1 joined a year-long biotechnology study group 
through a membership organization called the Minnesota Food Association. 
In 1990, after I had sold my cows, a farm woman who sits on the advisory 
board of our local agricultural experiment station called and asked me to at-
tend the station’s meeting on BGH. “I know you’ll ask good questions,” she 
said. I called another friend, a young woman who is taking over her father’s 
dairy farm, and on a cold day in January, we met about halfway to Grand 
Rapids, at the Swan River truck stop, and drove the next twenty miles to-
gether.
In a basement room, two animal science researchers from the University 
of Minnesota presented a six-hour lecture program on the hormone they 
called “BST” (bovine somatotrophin). During the morning, I took notes and 
asked a few questions including who had provided funding for the research. 
The public had provided some money, it turned out, but most had come from 
Monsanto and American Cyanamid, two pharmaceutical companies that 
planned to market BGH/BST. At the end of the morning session, one of the 
researchers waved me over and asked whether I meant to imply that he was 
“in the pocket” of the pharmaceutical companies. I told him it was not that 
simple in my mind, but I thought that we all ought to consider what it means 
when universities choose research projects based of the amount of money the 
research can solicit from private industry. We had a long, friendly discussion 
which cut into the lunch hour.
My friend and I were pushing plastic trays down the cafeteria line when 
the other researcher approached us and spat, in an exasperated voice, “What
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is it that you’re afraid of?’’Caught off guard, I spat back something like, “The 
destruction of our farms and our communities.” I meant to go on, hoping to 
make the uncomfortable exchange evolve into a more civil one, but when I 
paused for breath, the man twirled on his heel and hurried away. I felt my 
face flush with insult.
In the pickup on the way home, I thought about his question. He had 
misused it by trying to intimidate me, but it was a surprisingly deep ques-
tion. It occurred to me that we ought to examine our fears more often. Fears 
are not just embarrassing details; they are essential pieces of human equip-
ment. What other basis do we have for respectful, careful deliberation in the 
face of danger? How else can we define safety, except to say that it means the 
absence of good honest reasons for fear? Everyone seems to agree that safety 
is the one thing which citizens have a right to expect from products of animal 
biotechnology. The researcher’s question was right on the mark: What is it 
that I am afraid of?
First, I am afraid that animal biotechnologies will be just like other agri-
cultural technologies, pushing along existing trends that benefit agribusiness 
industries but damage the environment, farmers and rural communities. I 
am afraid animal biotechnologies may be piecemeal solutions that do not 
take into account ecological or social systems. I am afraid they will decrease 
normal, healthy variation within and among breeds. I am afraid they will 
hurt people in the Third World whose economies are already threatened by 
genetically engineered plant products such as sugar substitutes, vanilla fla-
voring and cocoa butter (Jamal, 1988).
I am even more afraid that animal product biotechnologies will be un-
like previously known technologies. I am afraid of disasters like the 1989 
L-tryptophan poisoning which so far has left 31 Americans dead and 1,500 
sick from a blood disease linked to a mysterious double molecule in a geneti-
cally engineered food supplement (Raphals, 1990a,b,c; National Wildlife 
Federation, 1990). If we know all we need to know about the safety of genetic 
engineering, it is hard for me to understand what went wrong in the L-tryp- 
tophan incident. I am also afraid of monster animals like the giant cloned- 
calves that could not be born vaginally, a failed experiment that drove Grenada 
Biosciences of Houston into receivership (Hodgkinson, 1992).
I am afraid of one more thing: human ignorance. Technologies are not 
inherently evil, but if recent history is any guide (See Dean Davidson’s list 
above for just three examples), we humans are not yet sophisticated enough 
to predict the impact of singular changes on large, interconnected systems. 
My own particular ignorance scares me, too. It may be that biotechnology is 
“going to require more of us as citizens than we can handle,” as Kansas ge-
neticist, Wes Jackson, predicted (Eisenberg, 1989). The issues are so complex 
—not just scientific and technical, but ecological, ethical, economic, social 
and political. To even begin to understand them, ordinary citizens need a
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crash course. Fortunately, some of us have been able to get that from non-
profit organizations like the Minnesota Food Association, the National Wild-
life Federation and the Rural Advancement Fund International.
The Minnesota Food Association’s biotechnology study group, in which 
I participated, makes an effective model for citizen study groups. The Asso-
ciation is a membership organization of people interested in food and agri-
cultural issues. Members identified biotechnology as an important upcoming 
issue in 1987, and decided to convene a study group. Association staff pro-
vided research and support, and they organized a series of informational 
meetings between study group members and various experts. Study group 
members included farmers, writers, a veterinarian, a biologist and a futurist. 
Experts included legislators, ecologists, ethicists, scientists, university ad-
ministrators and representatives of businesses involved in biotechnology.
The group met twice a month and heard from three experts at each meeting. 
After a year of study (including the meetings as well as the reading of relevant 
materials) staff and members collaborated to write and publish a report,
Food and Agricultural Biotechnology in Minnesota: A Citizens’ Perspective 
(Minnesota Food Association, 1988). The report helped spur the Minnesota 
Legislature into passing one of only two state laws in the country that regu-
late environmental releases of genetically engineered organisms.
We heard later that some of the scientists who met with the study group 
felt affronted to have their research questioned by nonscientists. Some of the 
nonscientists felt affronted by what they judged to be condescension from 
some of the scientists. No one yelled or was injured. We can bear such small, 
nonviolent discomforts. They are prerequisites for real communication 
among equals who do not necessarily agree.
In contrast, one-sided events, like the bovine growth hormone meeting 
described above, are not real communication. Today’s wary citizens know 
that. We have learned something from three decades of watching television 
commercials. We know that real communication is not a one-way street, not 
“reaching” someone with a message, the way public relations firms try to do. 
Real communication takes place between equals at an intersection with many 
points of view and many ways to go. Only through real communication can 
anyone hope to convince us that a product of animal biotechnology is safe— 
if, in fact, it is.
Consider the bovine growth hormone experience. Neither farmers nor 
consumers asked for BGH in the first place. That was the first mistake—to 
develop a product that met no clearly defined need. Neither farmers nor milk 
drinkers wanted it. Forty-six percent of Minnesota farmers have said they 
would never use it (Crooker and Otterby, 1990). Eighty-two percent of rural 
nonfarm North Carolina residents said they were very concerned or some-
what concerned about it (Sorenson, 1990). BGH is a textbook example of how 
not to develop a technology. Let us learn something.
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When considering new genetically engineered animal products in the fu-
ture, we should ask these fundamental questions: Who wants the technology 
that might result from this research? Do we hear citizens asking for this tech-
nology or will we have to try to manufacture their need for it through one-
sided promotional events? Who will profit? Who will pay?
Given current citizen activism and wariness, no one should expect to de-
velop a new technology without public comment, particularly if public funds 
are involved and if the research is being conducted at land grant universities 
that have inherent public interests. One thing is clear from the Minnesota ex-
perience: the nature of the public comment is negotiable. People can dialogue 
with structure and moderation, hearing many voices or they can monologue 
in strife and chaos, employing secrecy, name-calling, moratoriums and pro-
tracted battles over legislation and regulation.
Again, the Minnesota Food Association provides a model. In February, 
1992, members entered into a moderated dialogue with Gene Allen, a Univer-
sity of Minnesota Vice President who had signed testimony opposing regula-
tions that would implement Minnesota’s biotechnology law. This was the 
same law that the Minnesota Food Association’s biotechnology report had 
helped to pass three years earlier. People on both sides were apprehensive go-
ing into the dialogue, but coming out, Dean Allen quipped that, “We are 
formed by those whom we meet with, and thank God, I don’t meet only with 
vice presidents.” (Northern Tier Land Grant Accountability Project, 1992) 
Further, he invited members of the Minnesota Food Association to meet with 
the University’s Council of Biological Deans who, he allowed, were better 
suited to answer the members’ questions.
I hope that other proponents of biotechnology will open themselves to 
dialogue with citizens who have joined membership organizations and taken 
the trouble to educate themselves about biotechnology. Such dialogue is not 
just public spirited, it is also practical. Citizens already involved in the bio-
technology issue are the ones who are likely to cause trouble in the future 
should some technology look unsafe or ethically cloudy. By hearing their 
concerns in advance, biotechnology proponents can head off future disagree-
ments like the ones that have hobbled BGH.
Industry executives could also head off future trouble by implementing 
real communication. Instead, they are being secretive—withholding data 
that the companies judge to be “Confidential Business Information.” Take 
the case of Frito-Lay, the potato chip company. Under the Freedom of Infor-
mation Act, the National Wildlife Federation (NWF) has obtained nine of 
Frito-Lay’s USDA applications for environmental releases of genetically en-
gineered organisms. In six of those applications, according to the NWF, 
Frito-Lay withheld the identity of added genes and other information needed 
to assess environmental risks involved in the releases (National Wildlife Fed-
eration, 1992).
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Citizens are tired of being kept in the dark and we do not want to “be 
reached” by proponents of biotechnologies before we have a chance to say 
whether we need the technologies or their products. Right from the start, we 
want a chance to ask questions and express our fears. We want to know if a 
new technology is going to be like every other technology—if it is going to 
add to corporate balance sheets and subtract from the balance sheets of 
American farmers and Third World citizens. We want to know if the new 
technology is going to be unlike every other technology—if it has the poten-
tial to damage society or the environment in unforeseen ways. We want to 
know how we can educate ourselves so that we can participate as equals in 
political decisions being made about biotechnology. We want to know that 
people in the universities are there to listen and to help us get truly educated 
and that they are not trying to sell us technologies or products.
Minnesota writer and ethicist, Carol Bly, set a practical benchmark in 
her foreword to my oral history collection, Breaking Hard Ground (Hunter, 
1991). She wrote, “What we all want is a world in which small operators who 
like their work can live without any insult and injustice, can live in the places 
which are native to them and can consort with those they do business with 
without fear.”
With that ethic in mind, let us respect one another, study together and 
take all the time we need to arrive at careful decisions. Let us not give in to 
the profit-driven rush to develop genetically engineered animal products.
We humans have been practicing animal husbandry for at least 10,000 years 
(Lerner, 1986). We are not likely to hurt ourselves if we take another 10 or 15 
years to carefully test and deliberately study a new product. We might even 
move a step or two up the evolutionary ladder if we learn to manage a pro-
longed, civil discourse among disagreeing parties.
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Workshop Report
To set the stage for further discussions, the workshop began with presen-tations from two speakers who offered alternative viewpoints on the im-
pact of biotechnology on meat and animal product safety. The view of the 
first speaker, David Berkowitz, Office of Biotechnology, Food and Drug Ad-
ministration, was that healthy transgenic animals are as safe as traditionally 
bred animals if the transgene product is safe. Biotechnology provides the po-
tential to predict, understand and control the genetic basis of animal improve-
ment in precise ways.
The perspective of a rural resident, former farmer and member of the 
Minnesota Food Association, a nonprofit organization interested in food and 
agricultural issues, was provided by Dianna Hunter. She broadened the defi-
nition of safety beyond animal and meat product safety in the marketplace. 
Ms. Hunter defined safety as “the absence of good honest reasons for fear” 
and for her, there were many reasons to fear animal biotechnology.
Ms. Hunter also warned against public relations-style communication 
models which seek to tell in monologue rather than to listen in dialogue. She 
reinforced the need for dialogue between groups representing divergent 
views about biotechnology with open and honest communication and mu-
tual respect for alternative viewpoints.
A pre-meeting survey of registrants found over 80 percent of respon-
dents disagreeing that foods derived from the products of agriculture bio-
technology will be less safe than today’s food. However, workshop partici-
pants, after review, did identify some potential safety problems for discus-
sion. These included unanswered questions about bovine somatotropin 
(BST), allergenicity and questions about a number of products for which 
there are as yet no data bases, for example, transgenic animals and animals 
administered recombinant DNA products. On the positive side, the partici-
pants acknowledged the promise identified by past NABC attendees for new 
biotechnologies to produce diagnostic tools for food safety testing of animal 
products (See NABC Report 2, 1990).
*When this workshop was held, Dr. Harlander was with the University of Minnesota, 
Department of Food Science and Nutrition.
Finding common ground was more difficult and frustrating once the 
group moved past the fairly narrow, but controllable, technical hazards to 
the myriad of intellectual and social elements that people bring to a decision 
about the safety of any entity, food included. Before moving to the identifica-
tion of social issues, participants identified elements from three other cat-
egories—animal welfare, the environment and social concerns. The first was 
the topic of another workshop and was not pursued further. Some ecological/ 
environmental problems were mentioned including those arising from the 
release of transgenic fish, the possible narrowing of the genetic base for do-
mestic animals and the, as yet, unstudied effects of the “short-circuiting” of 
adaptation in domestic species of animals through genetic engineering.
At this point, participants stepped back to list the major concern of each 
of the participants about the safety of biotechnologically produced meat and 
animal products. The items fell into four different areas, each listed and dis-
cussed below, including two that had significant social aspects. Small groups 
were formed to discuss these issues and bring recommendations back to the 
total workshop group for discussion.
THE SAFETY OF TRANSGENIC ANIMALS AND ANIMALS ADMINISTERED 
RECOMBINANT DNA PRODUCTS
— Use of transgenic animals to produce pharmaceutical agents for use by 
humans. Certain transgenic animals are producing pharmaceuticals for use 
by humans, such as pigs producing human hemoglobin and sheep producing 
a blood clotting factor. These “pharm” animals may enter the human food 
supply, but before they do, their safety must be assured. All workshop partici-
pants agreed to the need for a data base on the nutrient composition and levels 
of relevant hormones and residues in these animals to reassure scientists and 
the public that there are no detectable differences from levels of these sub-
stances in traditional animal products. There was not a consensus in the 
group as to how extensive the data base would be and what it would contain.
—Animals administered recombinant DNA products: 1. hormones—there 
are provisions for their regulation by FDA already in place (i.e., regulation of 
recombinant BST); 2. vaccines of three types—inactivated, gene deletions 
and live-vectored. The latter two are the ones of concern. None are licensed 
for release yet although one is being field tested. There was consensus that the 
regulations under the National Environmental Protection Act (NEPA) and the 
testing protocols were probably adequate; and 3. direct-fed microbials—these 
are feed additives such as yeasts, bacterial enzymes and probiotics. FDA has 
the authority to regulate these but has not been doing so. Participants agreed 
that FDA should investigate direct-fed microbials more carefully in the future, 
when applications for recombinant products are received.
—Long-term consequences of breeding transgenic animals. The concern 
here is the unknown potential for unexpressed genes to cause other changes
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in animals that may not be expressed for several generations. Some in the 
group believed that animals should be observed for longer than one genera-
tion to detect any such changes. Others believed that observation of the first 
generation of offspring was sufficient. The group did not agree on whether 
other data bases should be developed on transgenic animals to assure the 
public that there are no differences in the levels of various chemical com-
pounds in the meat of these breeds compared to animals now on the market. 
The final recommendation in this area speaks to the need for remaining aware 
of the possibility of cloning defects in embryo transfer and cloning experiments.
BIOTECHNOLOGICAL TOOLS TO ENHANCE FOOD SAFETY 
AND QUALITY
—Animal products are the major source of microbial contamination in the 
food supply, so that use of DNA probe assays and immunoassays for the detec-
tion of pathogens is to be strongly encouraged. Large-scale detection of patho-
gens is impractical with present technology. Unavailability of rapid and eco-
nomically effective methods for detection of undesirable materials and con-
taminants during animal production and processing hinders application of 
intensive inspection protocols. Biotechnology is the most promising source 
of tools that can yield rapid, sensitive, specific and cost-effective diagnostic 
tests for the presence of microbiological pathogens, antigens, toxins and 
other compounds-of-interest to improve food safety. New diagnostic capa-
bilities can also be used to detect adulterated foods and as a screening 
method for allergens in the food supply.
The rapid detection of contaminants should lead to the development of 
improved processing methods and a decrease in the incidence of food borne 
illness in the population. There was consensus in the workshop that research 
and application of these tools should move ahead rapidly.
—Genetic markers also offer the potential to improve the healthfulness and 
safety of the food supply. They allow more rapid and effective application of 
traditional or conventional genetic selection practices. These new techniques 
can improve selection for multiple beneficial traits without a substantial loss 
of progress in other traits of interest. Improvement of resistance to diseases, 
or colonizations by parasites or human pathogens, decrease the frequency 
of application of therapeutic drugs and moderate degeneration of animal 
health, thereby reducing the presence of unwholesome products in the food 
supply. Genetic markers can also be used to breed for improved macronutri-
ent composition, such as decreased fat in animals. For these reasons the group 
also endorsed continued research on the use of the genetic markers techniques.
DEFINING FOOD SAFETY
—The larger issue here is how to define food safety. Some participants ar-
gued the present definition is too narrow, ignoring quality issues as well as
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the fact that food safety is a social construct, as illustrated by the different 
definitions and standards for food safety held by different cultures and coun-
tries. They felt that social, economic and political issues should be evaluated 
concurrently with the evaluation of efficacy and human and animal safety. 
Others disagreed with all of these ideas and argued for maintaining the 
present system of relying solely on technical data for safety decisions. The 
latter participants did recognize that social, economic and political issues 
should be discussed. After further comments the workshop debated a recom-
mendation that a mechanism should be set up for formal consideration of 
the social, economic and environmental ramifications of agricultural bio-
technology products. It was noted that there are already regulatory require-
ments for reviewing environmental consequences, but the group felt it im-
portant to state the need for review of environmental consequences. There 
was not consensus about whether the mechanism should be separate from, 
or integral to, the present system.
The participants also did not reach consensus on a recommendation that 
the products of agricultural biotechnology should be continued to be evalu-
ated on a case-by-case basis using current regulations or methods. Some ar-
gued that the recommendation was unnecessary; others that we might not 
want to exclude the possibility of improving or changing the regulatory process.
COMMUNICATING WITH THE PUBLIC
This section of the report and recommendations is premised on a consensus 
agreement that the public has a stake in maintaining public institutions pro-
vided they are responsive to public needs. The decline in the credibility of sci-
entists and public institutions should alert us to the fact that the public does 
not feel that its needs have been taken into consideration and that one of the 
reasons is the inability of the institutions and scientists to communicate with 
the public as equal partners in dialogue.
In the small group discussion the watchwords were: 1. know your audi-
ence and 2. listen to what they have to say. This is not as easy as it sounds be-
cause many (but not all) scientists have perceptions and biases that are quite 
different from the various perceptions and biases of public groups which 
makes it difficult for scientists to be good communicators. There is also the 
serious problem of lack of support for these activities in the reward struc-
tures of institutions and of an imbalance in funding going to high technology 
research versus research in policy and communications. These were all con-
sidered in the following set of recommendations, all of which were endorsed 
by all workshop participants.
—There is a body of knowledge about communications that scientists 
should use to improve the dialogue with the public. These include strategies 
like audience segmentation and use of focus groups. Ongoing survey research 
on scientist and consumer attitudes could be very helpful.
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—Regional research projects should be promoted and funded and the Na-
tional Research Initiative should be encouraged to put more funding into its 
policy and marketing line item to promote public understanding of agricul-
tural biotechnology. Other agencies and entities such as foundations, other 
nonfederal agencies, industry and academia should be encouraged to pro-
mote such research and programs.
—Interdisciplinary work between the biological and social sciences 
should be promoted and recognized as critical if serious progress in this area is 
expected.
—In all grant proposals the technical significance and relevance of re-
search should be communicated in terms the general public (or anyone outside 
the particular discipline) can understand. This is part of the ongoing discus-
sion on the balancing of academic freedom versus public input into research 
priorities. At this point there are inadequate mechanisms for receiving input 
from those who do not have the knowledge and funds to lobby at the state 
and federal level. Advisory committees that have a broad representation of 
the public and heterogeneous interests should be constituted to work with 
colleges or departments directly.
—Continuing education programs should be developed for scientists to 
teach them how to more effectively facilitate two-way communication be-
tween scientists and the general public. Scientists need to learn how to recog-
nize and understand the content and validity of a range of social, environ-
mental and economic concepts that include the discussion of food safety 
issues by the public. They also need training in media relations and the com-
munication process.
The workshop participants also recognized, as has been true in many 
other discussions of this type, that the public, starting at the grammar school 
level, would be well served by educational programs on the social, moral, eco-
nomic, political and scientific issues surrounding biotechnology.
In order to accomplish any wide-ranging change in faculty behavior in 
these areas it will be necessary to re-envision the mission of the land-grant 
colleges to serve all their publics and recognize that the responsibility for this 
is shared by all institutions of higher education. This will change the weight 
given to public service or extension activities in promotion decisions and 
bring this area into better balance with research and teaching.
The workshop was quite remiss in failing to discuss in any detail the is-
sue of labeling of products produced through biotechnology, and the contri-
bution and relationship of labeling to communication with the public. We 
see this as an important topic for a future NABC meeting. [Editor’s note: the 
NABC 5 optional seminar will address the topic of labeling.]
Meat & Animal Product Safety
REGULATORY ISSUES
USDA Regulation of Animal Biotechnology 149
John E. Frydenlund
Animal Pharmaceuticals 157
Martin Terry
The Regulation of Genetically Engineered Animals: 165
Going from Bad to Worse 
Margaret Mellon
Workshop Report 171
Bennie Osburn and Robert B. Nicholas
John E. Frydenlund
Deputy Assistant Secretary 
Marketing and Inspection Services 
U.S. Department of Agriculture
REGULATORY ISSUES_________________________________________________________
USDA Regulation of Animal Biotechnology
In this presentation I will share with you a U.S. Department of Agriculture (USDA) perspective on some of the regulatory issues associated with animal 
biotechnology. You are all aware of the Federal Coordinated Framework for bio-
technology oversight that has moved products of biotechnology from the labora-
tory to the marketplace. Under this policy, federal agencies use their existing 
statutory authority to regulate the products of biotechnology.
The product reviews focus on the nature of the product and the risk, rather 
than the process used in its development. Federal agencies are required to ensure 
protection for public health and the environment from any potential harmful ef-
fects of these products. Favorable evaluations of the job the agencies are doing 
were published by the U.S. General Accounting Office and by the Office of Tech-
nology Assessment in 1988.
The “Report on National Biotechnology Policy,” released by the Council on 
Competitiveness in the Office of the Vice President in 1991, reaffirmed the 
Administration’s commitment to maintaining the U.S. lead in biotechnology re-
search and product development over the long-term. The report provided an up-
date on the Coordinated Framework and restated several principles for guiding 
federal regulatory policy:
—Federal oversight should focus on the characteristics and risks of the prod-
uct, not the process, used in its development;
—Regulatory review should be designed to minimize burden while assuring 
protection of public health and welfare;
—Regulatory programs should be responsive to rapid advances in bio-
technology.
The Council on Competitiveness’ report also recommended publication of a 
document to help federal agencies make decisions, within the scope of au-
thority afforded by statute, on how to regulate planned introductions of bio-
technology products. The statement was published in February, 1992. It will 
ensure that federal oversight is used where it will do the most good—that is, 
where the risks are real.
We are using these principles to refine the management of our biotechnology 
programs at USDA. I would like to mention some of our management initiatives 
and then discuss the regulation of animal biotechnology.
USDA has both research and regulatory responsibilities for agricultural 
biotechnology and they are administered separately. The Assistant Secretary 
for Marketing and Inspection Services oversees the Department’s biotechnol-
ogy regulatory activities through a delegation of authority from the Secretary 
of Agriculture.
The counterpart for research is the Assistant Secretary for Science and 
Education. Together they co-chair the Committee on Biotechnology in Agri-
culture (CBA) which was established in 1986 as USDA’s policy-making and 
coordinating body for biotechnology.
The members of the CBA are the administrators of all the USDA agen-
cies that administer biotechnology programs—the Animal and Plant Health 
Inspection Service (APHIS), the Food Safety and Inspection Service (FSIS), 
Agricultural Research Service, the Cooperative State Research Service, the 
Economic Research Service and the Forest Service.
The CBA met recently (Spring, 1992) to review a strategy that we believe 
will improve the effectiveness of our biotechnology programs. Several of 
these initiatives are the result of a study of USDA management of critical is-
sues, including biotechnology, that cut across the jurisdiction of individual 
agencies:
—We have solicited proposals for the biotechnology risk assessment re-
search program stipulated in the 1990 Farm Bill. The purpose of the program 
is to strengthen the scientific basis of USDA’s regulatory programs.
—We approved a public information plan on biotechnology for the De-
partment. This is a priority program. We have been providing information 
for a long time on an agency-by-agency basis and the time has come to 
launch a Department-wide effort. We began the program this spring by co-
sponsoring a joint U.S. and European Community (EC) meeting on biotech-
nology communication in Dublin, Ireland.
—USDA agencies are implementing the President’s Biotechnology Re-
search Initiative. This involves reporting and monitoring of the Department’s 
$162.6 million 1992 research budget for biotechnology and reassessing our 
research priorities.
—We are committed to fostering trade through scientific meetings that 
will lead to international consensus on biosafety issues. USDA scientists are 
involved in the negotiations sponsored by the major international organiza-
tions including the EC and the Organization for Economic Cooperation and 
Development (OECD).
REGULATING PRODUCTS OF ANIMAL BIOTECHNOLOGY
Now I will turn to the activities of the two USDA regulatory agencies directly 
concerned with regulating the products of animal biotechnology—APHIS 
and FSIS. Both agencies have authority, in the broadest sense, for protecting 
animal health.
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Animal and Plant Health Inspection Service (APHIS)
The Virus-Serum-Toxin Act of 1913, as amended, gives APHIS the authority 
to regulate all veterinary biological products imported into the U.S. or ex-
ported, or those biologics shipped or delivered for shipment interstate or 
intrastate.
Veterinary biological products are defined in the regulations [9 CFR 
101.2(w)] as all viruses, serums, toxins and analogous products of natural or 
synthetic origin intended for use in the diagnosis, treatment or prevention of 
diseases of animals.
The licensing requirements [9 CFR Part 102] include tests to insure pu-
rity, safety, potency and efficacy. Pre-licensure evaluation of all veterinary 
biological products—regardless of the techniques used in their develop-
ment—is performed at the National Veterinary Services Laboratory (NVSL) 
in Ames, Iowa. The NVSL is the only federal facility in the U.S. engaged in the 
evaluation of veterinary biologies and the diagnosis of domestic and foreign 
animal diseases.
It was nearly ten years ago that APHIS issued the first license for a veteri-
nary biological product developed through biotechnological techniques. 
Since then, 48 product licenses have been granted for three broad categories 
of these products. The categories are based on the biological characteristics 
of the product and the kinds of safety issues it presents. Category one in-
cludes inactivated recombinant DNA-derived vaccines, bacterins, bacterin- 
toxoids and virus or bacterial subunits.
Hybridoma-derived monoclonal antibodies as well as genetically engi-
neered antibodies are also included in this category. These nonviable, or 
killed, products pose no risk to the environment and present no new safety 
concerns. An example of a category one product is the Escherichia coli 
bacterin used to protect swine against Colibacillosis, a disease that has severe 
economic effects on swine producers.
The diagnostic test kits classified as category one products represent a 
significant breakthrough in animal disease diagnosis and treatment. Pseudo-
rabies diagnostic test kits which can differentiate between reactions caused 
by wild type viral infections and immunization with recombinant vaccines, 
are used in APHIS’ Pseudorabies Eradication Program.
Category two products contain live microorganisms that have been 
modified by the addition of marker genes or the deletion of genes that code 
for virulence. Special precautions are taken to ensure that the addition or de-
letion of genetic information does not confer virulence, pathogenicity or sur-
vival advantages to these organisms that are greater than those found in the 
parent or wild type forms. All the licensed category two products are for use 
against pseudorabies in swine and involve gene deletions or additions.
Category three includes products containing live expression vectors car-
rying recombinant DNA-derived sequences that code for immunizing antigens
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or other immune stimulants. The transmission characteristics of such prod-
ucts must be carefully assessed before field studies are undertaken.
While no licenses have been granted in category three, one product is 
currently being field tested after a thorough evaluation of safety data. The 
product is a live recombinant DNA-derived vaccine-vectored rabies vaccine 
intended for oral use in raccoons in the wild. The incidence of rabies has in-
creased dramatically in the Mid-Atlantic States and public health officials 
have been enthusiastic about the potential of immunizing animals in the wild 
with the recombinant vaccine contained in food bait. Field tests have been 
conducted on Parramore Island in Virginia and in Sullivan County, Pennsylvania.
Additional tests have begun in a three-county area in New Jersey. Since 
December, 1989, there have been 1700 cases of rabies in New Jersey and 90 
percent of the cases have been in raccoons. The disease is moving from North 
to South in the State and New Jersey public health authorities hope to estab-
lish a rabies-free zone by concentrating the bait drops in Cape May County. 
There will be extensive monitoring before and after another bait drop in 
Fall, 1992.
The states must approve field tests of all experimental biologies so we 
have worked closely with state officials to provide the public with informa-
tion on the rabies vaccine field trials. APHIS scientists attended state-spon-
sored public meetings to answer technical and scientific questions and an 
APHIS spokesperson was interviewed in the Spring, 1992, on Cable News 
Network (CNN) about the New Jersey tests. The vaccine trials were also fea-
tured in a new publication on biotechnology distributed in March, 1992, to 
junior high school students throughout Pennsylvania.
Future generations of vaccines will combine the genetic information to 
immunize against several diseases into one virus or bacteria. We have now 
received an application for a genetically engineered category three vaccine 
with antigens against two disease agents in the same microorganism. This 
will improve the consistency of production from lot to lot of product, by 
eliminating variation in antigen content when different components are 
mixed together.
For the category two licenses and the field trials of the category three ra-
bies vaccine, APHIS prepared a complete environmental assessment of the 
proposed action in compliance with the provisions of the National Environ-
mental Policy Act. The environmental assessments provide the public with a 
discussion of scientific data on safety and a thorough analysis of environ-
mental impacts.
When any project has implications for public health, expert panels con-
sisting of representatives from federal agencies, academic institutions and 
professional societies are convened to review data. Additional review can 
also be requested from the National Vaccine Program in the Department of 
Health and Human Services which was done for the rabies vaccine.
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Early generations of veterinary biological products developed through 
biotechnology have proved effective in disease prevention and diagnosis. 
Succeeding generations will be even more effective and we look increasingly 
to global markets for these products.
The growth of international ownership of the biologics production in-
dustry and the advent of the European Community (EC) have increased the 
immediacy of the drive for internationally recognized standards and consis-
tency in testing procedures. We have worked with a number of international 
groups to further this process. In one of these efforts, U.S. and EC represen-
tatives met in France in January, 1992, to work toward the standardization of 
production practices. The discussions continued during that summer.
There is pressure on the U.S. to increase the potential for EC-produced 
biologics to enter U.S. markets. Many of these products are prevented entry 
because of the presence of foot and mouth disease and bovine spongiform 
encephalopathy in several EC countries. We are working to resolve these and 
a number of other issues.
Food Safety and Inspection Service (FSIS)
Turning now to the role of the Food Safety and Inspection Service in regulat-
ing animal biotechnology, this will be brief because Dr. Cross has already 
done such an able job on this subject (see page 121). The summary statement 
from last year’s NABC workshop on transgenic animals is a good place to be-
gin and I quote:
In general, workshop participants concluded that public issues 
associated with transgenics were not urgent, primarily because 
applications of transgenic technologies as they affect agriculture 
and the food supply seem remote at the present time. (Murray 
et al., 1991, p. 43)
We think that if we do our work well enough, public issues associated with 
transgenics will not become urgent. This means that we must continue to 
maintain an open dialogue on potential issues before they develop. We talk to 
our critics, as well as to the regulated public, and we join with other federal 
agencies in sponsoring workshops and discussion groups.
These statutes from which FSIS gets its authority for regulating the ani-
mal products of classical breeding and new technologies are the Federal Meat 
Inspection Act and the Poultry Products Inspection Act.
These statutes require that FSIS inspect cattle, sheep, swine, goats, 
equine, poultry and food products prepared from them intended for use in 
human food to assure that they are wholesome, not adulterated and properly 
labeled, marked and packaged. The FSIS policy statement in the 1986Coordi-
nated Framework established the applicability of the experimental animal 
regulations for the use of genetic engineering techniques in food animals 
[9CFR309.17and381.75].
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This policy was reaffirmed in a Federal Register notice published in De-
cember, 1991. The notice pointed out that only a small proportion of the ani-
mals in gene transfer experiments contain the intended gene [56 FR 67054- 
67055]. Before animals that do not contain the experimental transgene may 
be presented for slaughter, data must be submitted to FSIS demonstrating 
that the transgene is not present and that the animals are therefore “not adul-
terated.” Written approval for slaughter of an animal determined to be 
nontransgenic is granted by the FSIS Deputy Administrator for Inspection 
Operations and the animals are subject to the same inspection procedures as 
conventionally bred animals. Animals have been approved for slaughter un-
der these provisions. We expect a number of applications to be considered in 
the near future. We know that the cost of maintaining these animals is pro-
hibitively high.
A document is being prepared which pertains to the food safety evalua-
tion of transgenic animals being considered for slaughter. In making an 
evaluation, FSIS may consult with other agencies, including the Food and 
Drug Administration (FDA), the Environmental Protection Agency (EPA) 
and APHIS. Interaction among federal agencies to consider these issues has 
been taking place for several years through the meetings of the Food Animal 
Biotechnology Information Exchange Group. Through these discussions we 
are working to anticipate both scientific and consumer issues, and to avoid 
delays due to agency concerns about jurisdiction.
We know that research using molecular methods will bring revolution-
ary advances in animal science. The realization of much of this promise is in 
the future for the development of animals bred for special qualities such as 
disease resistance. However, this research has already brought us quantum 
increases in our knowledge of gene function. There have been many notable 
breakthroughs. Transgenic animals have proven very useful as models for the 
development and treatment of a variety of human diseases. The use of large 
animals as bioreactors has resulted in the development of sheep that secrete 
such substances as Clotting Factor 9 in their milk, and transgenic pigs that 
carry quantities of human hemoglobin in their blood.
There are any number of applications of biotechnology to animal science 
and production agriculture that are scientifically successful including the 
production and use of bovine and porcine growth hormones. One applica-
tion, in particular, must be singled out because it relates directly to the FSIS 
responsibilities for food safety. The availability of DNA probes to test for the 
presence of bacterial pathogens in meat and meat products has cut the detec-
tion time by one-half. These molecular methods are also highly sensitive and 
cost-effective.
The use of existing statutes and procedures to evaluate the products of 
animal biotechnology has allowed us to anticipate the testing and marketing 
of new products. We have ensured our capability for dealing with the new 
techniques by hiring specialists and through training programs for our staff
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scientists. We urge researchers to meet with us to discuss any questions they 
may have about regulations for testing and product development.
CONCLUSION
In closing, I would like to emphasize the point Dr. Cross made about the im-
portance of consumer interests and perceptions (see page 125). USDA agen-
cies, including FSIS and APHIS, work closely with consumer-interest groups 
to inform the public about our oversight policies and programs for biotech-
nology products and to discuss any safety concerns associated with produc-
tion and marketing.
The potential of biotechnology for improving animal health and the 
quality of meat and meat products is immense. We believe that risk-based 
regulatory programs will help realize the benefits of the technology for both 
U.S. consumers and producers.
REFERENCES
Murray, J., P.B. Thompson and R. Piggott. 1991. Transgenic Animals. In 
NABC Report 3, Agricultural Biotechnology at the Crossroads: Biological, 
Social and Institutional Concerns. J. Fessenden MacDonald, ed. National 
Agricultural Biotechnology Council. Ithaca, NY p. 43.
155
Regulatory Issues
REGULATORY ISSUES
Martin Terry
Vice President for Scientific Activities 
Animal Health Institute
Animal Pharmaceuticals
UNDEFINED TURF
The Food and Drug Administration (FDA) regulates animal drugs under the Food, Drug and Cosmetic Act, while the U.S. Department of Agricul-
ture Animal and Plant Health Inspection Service (USDA/APHIS) regulates 
animal biologicals under the Virus-Serum-Toxin Act. But the question of 
which agency has jurisdiction to regulate a given animal health product is not 
always a totally obvious one. The regulatory definition of a biological is in 
need of updating to clarify the status of some of the compounds being devel-
oped through biotechnology. Particularly difficult to classify are those com-
pounds which occur endogenously, modulate the immune response and have 
pharmacological properties. A classic example of this sort of regulatory am-
biguity can be seen in the handling of the interferons which are regulated as 
biologicals (by FDA’s Center for Biologics Evaluation and Research) for hu-
man use, but are regulated as drugs (by FDA’s Center for Veterinary Medicine) 
when labeled for use in animals. This disparity has more to do with inter-
agency politics than it does with the pharmacological/immunomodulatory 
effects of interferons. The Animal Health Institute (AHI) is currently work-
ing on a proposal to amend the regulatory definition of a biological, with 
the object of providing a more adequate taxonomy of drugs vs biologicals— 
which would ipso facto determine which agency should have jurisdiction to 
regulate a given substance or product.
PRODUCT VS PROCESS AND THE GLASS FOURTH HURDLE
A cornerstone of the final “Scope” policy statement of the Office of Science 
and Technology Policy as published in the Federal Register, February 27,1992, 
is the notion that regulatory oversight is appropriately applied in direct pro-
portion to the risk associated with a given product per se, independent of the 
technology employed in the manufacturing process. Interestingly, neither ob-
jective product risk assessment nor concern with the nature of the manufac-
turing process has occupied center stage in the controversy surrounding bo-
vine somatotropin (BST), the first high-profile product of biotechnology to 
be developed as an animal drug.
Since FDA finished its food safety evaluation of BST in 1986 and pro-
nounced that there were no human food safety issues arising from the
use of BST in lactating dairy cattle (Juskevich and Guyer, 1990), the public 
debate has focused on possible economic and social effects of the anticipated 
widespread adoption of the use of BST by the dairy industry. Questions have 
been raised and projections made as to the magnitude of the effects of wide-
spread BST use on volume of milk production, milk prices, dairy herd size 
and the continued viability of marginal, inefficient dairy operations.
FDA cannot legally take such socioeconomic considerations into ac-
count in the premarket drug approval process; animal drugs must be evalu-
ated on the basis of the objective criteria of safety and efficacy. However, FDA 
does not operate in a political vacuum and in a situation where heated politi-
cal debates on the socioeconomic aspects of a new animal drug run concur-
rently with the regulatory evaluation of the drug, it is hard to believe that the 
agency would not be affected to some degree in its deliberations on the drug. 
At the very least, the political heat radiating from the socioeconomic issues 
can be seen to make the agency even more cautious than usual in its evalua-
tion of the safety and efficacy data on the drug—which would logically result 
in a delay in the approval process.
Moreover, while the effects of socioeconomic criteria on the regulatory 
process may be subtle and unofficial at the federal level, they can be blatant 
and most official at the state level, as evidenced by the current legislative 
moratorium on the use of BST in Maine.
DOORS VS WINDOWS
Another issue which is by no means unique to biotechnology products, but 
158 which, as a matter of historical fact, emerged as the subject of public contro-
versy in the course of the ongoing BST debate, is that of regulatory transpar-
ency. In 1986 in the UK, headlines appeared about “secret trials” being con-
ducted with BST on undisclosed farms, with innuendoes of collusion be-
tween the animal health companies and the British Ministry of Agriculture. 
What, in fact, was happening was that animal health companies were field- 
testing a product for efficacy—the human food safety of the product having 
already been established to the satisfaction of the regulatory authorities—in 
accordance with the pertinent regulations, in exactly the same way as hun-
dreds of other animal health products had been tested previously. The brou-
haha arose, not because BST was receiving any favored treatment by the Brit-
ish government—that was clearly not the case—but rather because the public 
was totally unaware of the regulations and legal procedures routinely used in 
the testing and approval of animal drugs—until the BST critics sought to 
portray those procedures as some sort of conspiracy against the public.
At the heart of the transparency issue is a conflict between the public’s 
“right-to-know” and a drug sponsor’s legal right to confidential treatment 
of proprietary information on a product including the details of the tests 
conducted to demonstrate the safety and efficacy of the product in the regu-
latory approval process.
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In the U.S., the Food, Drug and Cosmetic Act provides that data which 
are submitted on a new animal drug by the drug sponsor will be evaluated 
on a confidential basis by FDA. The first regulatory hurdle which must be 
cleared in the drug approval process is that of establishing human food 
safety. Only when a new animal drug has been sufficiently evaluated and 
found to be safe from the point of view of humans consuming food produced 
by animals treated with the drug, may FDA approve an Investigational New 
Animal Drug Application (INADA) which authorizes the drug sponsor to 
conduct tests to demonstrate the efficacy and target animal safety of the drug.
In the FDA-monitored field trials conducted under an INADA, the issue of 
the safety of the food derived from the test animals has already been resolved 
by FDA. Thus, in terms of human food safety the drug is no longer an “ex-
perimental drug.” At the INADA stage, a drug is actually “experimental” only 
in regard to its efficacy and its safety to the target animal at dosages intended 
for commercial use. The food produced by the animals involved in such test-
ing is as safe as any other food produced with fully approved new animal 
drugs. Claims that the public is being put in jeopardy through exposure to 
food produced with an “experimental (INADA) drug” are ill-founded, and usu-
ally mischievous.
Yet there is a point of view which says that even if FDA says a product or 
technology is safe, the public has a right to know whether the food in com-
mercial channels was produced with that product or technology. Here the 
question of labeling rears its head and labeling is a highly controversial issue.
In principle, no one should object to providing the consumer with as 
much objective, nonproprietary information about food products as the con- 159
sumer has patience to read. However, in the reality of commercial food pro-
duction and marketing there are some difficulties involved in routinely pro-
viding certain types of information on the label of a food product. Let us 
consider, for example, the very topical notion of positively labeling a food 
product with something like: “Produced with xenophobein, a hormone de-
rived from recombinant DNA technology.” Let us say that this imaginary 
protein called “xenophobein” has been found by FDA to pass all the rigorous 
regulatory tests for human food safety and that food produced with xeno-
phobein is analytically identical to food produced with traditional technolo-
gies. In such a case, what are the consequences of putting the above-quoted 
information on the label of food produced with xenophobein? Four come 
immediately to mind:
1. Such labeling contributes nothing to the consumer’s knowledge in 
terms of safety or nutritional information, given that there is no objective 
difference between food produced with xenophobein and food produced 
without it. So, in a scientific sense, such labeling is gratuitous and of no con-
sequence.
2. To insist on detailed labeling as to the technology by which a food is 
produced when the food itself has been found by FDA to be safe, is essentially
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to discount FDA’s safety evaluation process. If we accede to demands that 
consumers should be given the opportunity to make their own safety assess-
ment (presumably on the basis of data purveyed by such prestigious scientific 
journals as The Wall Street Journal), the logical conclusion is that product la-
beling should be sufficient to allow consumers to protect themselves through 
the exercise of “informed” choice. But in that case FDA’s evaluation would be, 
at best, redundant and, at worst, in disagreement with the consumer’s per-
sonal evaluation. We could just as well dispense with the services of FDA and 
revert to a system of exhaustive labeling and caveat emptor.
It seems to me that, for all FDA’s imperfections.—and AHI is traditionally 
one of FDA’s most vocal critics—we as a society are better off with a govern-
ment-run agency making regulatory decisions on the basis of expert scien-
tific evaluation, than we would be in a system of “every man [sic] his own 
regulator,” where some would demand that an encyclopedia of product infor-
mation and manufacturing data be attached to each can of pork ‘n beans and 
the role of the agency would be reduced to that of an editor of encyclopedias.
3. As my colleagues in the European Commission learned when they 
proposed positive labeling of beef produced with hormones as a solution to 
the European hormone debate in the midi 980s, the use of emotive terms like 
“hormone” in labeling is likely to scare, rather than objectively inform, con-
sumers. (That, of course, is exactly the effect desired by many who advocate 
such labeling, as their interest is not in accurately informing consumers, but 
rather in politically motivating consumers through the manipulative use of 
“hot” language which serves to obfuscate rather than to educate.) Even with 
the best of intentions, what is intended as a neutral statement of fact on a la-
bel can be all too easily misinterpreted as a warning.
4. Labels generally are, of necessity, minor masterpieces of succinctness. 
Space on a label is available only at a cost and any statement that did not convey 
concrete information as to the safety or nutritional value of the contents of a 
food package would carry uncompensated added costs which would increase the 
cost of the product to the consumer without providing a benefit. I
I would emphasize that the above considerations apply only to positive 
labeling, e.g., “This product was produced with xenophobein.” There are no 
such objections to negative labeling, e.g., “This product was produced with-
out xenophobein.”Though the fact remains that the product produced with-
out xenophobein is identical to that produced with xenophobein—and there-
fore the negative labeling is scientifically as meaningless as positive labeling 
would be—the option of negative labeling allows consumers to exercise 
choice in the process by which their food is produced.
Negative labeling has the advantage of being equitable to all parties in-
volved in food production and consumption. If there is sufficient demand
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for a product produced by an “alternative” (which generally means low-tech, 
high-cost) technology—i.e., if producers find that it is commercially viable 
to exploit a niche market based on a perceived consumer preference for food 
produced without the use of a “mainstream” (generally high-tech, low-cost) 
technology—then by all means “let a thousand flowers bloom” in the market-
place. Let consumers decide with their checkbooks which products best sat-
isfy individual preferences—whether those preferences be based on cost, 
safety, nutritional quality, aesthetics, ideology, or a combination of factors. 
Let producers decide which markets they want to cater to, matching produc-
tion technologies with consumer preferences—as determined by the extent 
to which consumers are in fact willing to pay premium prices for products 
produced with the less efficient technologies.
COMMERCIAL PROMOTION VS POLITICAL SELF-DEFENSE 
Of current concern in the regulation of animal pharmaceuticals—and of par-
ticular relevance to those derived from biotechnology—is the issue of pre-
approval “promotion” or defense of a product by the manufacturer while the 
product is still under evaluation by PDA. The agency has defined “promo-
tion” so broadly as to impose very narrow limitations on the information 
that can legally be conveyed to the public by a manufacturer about a product 
in the pre-approval phase. The AHI has taken a quite different position on 
what kinds of activities constitute commercial promotion—as opposed to the 
pre-approval defense of a product in response to political attacks intended to 
prevent its approval.
The AHI view is that the severe limitations on the dissemination of in-
formation which FDA has sought to impose on AHI and its members are not 
dictated by the relevant regulations, are inconsistent with Administration 
policies to remove impediments to the development of new technologies and 
are seriously at odds with AHI’s and its members’ constitutionally protected 
rights to protect their property interests fully in the political arena. Negoti-
ations are underway to attempt to resolve this dispute which has far-reaching 
implications for the application of biotechnology in animal agriculture.
IMPEDIMENTS TO DRUG APPROVAL VS THE THREAT OF SNAKE OIL
The last issue I would like to touch on, namely, the need to revisit the statu-
tory efficacy standard for animal drugs, is in a sense a by-product of the cur-
rent debate on extra-label drug use. It is not unique to biotechnology prod-
ucts, but it has coincidentally arisen as a major regulatory issue at the time 
when the first biotechnologically produced animal drugs are in the latter 
stages of the FDA approval process—which is to say, at the time when these 
biotechnology products are undergoing efficacy testing.
The efficacy standard for animal drugs, as set forth in the Food, Drug 
and Cosmetic Act, is relatively simple and straightforward. In ordinary lan-
guage, FDA must require “substantial evidence” that a product is effective
Regulatory Issues
for the purpose for which it is intended, i.e., an animal drug cannot be ap-
proved by FDA until it has been shown not to be “snake oil.” The “substantial 
evidence” required is ordinarily in the form of “adequate and well-controlled 
studies.”
Unfortunately, this reasonable, bare-bones efficacy standard as set forth 
in the statute has undergone a sea-change of agency interpretation over the 
last few decades. Regulatory barnacles and mineral accretions have built up 
in the form of ever-more-complex policies for efficacy testing requirements. 
The problem has now reached such proportions that it often costs more for 
an animal drug sponsor to conduct the efficacy studies required for FDA ap-
proval than it does to conduct the safety studies which have traditionally ac-
counted for the major portion of the cost of product development.
Particularly onerous to sponsors seeking regulatory approval of new ani-
mal drugs is FDA’s current policy to require “optimal dose” titration studies, 
in which a number of doses (the majority of them irrelevant to clinical real-
ity) are tested for efficacy, in order to determine the lowest dose which is ad-
equately effective. Clearly this requirement adds greatly, and unnecessarily, 
to the cost and time required to get a drug approved. But it also has the addi-
tional long-term disadvantage of freezing the label dose at a level which may 
itself be clinically irrelevant by the time the drug has been used in the field 
for a few years. (For a good example of the latter problem, consider penicillin 
which is now universally acknowledged to be virtually useless in veterinary 
medicine at levels less than three times the once “optimal” dose which is still 
the only dose on the product label.)
To address these problems, AF1I and the American Veterinary Medical 
Association (AVMA) have filed a Citizen Petition proposing that FDA ap-
prove dosage ranges and eliminate the requirement for optimal dose titration 
in efficacy testing. The proposal applies only to new animal drugs which have 
adequate safety data packages and which would be restricted to use by or on 
the order of a licensed veterinarian. The statutory deadline for FDA to re-
spond to the Citizen Petition passed silently several weeks ago. In light of the 
recently launched AVMA legislative initiative to legalize extra-label drug use 
by veterinarians, this silence on FDA’s part could be pivotal. If FDA is per-
ceived as being unable to respond positively to proposals submitted in a reg-
ulatory mode to streamline current policies on efficacy testing, that would 
surely be interpreted by some in the industry as an indication that legislation 
is the only available remedy.
Regardless of whether it is eventually achieved through regulatory chan-
nels or through Congress, streamlining the efficacy testing requirements for 
animal drugs has clear advantages. It would free up agency resources to de-
vote to the crucial process of safety evaluation of new animal drugs. It would 
remove a major economic disincentive that currently discourages drug spon-
sors from seeking broader label indications for new drugs. And it would have 
a positive impact on the rate of approval of new animal drugs (including bio-
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technology products) which would mitigate the crisis in drug availability 
which currently besets animal agriculture.
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potentially call for regulation. Animals may pose human health risks if 
used as food, environmental risks if they escape from confinement, or animal 
health or food quality issues where they are genetically adapted to produce 
valuable drugs.
Since genetic engineering is capable of producing so many different 
kinds of animals for so many purposes, a thorough analysis of the adequacy 
of current regulation is well beyond the scope of this paper. Here I will con-
fine myself to environmental risks and summarize the current regulatory cli-
mate. What I have to say is genuinely discouraging. Not only are animals not 
being adequately regulated now, but, under the Bush Administration, there is 
little chance that they ever will be.
GENETICALLY ENGINEERED ANIMALS! ANYTHING BUT NATURAL
We must begin with the basic point. Genetic engineering is a radically new 
technology, and anything but natural. Modern gene transfer technologies 
permit artificial gene transfers across species, family and even kingdom lines. 
Genes from cows can be put in fish; genes from butterflies into tomatoes; 
genes from moths into potatoes. With genetic engineering the number of po-
tential new combinations is almost limitless. While we now have considerable 
experience with genetically engineered organisms, most of it involves micro-
organisms used under laboratory conditions. We have much less experience 
with environmental release of engineered organisms. In the case of released 
animals, we have almost no experience.
While the process of genetic engineering is not inherently dangerous and 
should not by itself lead to prohibitions, it does have the potential to modify 
organisms’ traits and behavior in ways that are not well understood and not 
easy to predict. Particularly where the animals will be released—accidentally 
or deliberately—into the environment, the process of engineering creates 
sufficient uncertainty that it warrants a red flag of caution.
enetically engineered animals raise a number of issues that might
ENVIRONMENTAL RISKS
Organisms with new combinations of genes can exhibit new combinations of 
traits, and new combinations of traits may enable new behaviors in the envi-
ronment. How organisms with new traits will fare in the environment is dif-
ficult to predict. The factors influencing success and competition are many 
and complex. But new trait combinations have the potential to improve an 
organism’s chances of success in the environment. If this happens, an organ-
ism can displace existing organisms or otherwise disturb existing ecosystems.
Consider fish. In contrast to some domesticated animals such as cows or 
sheep, which are unlikely to survive in the wild without human assistance, 
fish are wild animals well adapted to their environment. Even small modifi-
cations by genetic engineering could equip them to survive in a broader 
range of habitats.
A good example of a one gene change that could have dramatic impact 
on fish survival involves the so-called “antifreeze” gene. Such genes, available 
from flounder, code for proteins which can keep fish blood from freezing in 
arctic waters. So far, antifreeze genes have been transferred into several warm- 
water fish, including carp. With the antifreeze protein in their blood, the 
warm-water carp can survive in cold waters where they might displace native 
cold-water fish or in other ways disturb the aquatic ecosystem.
Another example involves genes for growth hormones. Auburn Univer-
sity scientists have recently transferred growth hormones from other fish and 
mammals into carp and catfish. Like cold tolerance, fast growth can enable a 
fish to displace other species and disrupt food chains. In both cases, the new 
166 gene can move into any fish that can breed with the engineered fish.
Generally, the same concerns apply to the release of any genetically engi-
neered animal into the environment. Whether an insect, a snail, a mouse or 
a cat, animals with modified growth rates or temperature tolerances or a 
multitude of other new traits pose the risk of disrupting ecosystems in harm-
ful ways. Since genetic engineering has the ability ultimately to transfer an 
unlimited number of new traits into animals, its risks are likely to be greater 
than those posed by traditional breeding.
Moreover, in addition to the desired modifications, some gene transfers 
may have effects the genetic engineers did not want, and could not predict.
A sad illustration is afforded by the so-called Beltsville pig. In this case, re-
searchers at U.S. Department of Agriculture’s (USDA) Beltsville laboratory 
succeeded in transferring human growth hormone genes to pigs in hopes of 
producing leaner meat. Instead, the pigs have proven to be crippled, cross-
eyed and immune-compromised. Other, less obvious, secondary effects may 
occur with other gene transfers. Some of these may affect behavior and im-
pact on release.
Finally, as shown by the unexpected effect of chloroflourocarbons 
(CFCs) on the earth’s atmosphere, our ability to predict the impacts of tech-
nology is limited. It is possible that genetic engineering, too, may pose novel 
risks that we have yet to appreciate.
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THE FEDERAL BIOTECHNOLOGY REGULATORY FRAMEWORK
The American Fisheries Society (AFS) has recently issued a position state-
ment highlighting the risks of the release of genetically engineered fish 
and concluding that such releases ought to be overseen by government 
(Kapuchinski and Hallerman, 1990).
Unfortunately, the American Fisheries Society also noted that the Fed-
eral Coordinated Framework does not require the necessary oversight.1 And 
the Fisheries Society is correct. No comprehensive federal authority exists un-
der which the releases of fish will be reviewed. In fact, little authority exists 
to control the environmental impacts of any genetically engineered ani-
mals—be they fish, fowl or insect. Right now, anyone who wished to geneti-
cally engineer and release a frog—or for that matter, mink, dog or rat—into the 
environment is generally free to do so without fear of federal repercussions.
This information may surprise some readers who perhaps believe that 
the federal government has a comprehensive framework in place. In fact, the 
framework that does exist ignored, from its inception, the environmental im-
pacts of animals. I will say a few words about its inadequacies below, but un-
fortunately, the framework is rapidly becoming a moot point. The Bush Ad-
ministration engaged in an effort not simply to stall or weaken implementa-
tion of the framework, but to dismantle it entirely.
APPLICABILITY TO ANIMALS
Before I turn to the 1992 efforts of the Bush Administration, let me briefly 
touch on the history and components of the federal framework and its rel-
evance to the control of environmental risks posed by animals. 
In 1983, the Reagan Administration orchestrated a multiagency effort to 
develop a policy to regulate biotechnology and its products. Operating out of 
the Office of Science and Technology Policy, Administration officials gath-
ered together representatives of USDA, the Food and Drug Administration 
(FDA), Environmental Protection Agency (EPA) and other agencies to evalu-
ate the statutes they administered for their applicability to biotechnology. In 
1984 and 1986, the Agencies published statements outlining how their stat-
utes would be applied to products expected from the new technology. Those 
statements constitute the core of Federal Framework for biotechnology regu-
lation.
Perhaps because so few engineered animals were under development in 
the 1980s, the Framework said little about the environmental risks posed by 
animals.1 2 Although a few of the statutes that make up the framework could 
potentially be applied to releases of animals, no attempt has been made to do so.
1 USDA officials have indicated that, instead of FIFRA, they intend to use the weaker
authority of the Plant Pest Act to regulate genetically engineered pest control 
agents. See Payne, 1992.
2 Almost all the discussion of animals related to the health effects of genetically
altered animals used as food.
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One of these statutes, the Plant Pest Act, for example, could apply to ani-
mals that meet its definition as plants pests. Release of such organisms, which 
might include genetically engineered insects, slugs or nematodes, could be 
covered by the existing Plant Pest Act program. The statutory definition of a 
plant pest, however, is severely restricted—covering only invertebrates. Ver-
tebrate animals, like fish or frogs, are completely excluded from the coverage 
of the statute.
The Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) is an-
other statute under which animals could potentially be regulated. Insects 
that prey on pest organisms, for example, are considered pesticides under 
FIFRA. Engineered animals developed for this purpose would be subject to 
regulation as pesticides under FIFRA. Currently, however, EPA exempts in-
vertebrate animal pesticides from regulation under FIFRA on the grounds 
that such animals are adequately overseen by the USDA. USDA, in turn, has 
made little effort to implement its authorities to regulate animals (Payne, 1992).
It should be also noted that EPA’s interpretation of the jurisdiction of 
the Toxic Substances Control Act (TSCA) is broad enough to cover all living 
organisms, including animals, but that as a matter of policy the Agency has 
restricted its TSCA program to microorganisms.
Finally, the National Institutes of Health (NIH) Guidelines require NIH 
approval for the release of genetically engineered animals used in research. 
The guidelines, however, cover only government-funded research. Private 
enterprises, for example, commercial fish farms or pet breeders, are not cov-
ered by the guidelines.
168 In summary, except for animals used in federally funded research, devel-
oped for pest control or invertebrate animals classified as plant pests, the re-
lease of genetically engineered animals is not, and does not have the potential 
of being, regulated under the Federal Framework for the Regulation of Bio-
technology. From anemones to zebras, most animals can be engineered by any-
one, for any purpose, and released at will.
THE COUNCIL ON COMPETITIVENESS
In retrospect, the evolution of the current (1992) biotechnology policy has 
been a steady downhill slide. The Biotechnology Regulatory Framework de-
veloped by the Reagan Administration promised at least four new rules or 
guidelines: two implementing USDA authorities3 and two implementing EPA 
authorities. Six years have now passed. Only one of the promised regulations 
has been promulgated—USDA’s regulations under the Plant Pest Act. Neither 
the EPA regulations under the TSCA or under the Pesticide Act, nor the 
USDA guidelines governing agricultural research have seen the light of day.
3 One of the promised guidelines would have implemented the USDA research 
authorities to establish a set of guidelines governing the release of geneti-
cally engineered animals in research. These guidelines would have covered 
an important set of activities involving genetically engineered animals.
Animal Biotechnology/ Opportunities & Challenges
The Bush Administration (working through the Council on Competitiveness 
in the Office of the Vice President) has gone beyond blocking implementa-
tion of the framework. It is now trying to dismantle programs—specifically the 
Plant Pest Act program—already in place.
The withdrawal from the arena of biotechnology policy was not insti-
gated by the relevant Agencies. To the contrary, both the USDA and EPA, 
implementing the Federal Framework, have sent successive versions of pro-
posed rules and guidelines to the White House for approval. Their efforts 
have been blocked by the group currently responsible for this policy-—the 
Council on Competitiveness .
With regard to animals, an adequate regulatory framework would re-
quire both new legislation and implementation of existing laws in ways not 
contemplated in the 1986 framework. Since the Council on Competitiveness 
will not allow even the implementation of the laws promised in the 1986 
document, there is no hope for the new initiatives needed for animals.
SUMMARY
As of this NABC meeting (May, 1992), the regulation of genetically engi-
neered animals is hopelessly inadequate, with little hope for improvement.
As long as the Council on Competitiveness sets policy, existing statutes are 
unlikely to be implemented to regulate genetically engineered animals and 
no new legislation will be sought to provide the new authority needed.
From an environmental standpoint, the current situation means that the 
risks posed by engineered animals to the environment—whether from acci-
dental or deliberate release—will go unassessed and uncontrolled. Moreover, 
without regulation there will be few opportunities for the public to know 
what is coming or to participate in decisions about the technology. The bot-
tom line is that the new policy leaves it up to industry and scientists to decide 
what kind of animals to make and when and how they should be released.
The rest of us must simply hope that their choices will not lead to environ-
mental degradation and disaster.
This policy of secrecy and exclusion of the public is a recipe for disaster- 
both for the environment and for the biotechnology industry.
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Workshop Report
The charge to the workshop participants was to identify and examine issues arising in regulatory treatment of animal biotechnology. This 
charge was addressed in an open forum in which free-ranging discussion 
among individuals with different perspectives was strongly encouraged. The 
two introductory talks by Martin Terry, Vice President for Scientific Activi-
ties, Animal Health Institute and Margaret Mellon, Director, National Bio-
technology Policy Center, National Wildlife Federation, gave rise to an initial 
discussion. The approach taken by the group was to list relevant issues, group 
those issues into three basic categories, discuss the issues category by cat-
egory and develop shared issue statements or recommendations. The issues 
raised by various members of the groups are listed below according to cat-
egory. While consensus was not sought nor achieved on the specific issues 
listed, these issues were deemed worthy of consideration by one, some or 
many of the members of the group and, as such, help to illustrate the range 
of concerns in this arena. Common themes of agreement did emerge and 
these were captured in the form of four issue statements or recommendations 
that represent points of consensus and, as such, they highlight important un-
derlying concerns in this arena. The three basic categories discussed are as 
follows:
THE REGULATORY PROCESS (how the process works)
This section deals with: 1. How the system works; 2. The issues in formulat-
ing and implementing regulations; and 3. Where there are gaps in the system 
that are of potential safety and/or environmental risks. The following issues 
and gaps have been identified:
Research Stage
The National Institute of Health has not adopted Appendix Q which 
contains guidelines for contained research on transgenic animals. These 
guidelines would be helpful for Institutional Biosafety Committees and oth-
ers. There are no mandated guidelines/regulations for industrial research of 
animal biotechnology.
Clinical Testing of Drugs
No obvious shortcomings were identified.
Field testing
-—There are no regulations for release of fish, wildlife, insects or pets; for 
micro-organisms in livestock feeds; or for zoonotic pathogens of animals 
and humans;
—Implementation of “Guidelines for Research Involving Planned Intro-
duction into the Environment of Genetically Modified Organisms” 
developed by the Agricultural Biotechnology Research Advisory Com-
mittee (ABRAC) should govern agricultural research;
—Absence of mechanism to deregulate similar genetically modified or-
ganisms that have been proven to be safe based upon previous case 
studies;
—The inability to gain access to some information on health and safety 
of products because of“confidential business information” designation.
Large Scale/Commercial Release
There are no oversight mechanisms, guidelines or regulations for large scale 
commercial release:
—Of products of animal biotechnology;
—Of second to nth generations of transgenic animals;
—Impact of the production system for the environment (e.g., genetically 
modified organisms replacing indigenous populations).
Regulatory Assessments (current regulations that relate to animal biotechnology) 
Animal safety: the current regulatory system for drugs and therapeutics 
appears to satisfactorily cover animals that receive or are altered by biotech-
nology.
Food safety: foods of animal origin are regulated by USDA‘s Food Safety 
Inspection Service and the FDA’s Center for Veterinary Medicine for safety, 
quality and efficacy. The gaps that are currently not covered include disposi-
tion of transgenic animals such as: Should they be reviewed case by case? 
Should transgenics receive prolonged testing before slaughter? Should fish, 
seafood and wildlife not be covered?
Efficacy: the efficacy of drugs is regulated by the FDA. Should transgenic 
animals used as pharmacoreactors receive special attention?
Market Place
Should consumers have the ability to make choices by knowing when they are 
purchasing products resulting from animal biotechnology?
ANIMAL BIOTECHNOLOGY REGULATIONS AND PUBLIC INVOLVEMENT
(who is involved in regulations)
The Public’s Role in Debate
There should be representation of broad interest. The access to informa-
tion and participation in debate should be improved for interested persons.
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A dear definition of process (where input and questions, etc. can be inte-
grated) should be known so that those wishing to participate could do so. 
Channels for participation may vary across agencies.
Possible mechanisms for improved access include:
1. Legislation regarding public participation in regulating decisions 
across the board;
2. Publication beyond the Federal Register;
3. Improved representation in decision-making processes;
4. Open forums;
5. Research on opening up scientific decision-making process; and
6. Rebuilding public trust and regulatory transparency.
Other Issues To Be Considered
—Role of states and industry in debate;
—Public education and who has responsibilities for keeping the public 
informed;
—Communication and knowledge can lead to choices by the public; and 
—Labeling products developed through biotechnology.
TECHNICALLY BASED REGULATIONS VS SOCIAL/ETHICAL/ECONOMIC IM-
PACT CONSIDERATIONS (What is the basis for regulations? Why are decisions made?) 
Regulatory Impact
The goals of regulations include:
1. Safety of the public and environment;
2. Safety and efficaciousness of food;
3. Quality assurance of products; and
4. The safety and welfare of animals.
Regulations can impact not only in the U.S., but also on international trade 
as well as trade relationships with third world countries. Patenting, however, 
impacts as a socioeconomic factor.
Information and Consumer Choice
Consideration was given by the group to the level of information available 
for consumer choice:
—Is there a need for labeling which would provide the public with a way 
to reflect their individual values?
—Should labeling be voluntary or mandatory?
—What information should be made available?
—What are the criteria for labeling?
—Can labeling be used as an education device? Concerns voiced by par 
ticipants included complexity of labels, definitions, etc.
The group acknowledged early on that many groups of people (e.g., mi-
norities, farmers, industry) were not well represented in its deliberations; the 
workshop’s report stems from a lower diversity of backgrounds than might
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be wished. Nonetheless, a wide diversity of positions relative to animal 
biotechnology regulations were represented. It is the hope of the group that 
its recommendations may contribute to positive actions and that its listing 
of issues may stimulate further debate in many other forums.
RECOMMENDATIONS
1. The regulatory gaps delineated deserve serious investigation. NABC 
may wish to establish a committee or other mechanism to assist this investigation.
2. A more acceptable policy-making process for rules of broad applicabil-
ity would be clearly understood or known (not ad hoc), transparent and par-
ticipatory. The group viewed the process leading to the recent FDA food safety 
decision as falling short of the goals for an acceptable process.
3. Social, economic and ethical questions need to be explored. What role 
do/should these issues have in research, development and approval processes 
for commercial use of new products? When should these factors be considered, 
relative to, but not necessarily as a part of the regulatory process?
4. With broader representation (such as food processors and consumer 
groups), NABC should conduct further exploration of the relationship be-
tween the government’s regulatory role, particularly the safety statutes and is-
sues of choice such as labeling provisions.
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